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Paratuberculosis is a chronic enteropathy of ruminants that presents as two 
distinct disease forms in sheep; paucibacillary (or tuberculoid) and 
multibacillary (or lepromatous) disease. The immunopathology of 
paucibacillary and multibacillary sheep paratuberculosis has been linked to 
inflammatory Th1/Th17 cell and Th2/macrophage responses respectively. 
IL23 and IL25 are key to the development of these responses by interaction 
with their complex receptors, IL23R/IL12RB1 and IL17RA/IL17RB. 
Furthermore, the polarization of T cells and the development of appropriate 
immune responses is controlled by the master regulator transcription factor; 
T-bet, GATA3, RORγt and RORα. In humans, variations in the structure, 
sequence and/or expression of the genes encoding these proteins have been 
implicated in the different pathological forms of tuberculosis and leprosy, and 
gastrointestinal inflammatory disorders such as Crohn’s disease. In the 
current study, sequencing has identified multiple transcript variants of sheep 
IL23R, IL12RB1 and IL17RB and a single IL17RA transcript. RT-qPCR 
assays were developed for the cytokine receptor variants identified in this 
study and known transcript variants of the transcription factor genes. 
Expression levels were compared in the ileo cecal lymph node of 
paucibacillary or multibacillary paratuberculosis diseased sheep. Of the 
cytokine receptors; the IL12RB1v3 variant, which lacks the receptor 
activation motif, was differentially expressed and was significantly increased 
in multibacillary disease; this may contribute to high Th2 responses. Full 
length IL17RB was differentially expressed and was significantly increased in 
multibacillary pathology, which may also contribute to Th2 polarization. 
IL17RA was significantly increased in paucibacillary disease. The contrast 
between the IL17RA and IL17RB results may indicate that, in addition to Th1 
cells, Th17 T cells are also involved in paucibacillary pathology. Of the 
transcription factor transcripts; full length TBX21 (T-bet) was differentially 
expressed and was significantly increased in paucibacillary disease; this may 
explain increased Th1 responses in these sheep. Full length GATA3 was 
significantly increased in paucibacillary compared to multibacillary sheep, 
suggesting a loss of Th2 responses in late-stage multibacillary pathology. 
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RORAv1 variant was differentially expressed and was significantly increased 
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Metazoans are, constitutively and transiently, colonized by a variety of 
microorganisms that engage in mutualistic interactions with their host. However, this 
relationship can also be antagonistic and the nature of such interactions is often 
poorly understood. Recent studies have begun to elucidate the receptor and signalling 
pathways involved in the host response to both commensal and pathogenic microbes 
(Iwasaki and Medzhitov, 2010). The immune system uses these sensing pathways to 
induce necessary defence mechanisms to maintain host-microbe homeostasis. 
Vertebrates possess two types of immunity: innate and adaptive, that work together 
to protect the host. The innate immune system is the non-specific first line of defence 
and is genetically programmed to detect shared features of invading microbes. Cells 
of the innate immune system include dendritic cells/macrophages, epithelial cells and 
neutrophils, eosinophils and basophils. In contrast, the adaptive immune system is 
highly specific and is composed of T and B lymphocytes. The adaptive immune 
system employs antigen receptors which provide the host with immune ‘memory’; 
allowing the induction of an appropriate immune response in the event of subsequent 
exposures to specific antigens. In the past, innate and adaptive immune systems have 
been viewed as two distinct organisations providing responses at separate stages of 
antigen exposure; however as research continues, it is becoming increasingly evident 
that each response requires the other to function and that these responses operate 
simultaneously to deliver effective host protection. The innate immune system can be 
described as the foundations upon which the adaptive immune system develops 
(Chaffey, 2003). Given that cells of the innate system are not always able to 
eliminate foreign organisms; cells of the adaptive immune response have evolved to 
provide a more complete means of defence. The successful control of pathogenic 
infection requires efficient communication between cells of both innate and adaptive 
immune systems. Adaptive immune responses are optimised by the activities of the 
innate immune system and efficient adaptive immunity is required to protect the host 
against persistent pathogens. This project is focused on components involved in the 
induction and maintenance of an adaptive T cell immune response to mycobacterial 






Paratuberculosis (paraTB or Johne’s disease - JD) is an infectious, granulomatous 
disorder that causes chronic inflammation of the gastrointestinal tract of ruminants. 
Infection occurs predominantly in cattle and sheep; although can occur in goats, deer 
and wild ruminants and results in wasting and loss of condition (Machackova et al., 
2004). Mycobacterium avium subspecies paratuberculosis (MAP) is the causative 
agent of paraTB. This slow growing, acid fast, bacterial infection is responsible for 
extensive economic losses worldwide related to shorter lifespan of infected animals, 
increased replacement costs and loss of productivity (Ott et al., 1999). Animals 
become infected at a young age with most infections occurring during the neonatal 
stage (Seitz et al., 1989). The main route of disease transmission is faecal-oral, 
including ingestion of bacteria from infected teats, water, feed or pasture which has 
been contaminated from the diarrhoea of infected animals (Manning and Collins, 
2001). Whitlock and Buergelt first classified the infection status of cattle into 4 
stages based on the severity of clinical signs (Whitlock and Buergelt, 1996):  
1. Silent stage represents young animals under the age of 2 that have no clinical 
symptoms of disease. These animals shed bacteria at low levels, difficult to 
detect in faeces, but have MAP present in the gut tissues.  
2. Subclinical stage where adult animals are infected but show no clinical 
symptoms. Antibodies and immune mediated cell responses can be detected 
during this phase of infection. Cattle with subclinical infection often develop 
problems with mastitis and infertility (Fawcett et al., 1995). 
3. Clinical paraTB infection resulting in weight loss and diarrhoea. Faecal culture 
of MAP gives positive results. 
4. Advanced clinical paraTB characterised by persistent diarrhoea, severe weight 
loss, oedema of the gut/throat. These animals are sent for emergency slaughter 
or will die of dehydration. 
Susceptibility of animals to infection with MAP is largely age-dependant with the 
greatest risk period being during the first few months of life. Animals develop 
increased tolerance to infection from 4 months to 1 year old, by which time they 
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achieve a level of resistance comparable to an adult (Arsenault et al., 2014). The 
higher susceptibility to infection seen in younger animals is thought to be due to the 
general immaturity of the innate and adaptive immune systems. As a result of 
transmission the majority of animals within a herd that has a case of infection will, in 
turn, become affected. Information on the host immune response in sheep paraTB is 
limited; immunological data is predominantly derived from studies of bovine paraTB 
where disease typically progresses from a subclinical to paucibacillary phase, to an 
eventual multibacillary endpoint. Although there have been instances of progression 
of disease noted in sheep (Dennis et al., 2011), paucibacillary and multibacillary 
forms of paraTB in sheep mostly appear to be distinct end points, separate from one 
another. Both paucibacillary/multibacillary pathologies are equally fatal in sheep; 
however there is little evidence to conclude that all asymptomatic animals (infected 




1.2 Economic impact of paratuberculosis 
 
There is limited information on the prevalence of ovine paraTB; it is estimated that 
approximately 0.9-1.3% farmed sheep herds in New Zealand (Morris et al., 2006) 
and 5-15% of sheep herds in Australia become infected per annum (Reddacliff et al., 
2006).  Between 1993 and 2002 there were approximately 465 recorded cases of 
cattle and sheep paraTB in Scotland (Stewart et al., 2005); however this figure 
reflects only reported cases. Not all cases are reported to Health Protection Scotland 
as Johne’s disease is not currently classified as a notifiable disease. Accurate 
determination of paraTB prevalence is difficult due to the limitations of available 
diagnostic techniques (Gillan et al., 2010).  In 2010 a DEFRA report estimated the 
annual UK cost of paraTB at ~£30min all species (Geraghty et al., 2014.DEFRA, 
2010). Efforts to control paraTB through improving animal management has had 
limited success. The ability of the pathogen to persist in the environment and the lack 
of a reliable detection method of infected animals make traditional approaches to 
control the spread of infection largely ineffective. Prevalence of the disease is 
increasing throughout most parts of the world, particularly in temperate climates with 
frequent rainfall (Pavlik et al., 2000). Animals that are housed in tight confinement 
show a higher incidence of disease as it has been shown that restrictive conditions 
contribute to the spread of disease within, and between, herds (Chiodini et al., 1984). 
The lack of a uniformly defined prevalence estimate hinders the comparison of 
prevalence across countries and regions. Nielsen and Toft reviewed the prevalence of 
paraTB in farmed animals in Europe and found that the true prevalence among cattle 
appeared to be approximately 20%, but further highlighted that there is a need for 
well-designed method of determining the prevalence of MAP infections within herds 




1.3 Symptoms and Pathology 
 
ParaTB is characterised by granulomatous lesions of the gut. These lesion are formed 
as immune barriers, functioning to limit infection and control disease progression. 
Although animals are infected at a young age, the chronic nature of the disease 
entails that clinical signs may not be visible for a significant period of time, up to 3-5 
years post infection (Chiodini et al., 1984). Clinical signs of MAP infection include 
weight loss; oedema of the abdomen caused by thickening of the abdominal wall and 
necrosis of lymph glands; diarrhoea (most common in cattle); and eventual death 
(Ayele et al., 2001). These are caused by inflammation within the intestine resulting 
in a loss of gut barrier function; lower absorbance of water and nutrients in the 
intestine contributes to pathology with animals developing anorexia. Three forms of 
the disease have been described in sheep based on gross gut pathology; with 
approximately only 30% of infected animals becoming clinically affected. Most 
animals (~70%) remain asymptomatic, in that they are infected but show no 
pathology and develop no clinical disease (Smeed et al., 2008.Clarke, 1997). The 
pathological forms are unambiguously differentiated into multibacillary 
(lepromatous) and paucibacillary (tuberculoid) forms. Post mortem examination of 
paucibacillary infected animals describes a corrugated thickening of the intestine 
with loss of convoluted villi structure. Further examination by histopathology reveals 
a lymphocytic infiltrate with very low/no mycobacteria present, observed by Ziehl-
Neelsen staining. Characteristically, paucibacillary lesions consist of lymphocyte 
infiltration with very few macrophages. In contrast, multibacillary infected animals 
have a large macrophage infiltrate; these macrophages are infected with intracellular 
MAP and so many mycobacteria are present in the intestinal tissues (Clarke, 1997). 
Again, thickening of the gut wall is noted with loss of villi integrity, this can be seen 
in figure 1.1. Given that paraTB presents as a spectrum of pathology, similar to that 
seen in human leprosy, a wide range of histopathology has been observed, including 
the development of lesions in the Peyer’s patches (Corpa et al., 2000). 
Similarities have been noted between the pathology of paraTB and the pathology of 
the major human diseases mycobacterial diseases, tuberculosis (TB) and leprosy. It is 
yet unknown what causes each of the disease outcomes; however as with TB and 
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leprosy, a host genetic susceptibility has been suggested; this is described in greater 
detail in section 1.10. 
 
  
Figure 1.1 Representative sections of ileum showing a) paucibacillary and b) 
multibacillary MAP infection. Histology sections stained using Zeihl-Neelsen (top) and 




1.4 Diagnosis and Detection of MAP infection 
 
A major difficulty when trying to diagnose paraTB is the identification of subclinical 
cases. Infected animals can show no symptoms of disease for up to 5 years after 
infection, by this time clinical symptoms are manifested and the shedding of bacteria 
will already have contaminated the environment. The most common way of 
identifying shedding of MAP bacteria by infected animals is faecal culture; however 
MAP has proven to be extremely difficult and slow to culture in the laboratory, 
especially when present in low abundance (Manning and Collins, 2001). MAP 
requires the addition of mycobactin, a growth factor derived from mycobacteria, to 
culture medium in order to grow and can take up to 16 weeks to be visibly detected 
in medium (Behr and Collins, 2010).Current tests are not highly sensitive or specific 
and so development of new tests is required. 
1.4.1 Detection of immune response 
 
Current bovine tuberculin skin tests detect delayed hypersensitivity and have been 
used for the diagnosis of bovine TB for many years. These tests are based on the 
measurement of a delayed-type hypersensitivity (DTH) to intradermally injected 
tuberculins. The single intradermal cervical comparative test (SICCT) consists of a 
comparative analysis of immune reaction to Mycobacterium bovis and 
Mycobacterium avium subsp. avium purified protein derivatives (PPD). When the 
skin thickness (due to DTH) to M. Bovis is 2mm greater than of the response to M. 
avium the animal is considered a TB reactor.  Similarly, tests involving intradermal 
inoculation of MAP extract (johnin) have been used to detect MAP infection; 
thickness of the skin at the site of injection is monitored. An increase in thickness of 
>4mm within 72hours is considered as a positive result for MAP infection (Strain et 
al., 2011.Strain, 2011). However, this test shows a lack of specificity due to cross-
reactivity with both M. bovis and M. avium avium, is highly subjective and provides 




Enzyme-linked Immunosorbent Assays (ELISA) are commonly used test for 
screening large herds/flocks of animals. Animals that have a positive ELISA for 
paraTB are confirmed by faecal culture. The sensitivity of these tests compared with 
faecal culture varies widely; from 13.7%, in which case animals are described as low 
shedders, to 100%; considered high shedders of MAP (Eda et al., 2006). An IFNγ 
ELISA (Bovigam CSL) is used to detect the increase in IFNγ production in pre-
clinical animals infected with MAP; in vitro IFNγ production is assessed following 
incubation of whole blood with MAP antigens. However responses to this test are 
time-dependant and in animals where an IFNγ response is short lived, the peak of 
IFNγ production may not be detected. An evaluation of five antibody detection tests 
based on ELISA technology for the diagnosis of bovine paraTB found that results 
were variable between the tests, highlighting the issue that antibody based 
diagnostics are not always reliable (Collins et al., 2005).  ELISA tests used to detect 
antibody levels can detect immune reactions to MAP specific proteins; however this 
test does not distinguish between multibacillary and paucibacillary disease forms and 
can often detect MAP antibodies in both forms of disease; rendering this test 
ineffective as a way of differentiating multibacillary and paucibacillary infection 
(Gillan et al., 2010). Research continues to identify new proteins in MAP that will 
have higher sensitivity than tests currently available (Collins, 2005. Fernández, 
2012).  
1.4.2 Detection of MAP DNA 
 
The MAP bacterium genome was sequenced in 2004 and it was found to share 
common genetic homogeneity with members of Mycobacterium avium subspecies 
(MAV) (Thorel et al., 1990); however the genotype of MAP can be specifically 
distinguished from other mycobacteria by the presence of the insertion sequence 
IS900 (Green et al., 1989.Bull et al., 2000). Amplification of this IS900 by 
PCR/qPCR methods has been widely used as a diagnostic tool to detect MAP in 
infected animals and humans (Autschbach et al., 2005). Selection of adequate 
primers for IS900 detection is essential for amplification of this element. Similar 
sequences, ‘IS900-like insertions’, have been identified in other mycobacteria; 
although these sequences are not identical to IS900, they are known to share 
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sequence identity often leading to complications when designing efficient detection 
assays specific to MAP. For instance, the IS1626 sequence of M. avium shares 
approximately 82% identity with IS900, other elements present in MAP are also 
present in M. intracellulare; therefore are non-specific and unable to be used as a 
diagnostic tool for the detection of MAP (Puyang et al., 1999). IS900 PCR is 
considered one of the most reliable detection methods when confirming MAP 
infection (Sidoti et al., 2011). 
1.5 Treatment and control of MAP infection 
 
Treatment and control of paraTB is extremely difficult and can be very costly. A 
potential way of reducing the occurrence of animals shedding MAP is by 
vaccination. The immune response elicited by the vaccine aims to reduce bacterial 
shedding from infected animals. The GudairTM vaccine is a whole cell preparation of 
heat killed MAP which elicits both humoral and cellular immune responses; however 
such responses can also be detrimental; approximately 50% of vaccinated animals 
will develop granulomatous lesions at the site of injection (Eppleston and Windsor, 
2007).  Cattle vaccinated with GudairTM generate a response that may interfere with 
the current M. bovis SICCT, rendering this test ineffective and leading to an increase 
incidence of false positive M. bovis reactors (Eppleston and Windsor, 2007). Current 
vaccines used to prevent paraTB are not DIVA (differentiating infected from 
vaccinated) and so often interfere with serological tests for both MAP and M. bovis 
infections (Bastida and Juste, 2011). Legislation in many countries states that 
animals that test SICCT positive for tuberculosis are banned from international trade 
and should be slaughtered; unless it can be proven that the positive result is a 
consequence of prior vaccination and not tuberculosis infection (Bastida and Juste, 
2011). Furthermore, there have been cases of vaccinated sheep that have gone on to 
develop paraTB of the multibacillary form; continuing to contribute to the spread of 
paraTB (Reddacliff et al., 2006). These are some of the hurdles affecting MAP 
vaccine approval by many regulatory and agricultural authorities throughout the 
world. Aside from these complications vaccination is expensive and the cost of MAP 
in the UK, especially with low milk prices, is not high enough to provide an 
incentive for farmers to prevent paraTB infection. Farmers do not find vaccination to 
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be economical and so most animals displaying symptoms of paraTB are culled 
(Bastida and Juste, 2011). More recently DNA vaccines have been used in mice and 
sheep but not in cattle. These consist of mammalian expression vectors containing 
MAP genes; however further investigation is required to determine whether these 
vaccine techniques will be successful (Velaz-Faircloth et al., 1999 Sechi, 2006).  
The development of anti-mycobacterium drugs has proven to be ineffective. MAP 
was shown to be highly resistant in vivo to standard anti-tuberculosis drugs; even 
though these drugs have been shown to reduce infection in M. tuberculosis infected 
humans (Ayele et al., 2001).  
The most cost effective practice to control the spread of paraTB is the careful 
maintenance of farmed environments. Preventing the introduction of infection into a 
new herd through methods such as: 
- Ensuring new stock are tested for the presence of MAP. 
- Managing risks when transporting animals at exhibitions through separation 
and hygiene. 
- Managing water flow from neighbouring land. 
- Managing disposal of manure. 
- Culling of any infected animals immediately. 
- Decontamination of areas where animals are kept in close confinement on a 
regular basis i.e. lambing/calving barns. 
These can all be effective strategies in reducing MAP prevalence(Weber, 2006). 
However it must be noted when implementing these practices that MAP has the 
ability to persist in soil and aquatic environments for upwards of a year. The 
bacterium is relatively susceptible to high pH in soil, longevity is reduced in areas of 
persistent urine and faeces exposure but this does not stop the spread of infection 
(Lovell et al., 1944). These factors attribute to the challenges faced in controlling the 
spread of infection once an animal/environment has become infected with MAP. 
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1.6 Transmission of MAP 
 
The factors that influence the transmission of MAP between susceptible hosts 
continue to be defined. Control of the disease has focussed on removing those in the 
relatively advanced stages of disease which contribute to the spread of infection to 
younger animals by shedding MAP in their faeces. Pre-natal infection has been 
described whereby calves have acquired infection in utero; however the widely 
known infection of newborn animals occurs by oral ingestion of the pathogen 
(Collins, 1994). Contamination of teats and the presence of MAP in the colostrum 
and milk result in the ingestion of large doses of bacteria by suckling neonates (Behr 
and Collins, 2010). Contamination of pasture, water and feed also contribute to the 
spread of infection in animals born from paraTB free dams (Kaevska et al., 2014). 
As the main site of infection is the lower region of the small intestine and 
corresponding lymph nodes, paraTB is largely excreted via the faeces of infected 
animals. Due to faecal shedding, the environment of infected herd/flock is often 
contaminated (Bannantine and Bermudez, 2013). High shedders are, of course, 
responsible for high rates of transmission. Whittington et al found that excretion of 
MAP by multibacillary infected Merino sheep occurred daily, showing that 
environmental contamination can be continuous on farms with endemic ovine 
paraTB (Whittington et al., 2005). It has been proposed that MAP can be transmitted 
during breeding as the bacteria can be cultured from the semen of infected rams and 
bulls (Larsen et al., 1981). Viable mycobacteria has previously been isolated from 
the reproductive organs of infected animals; however intrauterine transmission has 
not been regarded as the most important route of transmission when considering 
methods of control (Ayele et al., 2001). 
Similar to bovine tuberculosis, transmission of MAP between livestock and wildlife 
species that share the same habitat has been reported (Nugent et al., 2011). Infected 
wildlife have been detected in areas of significant prevalence of infected domestic 
ruminants (Greig et al., 1999). This adds to the difficulty of MAP eradication from 
domesticated livestock grazing areas as infected wildlife, such as rabbits and deer, 
tend to share grazing ground. 
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Following oral ingestion, MAP localises in the mucosa of the small intestine and 
associated lymph nodes. As the disease advances infection disseminates in organs 
distant from the primary, gastrointestinal site of infection via lymphatic vessels and 
blood. 
1.7 Intestinal translocation 
 
Once animals are infected with MAP, initially the mucosa of the small intestine and 
associated lymph nodes are targeted. The mechanisms by which MAP is able to bind 
to, and translocate across, the intestinal wall is a matter of ongoing research and 
debate (Coussens et al., 2010). It is thought that the binding of fibronectin (FB) plays 
a key role during mycobacteria invasion. MAP expresses a homologue to the 
fibronectin attachment protein which enables the bacteria to bind to FB(Bannantine 
and Bermudez, 2013). The bound FB is then able to bind to integrins on the surface 
of M-cells and translocate through the Peyer’s patches into the gut (Secott et al., 
2004). M-cells are a proposed target cell of MAP as they express integrins on their 
luminal faces unlike other intestinal epithelial cells; β1 integrins have been identified 
as the receptor for FB-opsonized mycobacteria in vitro and these integrins have been 
found in high density on the surface of  M-cells  (Secott et al., 2004.Bermudez et al., 
2010). Other studies have shown that MAP has the ability to attach to and cross the 
intestinal epithelium independently of Peyers patches, suggesting a role for 
enterocytes in MAP invasion (Bermudez et al, 2010). Enterocytes do not express the 
integrins required for FB binding and so other, yet unknown, receptors may be 
involved. Once MAP has crossed the intestinal epithelium, the bacterium is 
phagocytosed by macrophages; furthermore opsonisation of MAP by antibody and 
complement C3b can occur at this stage, increasing its uptake by macrophages 
(Tessema et al., 2001). The mechanism of host invasion likely contributes to the 
ability of MAP to propagate in a variety of host species; given that this bacterium can 
only persist, and not grow, outside the host, invasion and establishment within a 





1.8 Host immune response to MAP infection 
 
As previously mentioned, there are fewer studies investigating paraTB infection in 
sheep than cattle; however the paucibacillary and multibacillary pathological forms 
of disease in sheep are more easily defined (Clarke, 1997). These forms are more 
difficult to differentiate in other species and are largely time dependent whereas in 
sheep definition of the two endpoint pathological forms can be achieved based on 
examination of gross pathology and characteristics of host immune response. In 
many cases this makes research on paraTB infection less confusing in sheep. 
1.8.1 Macrophage response 
 
Typical bacterial infections involve the phagocytosis of the bacteria following 
recognition by cells of the innate immune system, including macrophages, and 
dendritic cells. Once internalised in the cell, lysosomes fuse with cytoplasmic 
phagosomes to form phagolysosomes, where the components of the bacteria are 
digested by hydrolytic enzymes. Bacterial peptides are then presented on the cell 
surface by MHC class II molecules and subsequently initiate the activation of an 
appropriate adaptive immune response. During paraTB infection the bacteria 
multiply within macrophages in the terminal section of the small intestine when 
phagocytosed; macrophages in turn proliferate leading to more cells harbouring the 
bacterium (Secott et al., 2004, Woo, 2008). Macrophages play a conflicting role in 
this disease whereby they are the primary site of MAP replication but are also 
important in the elimination of the bacteria by phagocytosis and stimulation of 
adaptive immune responses. The pathogenesis of MAP at a cellular level, within 
macrophages, is poorly understood. Macrophages possess several receptors that are 
involved in the uptake of mycobacteria. Ferwerda et al. investigated the recognition 
of MAP by PRRs and found that macrophages from TLR2 and TLR4 knockout mice 
produced less immune stimulating cytokines compared with control mice when 
infected with MAP. It was also shown that NOD2 knock-out human embryo kidney 
(HEK) cells but not NOD1 knock-out HEK cells responded to stimulation with 
MAP; these results indicate that TLR2, TLR4 and NOD2 molecules are involved in 
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pattern recognition of MAP by the innate immune system (Ferwerda et al., 2007). 
Other studies have shown CD11/CD18, CD14, complement receptors and mannose 
receptors as key initiators of phagocytosis in mycobacteria infections, including 
MAP infection (Souza et al., 2007.Woo and Czuprynski, 2008). During most 
bacterial infections, macrophages ingest the bacterial organisms via receptor 
mediated phagocytosis, internalisation leads to the formation of phagolysosomes 
which degrade the foreign bacteria by producing reactive oxygen and lysosomal 
enzymes (Hostetter et al., 2003). However, mycobacterial/MAP infection differs to 
that of other bacterial infections in that once MAP is phagocytosed, persistent 
infection is often established within the host by altering the functioning and gene 
expression of macrophages. These alterations lead to failure of some phagosomes 
containing MAP to progress through the endocytotic pathway by blocking vesicle 
maturation and, in doing so, avoiding phagosome-lysosome fusion (Tooker and 
Coussens, 2004). Souza et al investigated the effects of mannosylated-
lipoarabinomannan (Man-LAM), a mannose-capped lipoglycan cell wall component 
of MAP which has been identified as one of the ligands that modulates macrophage 
function, on survival of the bacteria when cultured with bovine macrophages. This 
study also looked at the effects of Man-LAM on IL10, IL12p40 and TNFα 
expression by bovine macrophages during initiation of an adaptive immune response 
and found that Man-LAM induces rapid expression of IL10 as well as a transient 
expression of TNFα and IL12p40. It was also shown that MAP-derived Man-LAM 
had the capacity to inhibit maturation and acidification of phagosomes and was able 
to attenuate bacteria killing in macrophages when co-cultured with Mycobacterium 
avium subsp. avium (MAA) reducing bacterial killing to approx. 8%; whereas in 
previous studies, incubation of macrophages with MAA alone resulted in killing of 
40% to 50% of bacteria (Souza et al., 2013). This is similarly seen in M. tuberculosis 
infection whereby many macrophages containing mycobacteria display a lack of 
maturation and phagolysosome formation (Clemens, 1996). 
Cell proliferation gives rise to extensive numbers of internalised MAP, leading to 
infiltration of the intestinal submucosa by macrophages, APCs and immune cells; 
this results in inflamed intestinal tissue and eventual reduction in gut absorption and 
protective function. As with other pathogenic infections, macrophages that have 
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successfully phagocytosed the organism migrate to the local lymph nodes where they 
present antigen to resident T cells and B cells; however  research has found that 
macrophages persistently infected with MAP are less efficient at T cell stimulation 
(Coussens, 2001). Thus suggesting that the stimulation of T cells may be restricted to 
macrophages that are successful in degrading/processing MAP or perhaps the other 
innate cell types,  such as dendritic cells (DC) , play a crucial role in antigen 
presentation to T cells during MAP infection (Coussens, 2004). 
1.8.2 B-cell and antibody response 
 
Antibodies to MAP produced by the host have proven to be ineffective at controlling 
the bacterial infection in many species. Antibodies to the MAP cell wall constituent 
lipoarabinomannan (LAM) have been identified in cattle and appear at approx. 130 
days post infection where infection has already established and these antibodies were 
not effective at creating protective response (Koo et al., 2004). Antibody can be 
detected in sheep from around 90 days post infection (Kurade et al., 2004); however 
Begara-McGorum et al. found that in lambs with experimentally infected ParaTB, B 
cell numbers in the mesenteric lymph node were significantly reduced; this was also 
seen in jejunal and ileal Peyer’s patches, resulting in high T:B cell ratios for infected 
lambs compared to uninfected controls, 8 weeks after infection (Begara-McGorum et 
al., 1998). 
One of the challenges faced when measuring antibody response is that of detection 
method. A study in cattle stated that the commercial ELISA test could not detect 
antibody until the animal is over 3 years of age (Ayele et al., 2001); whereas another 
study stated that the commercial ELISA was unable to detect antibody responses in 
cattle that had already shown to be seropositive through different methods (Waters et 
al., 2003). 
During late stages of infection, antibody levels correlate with severity of disease and 
bacterial load (Burrells et al., 1998a), this is similar to what is known in human 
tuberculosis infection (Neill et al., 2005). Both cattle and deer show a strong 
correlation between antibody levels and disease severity (Souza et al., 2006, 
{Mackintosh, 2007). Although sheep produce antibody, there is no evidence to 
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confirm this is protective to the animal. High antibody levels in sheep have mostly 
been correlated with the multibacillary form of pathology; it is thought that 
paucibacillary animals produce antibody at lower levels; however it is difficult to 
distinguish between the two forms using antibody data (Kurade et al., 2004, Burrells, 
1998). 
1.8.3 CD4+ T cell response and polarisation 
 
Macrophages, DC’s and other APCs provide a first line of host defence against 
intracellular pathogens including mycobacteria. The differentiation of the 
pathological forms of sheep paraTB, multibacillary and paucibacillary, have been 
associated with differential T cell activation (Smeed et al., 2007). Macrophages are 
key players in the initiation of immune response to MAP; these cells are infected and 
subsequently activate T cell responses; influencing development of differential T cell 
subsets. Once an infection has taken place the host response is primarily regulated by 
T cells. Cytokines secreted during innate responses can create environments that 
influence T helper (Th) cell differentiation into specific polarised subsets 
(Luckheeram et al., 2012). These subsets determine the immune response made to a 
particular type of antigen. Although numerous subsets continue to be identified; four 
main Th subsets have been characterised and studied in depth; Th1, Th2, Th17 and 
T-regulatory cells (Treg), each expressing a unique set of transcription factors and 
characterised by distinct cytokine profiles, shown in figure1.2 (Zhu and Paul, 2010). 
Transcription factors function to regulate gene expression in specific cell subsets and 
determine the cytokine milieu produced by cells, as well as receptor molecules 
expressed on that cell. The differentiation of CD4+ T cells into Th cell subsets is 
coordinated by cytokines and transcription factors and determines the outcome of 
immune response from each subset to different types of pathogens (Zhu and Paul, 
2010). Furthermore, cytokine receptors are crucial in the mediation of cytokine 
driven Th cell activity. These receptors are expressed by activated T cells in response 
to a specific cytokine environment (Drachman and Kaushansky, 1995). Protection 
against mycobacterial disease is dependent on T cell immunity (Orme et al., 1993) 
and this is the case in paraTB infection (Coussens, 2004). Insufficient or 
inappropriate control and/or regulation of Th cell response results in immune 
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mediated pathology, including that seen in paraTB. In both sheep and cattle, γδ T 
cells are increased early at the site of infection (Begara-McGorum et al., 1998 Beard, 
2000) with CD4+ and CD8+ T cells increased later in infection. In sheep the T cell 
response is polarised and results in the observed differences in pathology (Smeed et 
al., 2007). Once sheep are infected with MAP, approximately 30% of the 
symptomatic animals are affected by the paucibacillary form of paraTB; a 
tuberculoid state characterised by low levels of bacteria with γδ and CD4+ T cell 
infiltration of the gut. In this form of the disease MAP cannot often be seen in tissues 
by Ziehl-Neelsen (ZN) staining, used for staining of acid-fast mycobacteria, nor can 
be detected by bacterial culture. Initially, studies described the development of a 
predominantly Th1/Th17 cell response, characterised by release of pro-inflammatory 
cytokines including IFNγ, IL1α, IL12, IL17A, IL17F and IL2, in paucibacillary 
infected animals (Clarke, 1997, Begara-McGorum, 1998, Burrells, 1998 . Robinson 
et al., 2011). However; some studies have described a mixed Th1/Th17 
inflammatory and Th2 response in paucibacillary infection and a predominant Th2 
antibody response in multibacillary pathology (Coussens, 2001.Coussens, 2004). 
Interleukin-12 (IL12) secreted by cells of the innate system following pathogen 
recognition induce the development of a Th1 cell population. IL12 is secreted by 
activated APCs; this cytokine then, in turn, induces IFNγ production by Th1 cells 
and natural killer cells (NK) (Macatonia et al., 1995). Cells involved in the Th1 
phenotype predominantly provide the host with protective immunity to intracellular 
bacterial and viral infections. Type-1 Th cells are regulated by the transcription 
factors signal transducer and activator of transcription (STAT) 4 and T-box 
transcription factor (T-bet) (Zhu and Paul, 2010). T-bet is activated when IL12 is 
produced by dendritic cells and interacts with the IL12 receptor, also in response to 
IFNγ production by NK cells. Cytokines produced by Th1 cells activate phagocytic 
cells and favour the production of opsonising and complement-fixing antibodies, 
IgG1 and IgG3. This response provides optimum protection against intracellular 
bacterial and viral infections (Romagnani, 1999). Inadequate regulation of this 
response leads to chronic inflammation and granuloma formation (Crane and 
Forrester, 2005). Host immune responses to mycobacterial infection depend on the 
integrity of the type-1 cytokine pathway. It is well established that IFNγ is required 
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to control mycobacteria infection in a number of species (Cooper et al., 1993.Flynn 
et al., 1993). In human tuberculosis infection CD4+ T cells are critical in the 
regulation of infection, with CD8+ cells contributing to this control by producing 
IFNγ (North and Jung, 2004). This response aims to control infection by forming 
granulomatous lesions that control bacterial growth and can, in some cases of 
tuberculosis, clear the bacteria (Saunders and Cooper, 2000, Barnes, 1993). NK cells 
produce IFNγ in both human and bovine tuberculosis, resulting in increased 
mycobacterial killing by activated macrophages (Denis et al., 2007). Furthermore, 
mice deficient in IL12 show greater susceptibility to mycobacterium-induced 
diseases, more so in the absence of the IL12p40 subunit than of the IL12p35 subunit 
(Cooper et al., 2002). This may be related to the involvement of IL12p40 as a 
subunit of the heterodimeric cytokine IL23, this is described further in Chapter 3. 
Up-regulation of these cytokines and a cell mediated response is appropriate in the 
control of mycobacteria replication; however failure to correctly regulate the 
production of these cytokines leads to pathology caused by chronic granulomatous 
inflammation (Saunders and Cooper, 2000). This is typical of the immune response 
and pathology often described in the paucibacillary form of MAP infection (Clarke, 
1997. Smeed et al., 2010). 
In contrast to Th1, Th2 differentiation is activated in the presence of IL4, IL13, IL25 
and IL33.  IL4 have been shown to be produced by naive T cells following activation 
by DCs (Noben-Trauth et al., 2002). Another theory is the involvement of innate 
lymphoid cells (ILCs); a family of haematopoietic effector that have morphological 
characteristics of lymphoid cells but lack rearranged antigen receptors; a defining 
feature of adaptive immune cells. These cells share common functional and 
phenotypic features and are classified into three broad groups (summarised in table 
1.1). Furthermore, it is increasingly recognized that ILCs share conserved 
transcriptional mechanisms with CD4+ T cells as well as mirroring their Th cell 
counterparts in terms of cytokine production; thus ILC1s express T-bet, ILC2s 
express GATA3 and ILC3s express RORγt transcription factors that induce gene 
expression within these cells. Since ILC2s secrete the Th2 associated cytokines, IL5 
and IL13, in response to stimulation by I-25, IL33 and thymic stromal lymphopoietin 
(TSLP) produced by mast cells, epithelial cells and macrophages (Lund et al., 
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2013.Wolterink et al., 2012.Barlow et al., 2013), these cells may also produce IL4; 
however this is yet to be confirmed. IL4 induced STAT6 up-regulates the master 
transcription factor of Th2 cells GATA3 (GATA-binding protein 3), resulting in the 
initiation of gene transcription and secretion of IL4, IL5, IL13 and IL25 from Th2 
cells. These cytokines stimulate IgA and IgE production by B-cells as well as 
promoting eosinophil differentiation and activation (Van der Pouw Kraan et al., 
1998). Type-2 T cell immunity is typically seen during host response to helminthic 
infection and allergens; insufficient regulation of the Th2 phenotype has been 
identified in allergic reactions (Deo et al., 2010). Secretion of IL25 plays a key role 
in the maintenance of the Th2 phenotype (Wang et al., 2007). This cytokine is 
secreted by epithelial cells at mucosal surfaces in response to pathogen stimulation 
and aids the differentiation of naive T cells to Th2 cells. Furthermore this cytokine 
provides a feedback loop that up-regulates the production of IL4; continuing to 
stimulate the differentiation of naive T cells into Th2 cells (Wang et al., 2007). 
Expression of IL4 has been shown to inhibit Th1cell development and so directs cells 
towards type-2 immunity (Wurtz et al., 2004). During multibacillary (lepromatous) 
paraTB; high levels of acid fast bacilli in the gut tissues has been noted, with 
macrophage and B cell infiltration at the site of infection (Clarke, 1997). 
Multibacillary diseased animals can present with high levels of IgG plasma antibody 
and very low levels of IFNγ production; however this is not seen in all cases and 
antibody levels are often unreliable (Burrells et al., 1998b, Gillan, 2010.Collins et 
al., 2005). Disease occurs as a results of the formation of extensive and severe 
lesions that occur as a result of autoimmune reactions (Gillan et al., 2010.Perez et al., 
1999). These lesions contain few CD4+ T cells and an increased number CD8+ T 
cells which may attribute to the low levels of IFNγ found in these animals (Little et 
al., 1996, Burrells, 1999). Multibacillary animals are typically associated with Th2 
polarised immunity, showing up-regulation of Th2 associated responses and a lack of 
cytokines and IFNγ production found in Th1/17 cell responses. This results in a 
detrimental lack of macrophage activation and, although B cells are present and an 
antibody response is elicited it is unable to control the bacterial burden, thus the 
observed multibacillary pathology and eventual dissemination of infection (Navarro 
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In the presence of IL6, TGFβ and IL23 produced by macrophages and DCs, a Th17 
cell population is produced. Th17 cells excrete IL17A, IL17F and IL22 (Korn et al., 
2009). These cytokines are responsible for inducing inflammation, primarily by the 
stimulation of non-professional immune cells, including fibroblasts and epithelial 
cells, and macrophages to produce granulocyte colony-stimulating factor (CSF) and 
chemokines that subsequently recruit polymorphonuclear leukocytes, including 
neutrophils (Korn et al., 2009). Macrophage recruitment leads to an increase in IL6 
secretion, further stimulating the differentiation of naïve T cells to Th17 cells 
(Kimura and Kishimoto, 2010). This cell subset has been identified in various auto-
inflammatory diseases and was originally thought to be part of the Th1 immune 
response (Damsker et al., 2010). However, both IL4 and IFNγ have been shown to 
inhibit the development of the Th17 cell subset (Zhu et al., 2010). 
As noted above, regulation occurs throughout T-helper cell immune responses with 
each cell subset inhibiting/influencing development of other Th cell subsets. Whilst 
cytokines and transcription factors produced by each subset can redirect Th 




responses to a less polarised phenotype, all of these Th cell groups are also regulated 
by further subset of T cells known as adaptive T-regulatory (T-reg) cells (Zhu et al., 
2010). These cells exert suppression of other cell subsets by the production of 
suppressive cytokines TGFβ and IL10. (Romagnani, 2006). Human and mouse 
models of tuberculosis infection have shown an increased number of T-reg cells 
accumulating at the site of infection, preventing migration of immune cells to the 
site, ultimately reducing inflammation (Josefowicz et al., 2012). Furthermore, T-regs 
in mice and humans can inhibit the production of IFNγ in response to tuberculosis 
infection (Chen et al., 2007, Kursar, 2007) and have therefore been suggested as key 
influencers in tuberculosis pathogenesis. MAP pathogenesis in cattle differs to sheep 
in that a gradual progression from paucibacillary to multibacillary phenotype is 
observed - the trigger of transition from a Th1 to Th2 response is currently unknown 
(Coussens, 2004); however it has been suggested that this shift in immune response 
in bovine paraTB may be due to a population of MAP-reactive T-reg cells 
developing during subclinical, limiting Th1 responses to MAP antigens later in 




















Figure1.2 T-helper cell differentiation pathways and associated ILC subsets. 















1.9 Genetic and genomic studies of MAP infection 
1.9.1 Host gene expression studies 
 
Profiling of host gene expression during MAP infection has been the focus of 
numerous studies and such research is ongoing (Coussens, 2004.Coussens et al., 
2004.Lee et al., 2001.Smeed et al., 2010.Coussens et al., 2012).  It is thought that 
dysregulation of host gene expression contributes to the ineffective regulation of 
MAP-induced immune responses and subsequent pathology (Smeed et al., 2008). 
Investigation of gene expression at different stages of infection has provided insight 
into the biological pathways that are involved in immune responses to paraTB 
(Tanaka et al., 2005). Mostly, studies investigating the genetic basis of paraTB have 
been carried out in cattle with fewer studies looking at gene expression profiles in 
sheep. This may be due to the assumption that sheep profiles would be similar to that 
of cattle; Smeed et al. described the differential cytokine gene expression profiles in 
pathological forms of sheep paraTB. Here it was reported that paucibacillary and 
multibacillary infection is associated with the differential expression of IFNγ and 
IL10 respectively. Increased levels of pro-inflammatory cytokines including IL1β, 
IL18 and TNFα in both diseased groups is indicative of persistent inflammatory 
lesions (Smeed et al., 2008). In studies of cytokine gene expression in response to 
MAP infection in cattle, Lee et al. and Coussens et al have described comparable 
expression patterns of these cytokines in MAP infected calves compared with 
controls, with up-regulation of IFNγ and TNFα in infected animals (Coussens et al., 
2004.Lee et al., 2001).  A further study in sheep found that TNFα, IL1β and IL6 was 
significantly increased in infected ileum tissues when compared to uninfected 
controls (Alzuherri et al., 1997). Sweeney et al also found that progression of 
paraTB to clinical stages in cattle was associated with reduced expression of IFNγ at 
the site of infection and suggested that if the immune system could be manipulated to 
increase IFNγ in the later stages of infection, resistance in cattle might be enhanced 






1.9.2 Host genomic studies 
 
With the advance of next generation sequencing (NGS) technologies, microarray 
analysis, RNA-seq and genome wide association studies (GWAS) have also been 
utilised in the identification of genes which may play a role in the severity and/or 
progression of paraTB. Coussens et al. investigated the differences in gene 
expression profiles of peripheral blood mononuclear cells (PBMC) from subclinical 
and clinical paraTB positive cattle following in vitro stimulation with MAP. The 
expression profiles were compared using a bovine-specific cDNA microarray 
platform with 721 expressed sequence tags (EST) representing known genes. It was 
shown that stimulation of PBMCs from clinically infected cows with MAP decreased 
expression of 83 genes, including genes encoding fibroblast growth factor and Lyn B 
protein kinase, and only 8 genes were recorded to have a modest up-regulation. In 
contrast, stimulated PBMCs from subclinically infected cattle resulted in an up-
regulation of 71 genes and only 16 genes were down-regulated, concluding that the 
gene expression profiles from clinically and subclinically infected cattle are notably 
different following exposure to MAP (Coussens et al., 2002). Microarray analysis of 
ileal gene expression in sheep with clinical paraTB identified significant differential 
expression of 36 genes; variation in cellular composition of multibacillary and 
paucibacillary infected sheep were reflected in difference of gene expression 
between the two groups. The chemokine CXCL10 was significantly raised in 
paucibacillary animals; this gene is associated with chemo-attraction of type 1 T cells 
and would explain T cell infiltration common in paucibacillary infection. IGF2R 
plays a key role in the activation of TGFβ, both genes were found to be up-regulated 
in multibacillary animals (Smeed et al., 2010). 
Discussions from such studies also highlight the limitations of NGS when trying to 
identify genetic variations that are of consequence to phenotype. Recently, Zare et al. 
investigated susceptibility to paraTB infection in Jersey cattle, the second most 
common breed of dairy cattle in America, using the bovine SNP50 BeadChip 
platform. Sample groups consisted of ‘cases’ that tested positive for MAP infection 
by ELISA and faecal culture, and controls that were free of MAP in results from both 
tests, from an initial pool of  ~5000 cattle.  Comparative analyses of results from the 
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SNP50 platform found that, although many SNPs were identified in both groups, the 
significance of polymorphisms were relatively low. This was explained as the 
complexity of genetic architecture associated with susceptibility to paraTB. NGS 
studies have the power to identify a vast array of genetic information and identify 
numerous variants; however the ability to identify which of these variants has an 
influential effect on disease phenotype and those which are of biological relevance in 
a whole animal system is limited. In order to overcome this limitation, larger scale 
studies are required to identify the most frequent and significant variants/SNPs 
present between infected and non-infected groups (Zare et al., 2014). In the case of 
paraTB, the number of samples required from naturally infected animals for such a 
study is often difficult to obtain; therefore smaller scale studies are used as an initial 





1.10 MAP and human inflammatory diseases 
 
The cause of the differential pathology of paraTB is currently unknown; however as 
previously noted, several studies have suggested that the host genetics play a key role 
in the clinical outcome of mycobacterial infection (Fortin et al., 2007. Coussens, 
2002). ParaTB pathology is associated with differential T cell activation in sheep, 
with genes that control this activation playing a key role in the pathological outcome 
of infection. Similarities in gene expression patterns, immune responses and 
pathology is noted when comparing human diseases such as TB, leprosy and 
inflammatory bowel disease to paraTB (Neurath, 2014, Sartor, 2005. Ashenafi, 
2014). These similarities are not always surprising given the presence of 
mycobacterial causative agents in TB, leprosy and paraTB. These human diseases are 
also associated with Th cell differentiation and it is thought that genetic and 
transcriptional variants of the genes that influence T cell differentiation in human 
diseases may also play a role in the pathological outcomes of paraTB. This section 
describes TB, leprosy and Chrone’s disease in humans and highlights the genes that 





Tuberculosis is a major health issue throughout the world causing more deaths than 
that of any other single infectious agent disease. A report was released by the World 
Health Organisation stating the TB situation in 2013. Approximately 9 million cases 
of ill health caused by TB were reported with 1.5 million of those resulting in death 
from the disease. Similar patterns are seen in paraTB whereby many animals are 
infected but do not become diseased. Although TB incidence is falling globally, 
reported at a rate of around 1.5% per year between 2000 and 2013, this infectious 
agent is still of concern (www.who.int). Mycobacterium tuberculosis is the causative 
agent of human tuberculosis; an aerobic, intracellular pathogen which infects lung 
tissue rich in oxygen. From the site of infection the bacterium can migrate 
throughout the body, primarily disseminating across the lungs and regional lymph 
nodes, via the blood or lymphatics. Similar to MAP, many individuals infected with 
TB do not show clinical signs and remain asymptomatic (Wang, 1999). Similarities 
are also noted in the immune responses to TB and paraTB infection; M. 
tuberculosisis recognised by antigen receptors on the surface of macrophages and is 
phagocytosed, this contact between host and pathogen triggers the host’ adaptive 
immune response and triggers differential T cell polarization (Ernst, 1998). In active 
(pathological) TB, a Th1 cell mediated immune response develops with an influx of 
lymphocytes and activated macrophages to the site of infection, leading to the 
formation of granulomatous lesions; similar to that seen in paraTB pathology. 
Although the cell mediated response is necessary for the control of M. tuberculosis 
infection; it is also responsible for much of the pathology associated with TB 
(O'Garra et al., 2013). Host antibody mediated immune responses provide poor 
protection due to the intracellular nature of M. tuberculosis and its ability to evade 
recognition whilst residing within macrophages. Although highly infectious, only 
10% of the infected human population progress to active tuberculosis (Moller and 
Hoal, 2010). The defining factors which lead to pathology in some infected humans 
whilst others remain asymptomatic are unknown (O'Garra et al., 2013); as seen with 
paraTB. Genetic predisposition is thought to play a key role in the determination of 
symptomatic and asymptomatic, as well as tuberculoid/lepromatous, outcomes 
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during TB infection in humans (Abel and Casanova, 2000). Individuals susceptible to 
TB infection are often diagnosed with a rare human syndrome known as Mendelian 
susceptibility to mycobacterial disease (MSMD) (Qu et al., 2011).  Most commonly 
affected by TB and salmonella infections, these patients have an increase 
susceptibility to even non-pathogenic mycobacteria. Genetic mutations in the genes 
of the IL12/IL23/IFNγ axis including IL12RB1, IFNGR1 and IFNGR2 have been 
identified in MSMD patients (Schurr, 2011). A functional 874A>T SNP found in 
IFNG gene was associated with TB infection, this variant reduces IFNγ induction 
due to inferior binding afforded to NFκB (Filipe-Santos et al., 2006). It is assumed 
that many contributing genetic factors are associated with TB/MSMD susceptibility, 
many of which are associated with IFNγ inducing pathways (Bellamy, 1998, Al-
Muhsen, 2008); however the specific functional involvement of many of the variants 
identified in these genes is yet unclear. IL12RB1 is crucial in the induction and 
stabilization of efficient Th1 responses. This cytokine receptor is required for 
IL12/IL23 signalling and subsequent Th1/Th17 activities; including induction of T-
bet, a transcription factor that functions to stabilise Th1 cell activity by initiating 
transcription of the IFNγ gene (described in more detail in chapter 6). Robertson et 
al. have described a splice variant of the IL12RB1 gene that occurs in response to TB 
infection. The novel isoform of human IL12RB1 lacks a transmembrane domain and 
was found to increase DC migration and activation of TB specific T cells (Robinson 
et al., 2010). Another study found that genetic variants of IL12RB1 confer genetic 
susceptibility to TB and contribute to severity of disease in a Japanese population 






Leprosy, a chronic inflammatory condition caused by infection with Mycobacterium 
leprae (M. leprae), shows a wide spectrum of clinical features. Differential 
pathology is associated with differential T-cell activation, similar to that seen in 
paraTB, with developing symptoms of granulomata formation occurring in the 
respiratory tract, skin and nerves. At one end of the spectrum is the tuberculoid form 
(T-lep) and at the other end is lepromatous leprosy (L-lep). Similarly to 
paucibacillary form of paraTB, T-lep is characterised by predominance of CD4+ T 
cells, high levels of IFNγ and Th1 cell mediated immune responses stimulated by M. 
leprae; patients affected with the T-lep form of disease show higher resistance to 
infection with less severe clinical manifestations and is often described as ‘self-
curing’ (Moubasher 1998. Modlin, 1994). Patients infected with L-lep form of 
disease are comparable to that of multibacillary paraTB infected animals; 
characterised by a predominant CD8+ T cell infiltration and Th2 cytokine 
production. High numbers of infected macrophages and low Th1/cell mediated 
immune responses mean that those affected by L-lep form of disease are unable to 
contain the infection and disease progression occurs (Modlin, 1994). Studies 
investigating the factors associated with susceptibility and resistance of host species 
to M. leprae have identified candidate genes, many of which contain polymorphisms, 
conferring susceptibility/protection to leprosy. Most of the genes identified are 
regulators of immunological events involved in M. leprae. A toll-like receptor 2 
(TLR2) mutation resulting in a Arg>Trp substitute in a conserved region of the 
protein was found to be present in L-lep patients but not T-lep patients or control 
subjects, indicating a role for this mutation in susceptibility to L-lep  (Kang and 
Chae, 2001). Smeed et al found that TLR2 expression was greatly up-regulated in 
multibacillary lesions from paraTB infected sheep when compared with 
paucibacillary infected and uninfected control animals; suggesting that TLR2 
induced signalling pathways are important in lepromatous pathogenesis (Smeed et 
al., 2010). Many of the genes associated with the differential pathologies in leprosy 
are regulators of the Th1/Th2 cell paradigm and some of these genes confer 
susceptibility to disease (Fitness et al., 2002). 
31 
 
1.10.3 Crohn’s Disease 
 
The clinical outcomes of MAP infection have been associated with differential T cell 
activation and is similar to that seen in human intestinal pathologies including 
Crohn’s disease (CD) and ulcerative colitis (UC) (Kobayashi et al., 2008.Grant, 
2005). 
CD and UC are the principle types of inflammatory bowel disease (IBD) in humans 
and are of unknown aetiology. CD is driven by the production of IL12 and IFNγ in a 
predominant Th1 associated response, whereas UC is driven by the production of 
IL13 in a predominantly Th2 associated immune response; immune dysregulation 
and uncontrolled production of pro-inflammatory cytokines leads to inflammation of 
the gastrointestinal tract in both CD and UC (Lennard-Jones, 1989.Bouma and 
Strober, 2003). IL25 is a potent activator of Th2 responses in the intestine; blocking 
IL25 signalling protects against gut inflammation in a mouse model of colitis by 
reducing IL13 production (Camelo et al., 2012). It has also been shown that IL23 
drives T cell mediated intestinal inflammation and promotes inflammatory Th17 
activity (Yen et al., 2006).  
The pathology and immunology of the IBD disease forms are comparable to that of 
paraTB (Davis and Madsen-Bouterse, 2012a). Both paraTB and IBD result in the 
breakdown of the intestinal barrier, whereby bacterial invasion of gut tissues and 
chronic inflammation contribute to the persistent continuation of disease (Chacon et 
al., 2004). Although CD is considered to be an autoimmune disease; increasing 
evidence suggests that there may be an infectious stimulant (Sartor, 2006). 
Controversially, many studies have stated that infection with MAP may lead to 
immune dysregulation and inflammation in Crohn’s disease patients. Isolates of 
MAP found in animals are linked to active paraTB; whereas the isolation of MAP 
from human specimens is yet to be consistently confirmed as the potential cause of 
CD (Sartor, 2005). 
It is thought that MAP transmits from infected animals to humans via the 
consumption of milk, dairy products and possibly contaminated water sources as 
described in figure 1.3. Due to the resilience of MAP in the environment; the 
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potential of the bacterium to infiltrate water supplies is highly possible (Pierce, 
2009). Members of the M. avium complex (MAC) have been shown to be resistant to 
chlorine and other disinfectants (Taylor et al., 2000). Normal water treatment 
processes involve filtration and disinfection, usually by chlorination; however these 
processes have little or no effect on mycobacteria (Whittington et al., 2005.Hilborn 
et al., 2006). MAP can be detected by IS900 PCR in raw and pasteurised milk 
(Ellingson et al., 2005.Paolicchi et al., 2012), and commercial cheese samples (Clark 
et al., 2006). An extensive study carried out from 1990-1994 across England and 
Wales found that 7% of bottles and cartons of retail pasteurized cow’s milk tested 
positive for IS900 by PCR (Millar et al., 1996). 
Schwartz et al. investigated the presence of MAP in tissue specimens from CD 
patients and healthy control subjects using short term culture media; 37% of CD 
samples tested positive whilst only 5.6% of control specimens contained viable MAP 
(Schwartz et al., 2000). In a similar study, Bull et al. detected MAP in 42% of CD 
patients and 9% of control subjects using a mycobacterial growth indicator tube; this 
was confirmed as MAP by IS900 PCR (Bull et al., 2003). One study used PCR and 
culture methods to identify MAP in humans with CD, ulcerative colitis (UC) and 
healthy individuals. Results found that MAP was present in 46% of individuals with 
CD, 45% with UC and 20% of healthy individuals (Naser et al., 2004). Furthermore, 
Nazareth et al. found the prevalence of MAP detected by IS900 PCR to be 68% in 
peripheral blood samples from 202 IBD patients (Nazareth et al., 2015). It is yet 
unknown whether MAP can influence the development of CD or whether the 
presence of MAP in IBD patients occurs due to a loss of protective barrier function 
in these cases, i.e. is a secondary effect. Other studies have used GWAS analyses and 
have suggested that there is no clear association between MAP and Crohn’s disease 
and that intestinal inflammation is more likely due to an autoimmune dysregulation 
caused by changes in the microbiome (Chacon et al., 2004. Davis and Madsen-
Bouterse, 2012b). 
Studies have been carried out to investigate genetic susceptibility to Crohn’s disease 
in humans and have found that genes associated with immune regulation confer 
susceptibility to IBD. The NOD2 protein (also known as CARD15) is present in the 
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gut tissues and plays an important role in recognizing bacterial molecules and 
stimulating immune reactions (Philpott et al., 2014); variants identified in this gene 
have been associated with susceptibility to CD, although the specific functions of 
these variants are unclear (Ogura et al., 2001. Hugot et al., 2001). NRAMP1 
(encoded by SLC11A1 gene) plays an important role in innate immunity, preventing 
bacterial growth within macrophages during early stages of infection. When 
investigating nine SLC11A1variants in biopsy tissues from CD patients, three 
polymorphisms were significantly associated with CD when compared to healthy 
controls; speculating that over expression of the mutated alleles in CD patients could 
lead to increase severity of disease (Gazouli et al., 2008). Similar variation has also 
been described in paraTB infected cattle; significant association of SLC11A1 
microsatellite frequency was found in paraTB when compared with uninfected 
controls (Pinedo et al., 2009). The IL23R gene has been described as the 
‘inflammatory bowel disease gene’ as this gene has been associated with IBD in 
several studies. This gene is required for efficient Th1/Th17 cell responses and 
production of subsequent cytokines via stimulation of these cells by IL12/IL23 (Yen 
et al., 2006). The role of this gene in human disease is described in greater detail in 
section 4.1. 
Common disease pathways are found in paraTB and IBD and it is suggested that 
anti-MAP therapies have the potential to be utilised in prevention and/or treatment of 
CD. The evidence of MAP present in CD patients and comparable pathology 
supports association rather than causality; therefore further investigation is required 






Figure 1.3 Potential sources of MAP transmission from animal to 
human. Humans can become infected from consumption of milk, 
dairy products and contaminated water supplies. Image adapted from 
(Chacon et al., 2004). 
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There is a recurring link between the differential polarization of T cell subsets and 
the outcomes of pathology in human inflammatory diseases (Romagnani, 1996). 
Particularly in relation to genetic variants within genes that influence T cell 
polarization. Information collected from studies on human diseases has provided a 
basis for the hypothesis that genes which influence differential T cell polarization are 
crucial to the differentiation of immune response to paraTB infection in sheep, and 




1.11 mRNA transcription and alternative splicing 
 
The effects that variation within immune regulating genes can have on subsequent 
immune responses and disease phenotype have been described. This section 
describes the ways in which this variation can occur and how changes in protein 
structure, as a result of gene sequence variants, can affect downstream activity. 
Before synthesis of particular proteins can occur, an mRNA molecule corresponding 
to that protein must be synthesised by transcription; this process occurs in the 
nucleus of cells. In eukaryotes, RNA polymerase II is required for transcription of all 
genes that encode proteins. In order for RNA polymerase II to imitate transcription at 
the promoter region of a gene it requires a series of additional proteins, including 
transcription factors, which function to position the polymerase at a specific DNA 
template and separate the DNA strands; allowing transcription to begin. Further 
proteins recruited during initiation of transcription are responsible for histone 
modification and chromatin-remodelling (Chaffey, 2003). Certain transcription 
factors function to regulate the rate at which a particular gene is transcribed – 
described in more detail in chapter 7. Once the RNA polymerase II assembled with 
the proteins required to initiate transcription, now termed the transcription initiation 
complex, a series of conformational changes occur to tighten the binding of the 
polymerase to the DNA template; following which the polymerase disengages from 
the transcription factors and begins elongation of the mRNA transcript. Once 
elongation is underway, the transcription factors release from the DNA and can 
initiate further rounds of transcription.   
During the elongation stage of transcription the RNA undergoes three particular 
processing events; 5’ end capping, intronic splicing (alternative splicing) and 
cleavage/polyadenylation of the 3’ end. Following these processes the newly 
synthesised mRNA is transported from the nucleus, through nuclear pore complexes, 
into the cytosol where subsequent protein translation is initiated (Chaffey, 2003).  
Alternative splicing (AS) is a crucial mechanism for gene regulation and the 
generation of proteomic diversity; leading to synthesis of different protein products 
that function in a vast number of cellular processes including cell growth, cell 
37 
 
differentiation and cell death. Splicing is carried out by the spliceosome; a large 
structure which functions to accurately recognise the splice sites of a gene and 
catalyse the splicing reaction. Pre-mRNA splicing involves the removal of introns 
from the mRNA precursor. Decisions of which sequences of a gene are to be 
included in the final mRNA transcript rely on the ability of the splicesome to 
recognise specific splice sites located in the intron-exon boundaries of the pre-
mRNA (Martinez and Lynch, 2013). Selection of exons to be included in the mRNA 
transcript depends on the positioning of the cis-regulatory elements - DNA sequences 
in the vicinity of a gene that are required for gene expression via complex networks 
of protein-DNA and protein-protein interactions. Cis-elements include sequences 
within exons such as exonic splicing enhancers (ESEs) and exonic splicing silencers 
(ESSs) as well as intronic splicing enhancers (ISEs) and intronic splicing silencers 
(ISSs). AS can be regulated at different steps of the spliceosome assembly by 
different splicing factors, most of which rely on cis-acting elements (Chen and 
Manley, 2009). AS refers to any variable of transcript that results from the 
inclusion/exclusion of an intron, exon or portion-thereof from a given gene. The 
main forms of variation that occur as a result of alternative splicing are shown in 
figure 1.4. The most common form is cassette-type alternative exon, also known as 
exon skipping. Intron retention in human transcripts is usually found in the 
untranslated regions (UTR) and has been associated with weaker splice sites and the 
regulation of cis-regulatory elements (Sakabe and de Souza, 2007). Differential 
splicing in the 5’ or 3’ UTR can alter the structure or presence of regulatory motifs 
including miRNA binding motifs and promoter binding sites, resulting in changes to 
mRNA stability, expression and/or translation; thus in turn has a profound effect on 
the expression pattern of resulting proteins (Martinez and Lynch, 2013). Alternative 
selection of exon splice sites often results in changes to protein structure which in 
turn can lead to changes in protein function. Protein changes also occur as a result of 
mutually exclusive alternative exon selection (Pohl et al., 2013). Conservation of 
specific alternative splicing patterns within a gene indicates evidence of biological 
function, as non-functional isoforms are more likely to be subject to negative 
selection (Keren et al., 2010). In particular, it has been shown that alternative 
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splicing plays a crucial role in the function and mediation of T cell and adaptive 
immune responses (Martinez and Lynch, 2013). 
 
  
Figure 1.4 Main forms of alternative splicing events. A) constitutive 
splicing; B) mutually exclusive exons; C) cassette alternative exons; D) 
alternative 3’ splice site; E) alternative 5’ splice site; and F) intron 
retention. (Wang et al., 2015). 
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The adaptive immune response has the ability to respond efficiently to an array of 
stimuli including pathogens, allergens and tumours; and utilises AS mechanisms to 
create multiple and distinct mRNA transcripts with diverse functions. AS isoforms 
occur in a tissue specific or stimuli dependant manner and function to regulate 
immune responses; common AS genes include cytokines and cytokine receptors 
(Wang et al., 2015). Alternative splicing of cytokines and associated signal 
transduction molecules results in altered structure and function these molecules and 
can have a detrimental effect on subsequent downstream signalling and immune 
outcomes (Atamas, 1997). Splice variants often result in functional antagonists of 
their wild-type cytokine or can be expressed as soluble or membrane bound proteins. 
Examples include; an identified splice variant of IL10, IL10δ3 that was observed in 
leukemic cells from children with relapsed acute lymphoblastic leukaemia (ALL). 
Expression of this variant was found to correlate with a significantly better response 
to chemotherapy and clinical outcome of disease in children, indicating that the 
spliced isoform of IL10 may have a critical role in modulating the function of wild-
type IL10 (Wu et al., 2005). The IL4 receptor alpha subunit (IL4Rα) exists in two 
forms; one membrane bound and one soluble form which lacks the exons for the 
transmembrane and intracellular regions. It has been shown in mice that the soluble 
form can inhibit IL4-mediated cell proliferation and upregulation of IL5 by T cells; 
furthermore levels of IL-4, in the presence of IL4Rα isoform, was altered in 
asthmatic patients when compared to healthy controls (Atamas et al., 1996. Kruse et 
al., 1999. Bergin et al., 2006). 
These studies are just two examples of a vast array of identified AS variants in 
cytokine and cytokine receptor genes; and highlight the profound effects that AS 
variants can have on immune activity and outcomes of clinical disease. There is little 
known of the presence of transcript variants in MAP infected animals or the 
association of AS variants with the pathological outcomes of disease, particularly 
within genes that influence the differential Th cell polarisation. This project has 
investigated the presence of AS transcript variants in genes that influence Th cell 
polarization, and have been associated with Th polarization in human diseases, in the 
two pathological forms of sheep paraTB; including cytokine, cytokine receptor and 
transcription factor genes. 
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1.12 Aims and Hypothesis 
 
T cell polarizing cytokines determine the differentiation of Th cell mediated immune 
responses and differential expression of these cytokines are associated with the 
different immune responses observed in pathological, multibacillary and 
paucibacillary, forms of paraTB. This study has primarily focussed on the IL23 and 
IL25 (also known as IL17E) cytokines and their receptor complexes; 
IL23R/IL12RB1 and IL17RB/IL17RA respectively. These cytokines have been 
implicated in other species, as key players in the polarization of T cell differentiation, 
driving adaptive Th1/Th17 and Th2 immune responses. These cytokines and 
receptors are associated with disease characterised by gut pathology and/or 
inflammation including TB, leprosy and IBD (Dubinsky, 2007.Kobayashi et al., 
2008). It is therefore suggested that these genes may influence the T cell immune 
responses that contribute to the pathological outcomes of paraTB in sheep. In order 
to obtain a more in depth view of the Th cell differentiation pathways, this project 
has also investigated the transcription factors that function to initiate expression of 
genes that are associated with Th cell profiles. 
The aims of this project were to: 
- Identify genetic variants in the IL23/IL25 cytokine receptor genes by 
obtaining and aligning gene sequences from sheep infected with the 
multibacillary and paucibacillary forms of paraTB, using reverse transcription 
PCR and cloning methods. Sequences were analysed for differential exon 
usage that may play a role in the biology of disease. 
 
- Investigate expression levels of full length gene transcripts and variant 
transcripts of the IL23 and IL25 cytokine and cytokine receptor genes using 
real-time PCR analysis and determine whether differential expression of these 
genes, and/or variants therein, are correlated with the pathological outcomes 




- Investigate expression levels of full length gene transcripts and variant 
transcripts of transcription factors associated with Th1, Th17 and Th2 cell 
differentiation, using real-time PCR analysis and determine whether 
differential expression of these genes, and/or variants therein, are correlated 
with the pathological outcomes of sheep paraTB. 
By investigating the above points, this project will contribute to the overall 
understanding of how the sheep immune system responds to MAP infection. 
Information obtained from the chosen genes aims to determine whether these genes 
are related to the clinical outcome of paraTB. 
The hypothesis tested was that differential gene expression and/or genetic variants of 
IL23 and IL25 cytokines, their receptors and transcription factors associated with 
Th1, Th2 and Th17 cell subsets contribute to the differential polarization of the T cell 























2.1 Experimental animals and tissues 
 
Animals were outbred Blackface female sheep with naturally acquired MAP 
infection. All sheep were between the ages of two and five years and were assessed 
for the presence of gastrointestinal strongyle nematode infection; details of the ID 
number, age, breed and faecal egg count (FEC) of these sheep are shown in table 2.1. 
Animals were euthanized and diagnosis of paraTB was confirmed by physical 
examination at post-mortem, haematoxylin & eosin and Ziehl-Neelsen 
histopathology and the presence of MAP specific insertion sequence IS900, by PCR 
using extracted genomic DNA (gDNA). There were six animals in each of the three 
groups; multibacillary (M), paucibacillary (P) and uninfected controls (C). Ileocecal 
lymph nodes (ILN) were removed immediately after post-mortem and approximately 
~0.5g was placed into five volumes of RNAlater (Ambion, UK) that were then 
incubated at 4oC overnight before storing at -80oC. All animal experiments were in 
accordance with, and approved by, the Moredun Research Institute Experiments and 
Ethics Committee and conducted under the Animals (Scientific Procedures) Act 
1986 project Licence. 
2.2 IS900 PCR 
 
Genomic DNA was extracted from approximately 20mg of ileocecal lymph node 
tissue from each animal sample under sterile conditions. The Wizard® SV Genomic 
DNA Purification System (Promega Ltd) was used to extract DNA from samples as 
stated in manufacturer instructions. Concentrations of each DNA sample were 
measured using a NanoDrop ND-1000 spectrophotometer (Labtech International 
Ltd). ForIS900 PCR detection of MAP DNA, primers were used as stated by Eishi et 
al. and Bauerfeind et al.(Bauerfeind et al., 1996. Eishi et al., 2002). All PCR 
reactions were performed using FastStartTaq DNA Polymerase (Roche Diagnostics 
Ltd.) as stated in manufacturer instructions, using 500ng of gDNA and 0.2μM of 
each primer. The PCR cycle consisted of an initial denaturation step of 5 min at 
95°C, followed by 35 cycles of 15 sec at 95°C, 15 sec at 55°C, 58°C, 60°C and 62°C, 
and 30 sec at 72°C, and a final elongation step of 72°C for 10 minutes. PCR products 
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were visualised on a 2% agarose gel before being purified, cloned and sequenced 
(see chapter 2 sections 2.4.5 – 2.6.5).  
Sheep of similar age that presented no signs of clinical pathology and were negative 
for IS900 were considered uninfected controls (IS900 PCR/analysis carried out by 




*FEC counts and categorisation from SCOPS manual (Abbot et al., 2009) 
Table 2.1 Details of ID number, age, breed and FEC of sheep used in this study. 
 
2.3 RNA extraction and RNA quality analysis 
2.3.1 RNA extraction 
 
Sheep ID Breed Age (years) FEC* 
(eggs/g) 
    
SH139 Blackface 3 <250 
SH140 Blackface 3 <250 
SH146 Blackface X Bleu du Maine 2.5 <750 >250 
SH204 Blackface 4.5 <750 >250 
SH190 Blackface 3 >750 
SH199 Blackface 2 <250 
SH107 Texel X Blackface 2.5 <750 >250 
SH147 Blackface X 2 <250 
SH155 Blackface 3 <750 >250 
SH160 Blackface X 3 <250 
SH188 Blackface X Bleu du Maine 4 >750 
SH205 Blackface 4 <750 >250 
K207 Blackface 2.5 <250 
K208 Blackface 2.5 <250 
K213 Blackface 2.5 <250 
K224 Blackface 2.5 <250 
K227 Blackface 2.5 <250 
K229 Blackface 2.5 <250 
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RNA was extracted from lymph nodes using the RiboPure™ RNA extraction kit 
(Ambion, UK), according to the manufacturer’s instructions. Lymph node, stored at -
80oC in RNAlater™, was thawed and a piece of tissue was cut (20mg). Tissue 
samples were homogenised in 1ml of TriZol and proteins were precipitated with 
200μl chloroform for 5 min at room temperature. Samples were centrifuged at 12,000 
x g for 15 min at 4oC before transferring the aqueous phase (top layer), containing 
RNA, to a fresh microcentrifuge tube. One sample volume of 70% ethanol was added 
to each reaction to precipitate the RNA. RNA was bound to spin column membrane 
as stated in manufacturer’s protocol. 
2.3.2 DNase treatment 
 
DNase treatment was carried out in order to prevent genomic contamination of RNA 
samples. According to the On-column PureLink®DNase treatment protocol, 80μl 
DNase mastermix was prepared for each sample. Each mastermix contained 8μl 10x 
DNase I Reaction Buffer, 10μl resuspended DNase and 62μl RNase free water. 
Following binding of RNA to the spin column, 80μl DNase mastermix was added 
and columns incubated at room temperature for 15 min. Following 15 min incubation 
column membranes were washed with buffer I and II as stated in manufacturers 
protocol. RNA samples were eluted in 60ul RNase-free water. 
2.3.3 Assessment of RNA quality and concentration 
 
The concentration of RNA in each sample was measured using the Nanodrop 1000 
spectrophotometer (Nanodrop Technologies, Inc). RNA quality was assessed using 
Agilent®Bioanalyzer with a RNA 6000 Nano LabChip kit (Agilent Technologies). 
This provides information of RNA integrity based on degradation level. This is 
measured on a scale of 1-10 for all RNA samples and each sample should contain a 
score of at least 7 RNA integrity number (RIN). RNA concentrations (ng/μl) and 









RNA Concentration (ng/μl) 
 
RIN 
   
SH139 1204.1 7.7 
SH140 539.8 7.4 
SH146 1165.7 8 
SH204 2308.4 8.6 
SH190 2344.6 8.3 
SH199 1736.4 8.6 
SH107 1348.6 8.4 
SH147 1355.8 7.9 
SH155 2004.9 7.9 
SH160 1529.8 7.9 
SH188 1064.7 7.5 
SH205 2240.7 8.7 
K207 1858.9 8.8 
K208 1344.3 8.8 
K213 454.9 8.7 
K224 1998.2 8.5 
K227 1945.6 8.8 
K229 1750.4 9 
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2.4 Reverse transcription polymerase chain reaction (RT-PCR) 
2.4.1 SuperScript™ II RT cDNA synthesis 
 
Complementary first-strand DNA was synthesised with SuperScript™ II RT using 
oligo-dT (Invitrogen, UK cat no. 10777-019). Each reaction contained 1μg total 
RNA, 1μl oligo-dT, 1μl 10nM dNTP mix, made up to 12μl with deionised water. 
Reactions were heated to 65oC for 5 min then chilled on ice before adding 4μl 
5xFirst-Strand buffer, 2μl 0.1M DTT, then incubated at 42oC for 2 min. 1μl of 
SuperScript™ II was added before final incubations of 42oC for 50 min and 70oC for 
15 min to inactivate the reaction. cDNA samples were either diluted 1:10 in 
deionised water or stored as undiluted samples at -20oC to be used as template for 
amplification in RT-PCR and standard curve analysis in real-time quantitative PCR 
(RT-qPCR). 
2.4.2 RT-PCR Primer Design 
 
Primers were designed for genes of interest based on ovine (predicted) sequences 
using Primer-BLAST, available from National Centre for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast), and NetPrimer 
(http://www.premierbiosoft.com/netprimer/index.html) software. Primers were 
selected using the following criteria; GC content between 40-65%, primer length of 
19-25 base pairs, minimal secondary structure and  self-complementarity. For genes 
greater than 800bp, overlapping sections were amplified individually using several 
primer pairs. Once gene section consensus gave sequence for the full length of the 
gene, primers were designed to obtain the full gene sequence in a single 
amplification. Primer sequences for full length gene amplification are shown in table 
2.3. 
2.4.3 Primer optimisation 
 
Each primer set was optimised for use in RT-PCR using FastStart Taq DNA 
polymerase (Roche Applied Sciences) or Platinum Taq DNA polymerase High 
Fidelity (Invitrogen by Life Technologies) with reactions prepared as stated in 
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manufacturer manuals. Nested RT-PCR replaced required volume of DNA template 
with 1μl of PCR product from first-round amplification. Primers were optimised for 
annealing temperature (using a range of 45-65oC) and elongation time period, 
calculated to 1min/kb.  
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IL23R For AAATTGACAGGCAGCAGTGAGG 55 2030 
 Rev TCTTCAGATTTCAAGGCAGGTTCT   
 For* AAGGAAGACGTGAGGCCGATAC 62 2000 
 Rev* TTTCAAGGCAGGTTCTGACTACAC   
     
IL12RB1 For ACCGGCAGCACAGAAGTTCA 55 2382 
 Rev GCCCTCTCTGAACCTCACTG   
     
IL17RB For AATAAGAGCGCGCGGCCCGAAG 55 1630 
 Rev ACTTCAGATTCTCACAGACACTT   
 For* CGGCCCGAAGCCGATCCGGA 60 1575 
 Rev* GGGTCAGAAGGCTTTAGGG   
     
IL17RA For TTCCCGTGGTTCACATCGAG 52 539 
 Rev CAGGGTGACCGTGATGTGG   
 3’ RACE ACCGTCCACCACCTGCCTAAGCCCA 60  
 3’ RACE* ACATCACCGTGGAGACCCTTGAGG 68  
 5’ RACE TCCATGGGGTGAAGCTCAGCCGCAG 60  
 5’RACE* CGTCAGGGATGGGCTTAGGCAGGT 68  
 5’ UTR For CTGTCTGCAAATACAAGGTCCTG 52 399 
 5’ UTR Rev TCCACTCGATGTGAACCACG   
Table 2.3 Detail of primers used to obtain full gene sequence. * depicts nested primer sets. 
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2.4.4 Agarose gel electrophoresis and PCR product purification 
 
Agarose gels were prepared to visualise DNA fragments from PCR products and 
plasmids containing DNA inserts. PCR products were visualised on 1% gels. Gels 
were prepared by adding agarose (Sigma-Adrich) to 1x Bionic Buffer (Sigma-
Aldrich) (1% = 1g:100ml) and heating until fully dissolved. GelRed nucleic acid gel 
stain (Cambridge Bioscience) was added to the dissolved agarose (1μl/100ml) to 
visualise PCR products. 2% agarose gels were adjusted accordingly. Electrophoresis 
was run at a constant 130V until DNA separation was achieved. Gels were 
viewed/images captured using an ultraviolet transilluminator with FluorChem™ 
imaging software. PCR products were separated by 1% agarose gel electrophoresis at 
130v. Primers which gave a band of expected size were regarded as useable. PCR 
DNA products were then purified using either; Qiagen MinElute PCR purification 
Kit or excised from the agarose gel and purified using Qiagen MinElute Gel 
Extraction Kit (Qiagen, Crawley, UK). Protocols were followed as stated in Qiagen 
‘bench-top’ user manual, centrifuge method. PCR products were eluted into 10μl EB 






2.5 Cloning and sequencing of PCR product 
2.5.1 pGEM®-T Easy Vector ligation 
 
Purified PCR product was ligated into Promega pGEM®-T Easy Vector (Promega, 
UK) according to manufacturer’s protocol. Each reaction contained; required volume 
of PCR product to give a 1:5 DNA to vector ratio, 5μl 2xrapid ligation buffer, 0.5μl 
pGEM®-T easy vector (25ng), 1μl T4 DNA ligase (3 Weiss units/μl), made up to 
10μl with deionised water. Ligations were either refrigerated overnight or incubated 
at room temperature for 1 hr before transformation into competent cells. 
 
2.5.2 Transformation into JM109 cells 
 
Ligated pGEM®-T easy vector samples were transformed into JM109 High 
Efficiency Competent cells (Promega, UK) by adding 2-10μl of ligated reaction to 
20μl of cells and chilling on ice for 20 min. Samples were heat shocked for 45 sec at 
42oC before returning to ice for a further 2 min. Cell transformations were suspended 
in 980μl room temperature SOC (super optimal broth with catabolite repression) 
medium and incubated at 37oC shaking for 1.5hr. Reactions were plated onto 
LB/Amp/IPTG/XGAL plates and incubated at 37oC overnight. This method was used 
to allow for blue/white selection of colonies. The presence of white colonies 
indicates uptake of vector/DNA insert. Single white colonies were picked and 
transferred to 3ml LB broth and cultured overnight at 37oC. 
 
2.5.3 Purification of plasmid DNA 
 
Plasmid DNA was purified from cloned JM109 cells using either Invitrogen 
PureLink Quick Plasmid Miniprep Kit or Promega Wizard® Plus SV Minipreps 
DNA Purification System. 1.5ml of overnight culture was lysed by the addition of 
reagents provided by manufacturer and spun at >12,000 x g to clear the lysate. 
Supernatant was then transferred to a separation column with a silica membrane 
designed to bind DNA. Following wash steps stated in manufacturer’s manual, DNA 
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was eluted into 75μl of deionised water and analysed using a NanoDrop1000 
spectrophotometer (Nanodrop Technologies) to determine DNA concentration.  
 
2.5.4 Restriction enzyme digestion 
 
Plasmids were digested using EcoRI High Fidelity restriction enzyme with CutSmart 
buffer (New England Biolabs) to check for the correct size of DNA insert within the 
plasmid. Restriction digest reactions contained: 2μl x10 restriction enzyme buffer, 
0.5μl EcoRI restriction enzyme, required volume of plasmid DNA (~200ng), made 
up to 20μl with deionised water. Reactions were incubated at 37oC for 1hr and 
visualised on a 1% agarose gel.  
2.5.5 Sequencing of DNA 
 
Plasmid DNA samples were sequenced on both strands using SP6 promoter 
(ATTTAGGTGACACTATAG)and T7 promoter (TAATACGACTCACTATAGGG) 
primers (Promega) in separate reactions with BigDye® Terminator v3.1 Cycle 
Sequencing Kit with protocol followed as stated in manufacturer’s manual (Applied 
Biosystems, Warrington, UK). Each reaction contained; 0.5μl BigDye®, 1.75μl 5X 
sequencing buffer, 3.2μl 1μM T7/SP6 primer, required volume of plasmid DNA 
template (200ng), made up to 10μl with deionised water.  Reactions were cycled as 
follows: 96oC for 1 min, then 25 cycles of 96oC for 10 sec, 50oC for 5 sec, and 60oC 
for 4 min, then held at 4oC. Reactions were sent to The GenePool, Edinburgh 
Genomics (University of Edinburgh) for sequencing.  
2.5.6 Analysis of gene sequences 
 
At least 2 clones of each amplified PCR product were sequenced three times, in two 
directions (i.e 2 forward, 1 reverse or 2 reverse, 1 forward direction) from 2 separate 
RT-cDNA synthesis reactions (see section 2.2.1), from multibacillary and 
paucibacillary sheep. Sequences from individual clones were compared to sheep 
genome assembly OARv3.1 
 (http://www.livestockgenomics.csiro.au/sheep/oar3.1.php/) by NCBI-BLAST 
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(http://blast.ncbi.nlm.nih.gov/Blast.) to ensure the correct region had been amplified. 
Sequences were then compiled using CLC Workbench v6.7.1 (www.clcbio.com) 
producing a consensus sequence for each sample. Consensus sequences were aligned 
using ClustalW v2.1 (www.ebi.ac.uk). Differences between consensus sequences 
were considered to be transcript/splice variants where the same variation was 
consistent in three or more consensus sequences. Sequences were translated from 
nucleotide to protein sequence by using ExPASy TRANSLATE tool (Bioinformatics 





2.6 Reverse transcription real-time Polymerase Chain Reaction 
 
RT-qPCR experiments were carried out in the Corbett Rotor-Gene 6 real-time PCR 
machine. SYBR Green FastStart Roche Taq DNA polymerase was used for all 
reactions. 
2.6.1 RT-qPCR primer design and assay optimisation 
 
Primers were designed based on sequence obtained from reverse transcription PCR 
method. Primer-BLAST and NetPrimer software was used to design primers specific 
to each gene. Primers were selected using the following criteria; GC content between 
40-65%, primer length of 21-27 base pairs, minimal secondary structure and  self-
complementarity, single product size of between 75-220bp as shown in figure 2.1. 
Where possible, primers were located in different exons or in exon-exon boundaries. 
PCR products were sequenced to confirm product specificity.  Primer designed to 
identify gene variants were designed with the variant region within the primer 
sequence. Sequences for each primer are shown in Table 2.4. RT-qPCR assays were 
optimised for template concentration using template serial dilutions of cDNA from 
paraTB infected animals (paucibacillary and multibacillary) and non-infected 
animals, primer concentration and annealing temperature. Assays were carried out 
using FastStart Universal SYBR Green Master (ROX) (Roche Applied Sciences). 
Each reaction contained 7.5μl SYBR green master, required volume of primer and 
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Figure 2.1Representative gel electrophoresis image of RT-qPCR assay 
product (IL17RBv3 - 122bp). Lanes 1-12; SH139, SH140, SH146, SH204, 
SH190, SH199, SH107, SH147, SH155, SH160, SH188 and SH205. No 
PCR product present in no template control (NTC). Amplified PCR 
products were sequenced to confirm specificity. 
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2.6.2 Selection of reference genes 
 
Template serial dilutions, from paraTB infected animal cDNA, were used for 
reference genes SDHA and YWHAZ to provide control genes for future 
experiments. These genes were selected as they are constitutively expressed in the 
sheep samples and expression levels of these genes covered the range of expression 
of genes of interest (20-30 cycles). Each reaction contained 0.45μl, 0.5μl and 0.5μl of 
each reference gene primer (10mM), respectively, and annealing temperature of 62oC 
was used for all genes. 
2.6.3 Generation of standard curves& positive controls 
 
RT-qPCR assays were optimised by generating a standard curve from a cDNA 
dilution series; this was carried out for all genes of interest. Each dilution point 
should have an equal difference between cycles to give acceptable efficiency. 
Standard curves with efficiency between 0.9 and 1.1, an M value (measurement of 
the gradient of the slope) of around -3.3 from at least four dilution points, R2 values 
of as close to 1 as possible and a single melt peak, were considered acceptable. 
Figure 2.2 shows a representative image of an optimised assay. Assays where gene 
expression was late (>30 cycles), standard curves of acceptable efficiency were 
unable to be generated. These gene were considered too lowly expressed for accurate 
measurement in the samples used for this study. Positive control assays were carried 
out for these genes by adding PCR product (2-5ng) that is known to contain the gene 
region being amplified to the RT-qPCR reaction; this ensured that the assay was 
valid when a measurable level of the gene was present. 
2.6.4 Data analysis & statistics 
 
Relative gene expression levels were calculated using GenEx (MultiD Analyses AB) 
using the comparative 2-(ΔΔCq) method (Livak and Schmittgen, 2001). Data was 
collected from three separate biological replicates (3x RT reactions) per animal and 
two technical replicates for each animal. All genes were normalized to the mean of 
SDHA and YWHAZ reference genes. Fold changes were calculated from ΔCq values 
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using GenEx; the difference between group means for each gene was analysed by 
one-way ANOVA (with Tukey’s pairwise comparison) with a significance threshold 
























Figure 2.2 Generation of cDNA standard curves for RT-qPCR. A) single 
melt peak indicating single product amplified B) serial dilution standard 
curve with equal cycles between dilution points C) Efficiency calculated 











     
IL23R For GGTGTACGTGAAGAGTTTAGAGACAG 62 131 
 Rev CAGTACATTTGAAGCTTGGACCC   
IL23Rv1 For ACAGGTCGTAAGAGAGCGACAAAG 58 120 
 Rev AATCCCTCCATGACACCAACTGAA   
IL23Rv2 For CATAGACACAAATTTAGAGACAGAA 60 129 
 Rev CAGTACATTTGAAGCTTGGACCC   
IL23Rv3 For ACTTGGAACGTAAGCTAAATTCACT 58 85 
 Rev AATTCTGACTGTTGCTCATATGTAA   
IL23Rv4 For TCCTGAAATAGACAACGGGAAAC 58 79 
 Rev AGAACTGACAGCATAACAGCAAA   
IL23Rv5 For ACACCTTACTTCTGAATTAAAAGAAG 58 195 
 Rev CTGGGAGAATGATTTCTATCTCTG   
IL12RB1  For AGGATTCGGTGTCTGTGGACTGGA 61 110 
 Rev CAGACGCTTGGTTGCTGTCCTCCT   
IL12RB1v1 For TATCCGTGCTCCACAATGTCACTCT 60 150 
 Rev GCAAAGCTGCTCTTGGACATCTTGA   
IL12RB1v2 For CTGCTCTTCTCAAGGACCGGATGGG 60 82 
 Rev TTCAGGGGGGATGCACAAGAGGAGAA   
IL12RB1v3 For CTGAGCTGGAGCAGCCCTGTGTGCAT 62 120 
 Rev GCTGCTCATGTAAGGCCACCTGCC   
IL12RB1v4 For  CACCATACCCAGATGCAGACTCA 61 187 
 Rev CGCAGAGCCTGTGGCAAAGA   
IL17RB For CGGGCAGATGTGGACGTTTTC 60 130 
 Rev TGAAGTTCACAGCCATGGAGGG   
IL17RB v1 For GATCATGAGAGAAGTGTGCTGGG 58 118 
 Rev GAAGTAACAAACGTGCCTCCAGA   
IL17RB v2 For CGGGCAGATGTGGACGTTTTC 56 129 
 Rev TGAAGTTCACAGCCATGGAGGG   





IL17RBv3 For TAACTCGAACTTCTGTGGTGGTCC 58 122 
 Rev GGTGCAGTGGGTCTTCAGTGAG   
IL17RA For CACACTGAGGCATCATCACAAGC 60 144 
 Rev GAAGTTTCTGGATTGGTGGTTTGG   
TBX21 For CCTGTTGTGGTCCAAGTTC 60 120 
 Rev CGGTAATGGCTGGTGGGCTC   
GATA3 For CCACAAGATGAACGGACAG 62 129 
 Rev GGCATTTCTTCTCCACAGAGTCGT   
GATA3v1 For GCGAGATCCAGCACAGGCC 60 130 
 Rev GTTCTGTCCGTTCATCTTGTGG   
RORC2 For CGCTGTGCCCACCGACTCACCGAG 62 136 
 Rev TGACCAGCACCACTTCCATG   
RORC2v1 For TTGAAGGCTGCAGTGAACTC 60 116 
 Rev GGCATTGATGAGCACGAGG   
RORAv1 For GTGATCGCAGCGATGAAAGC 60 101 
 Rev CCTTGCAGCCTTCACATGTAATG   
RORAv2 For AGTTCTCTGCTGCAGTTGCTAAC 62 124 
 Rev GACGAGCTCATGGGCAAGG   
RORAv3 For TGCGCAGACAGAGCTATTCC 58 112 
 Rev TGGGTCTTCTTTGTTACTGAGATACC   
RORAv4 For GCAGCTTTCTTCTGGTGTCGTC 62 113 
 Rev TGGGTCTTCTTTGTTACTGAGATACC   
RORAv5 For GGCTTTCTGTGGATGGGATC 63 133 
 Rev TGGGTCTTCTTTGTTACTGAGATACC   
YWHAZ For TGTAGGAGCCCGTAGGTCATC 60 101 
 Rev TCTCTCTGTATTCTCGAGCCATC   
SDHA For ACCTGATGCTTTGTGCTCTGC 62 126 











*Depicts nested primer sets 
3.1 Introduction 
 
MAP infection in sheep can give rise to two distinct pathological forms of disease. 
Approximately 30% of symptomatic animals are affected by the paucibacillary 
form; a tuberculoid state characterised by low bacteria levels and T cell infiltration 
of the gut causing pathology by chronic granulomatous inflammation. The other 
70% of symptomatic cases have the multibacillary (lepromatous) form of disease; 
showing high levels of acid fast bacilli in the gut tissues, with macrophage and B-
cell infiltration at the site of infection, leading to the formation of intestinal lesions 
(Smeed et al., 2008.Clarke, 1997). 
Previous studies have described the histopathology of intestinal samples from 
paucibacillary and multibacillary affected animals and have defined characteristics 
of the two pathologies of paraTB in sheep; multibacillary tissues contain numerous 
macrophages infected with acid-fast organisms, whereas paucibacillary tissues 
have very few macrophages, lymphocyte infiltration and very few or no acid-fast 
organisms found (Clark et al., 2010.Corpa et al., 2000). Previously, there have 
been very few studies that have investigated the presence of MAP using histology 
of lymph node tissue samples.  
Results from physical examination of gut tissues at post-mortem, IS900PCR 
(carried out by collaborators Dr. Craig Watkins, Moredun Research Institute and 
Dr. Anton Gossner, Roslin Institute), and microscopy of histological section slides 
of the ileum and lymph node tissues collected from each animal at post-mortem, 
were combined in order to confirm the presence of para TB and distinguish MAP-
infection status of each animal. 
The aim of this work was to identify and characterise the paraTB status of each 
animal to be used in this study as either multibacillary, paucibacillary or control 
(uninfected). This was done by combining data from post-mortem examination, 





3.2 Histology and ZN analysis 
 
Ileum and ileocecal lymph node tissue samples from suspected MAP infected sheep 
were stained by ZN or H&E methods (carried out by collaborator Dr. Francesca 
Chionini, Moredun Research Institute). Images of each stained section were taken 
using a light microscope (NikonNi2-Zeiss-105) to contribute to the final 
confirmation of multibacillary or paucibacillary infection status of each animal. 
Representative images of H&E and ZN stained ileum and lymph node tissue 
sections from suspected multibacillary/paucibacillary infected sheep and subclinical 
samples, to provide comparison, are shown.  
The images shown in figure 3.1 and 3.2 indicate multibacillary infection given the 
presence of bacteria in both the ileum and lymph node tissues, identified by ZN 
staining (purple stain) characteristic of a multibacillary infection. The presence of 
MAP was confirmed in these tissues by identification of the specific IS900 through 
RT-PCR (see figure 3.6). In contrast, the ZN stained sections shown in figures 3.3 
and 3.4 showed no bacteria present in either the ileum or lymph node tissues, 
however a positive IS900 RT-PCR result shows that MAP is present in these 
tissues; these samples are defined as a characteristic paucibacillary infection status.  
Inflammation of the ileum can be observed in histology samples from both 
multibacillary and paucibacillary infected animals. Loss of villi structure is noted 
when comparing these samples to representative images of the ileum of sheep that 
are not infected with MAP (figure 3.5). Previous work carried out in our lab has 
identified the cell types causing this inflammation as predominantly macrophages 
and B-cells in multibacillary samples, and CD4+ T cells in paucibacillary samples 







Figure 3.1 Representative histology images of a multibacillary infected 
sheep. Ileum tissues are shown with both H&E A) and ZN B) staining. 







Figure 3.2 Representative histology images of a multibacillary infected sheep. 
Mesenteric lymph node tissues are shown with both H&E A) and ZN B) staining. 







Figure 3.3 Representative histology images of a paucibacillary infected 
sheep. Ileum tissues are shown with both H&E A) and ZN B) staining. 





Figure 3.4 Representative histology images of a paucibacillary infected 
sheep. Mesenteric lymph node tissues are shown with both H&E A) and ZN B) 









Figure 3.5 Representative histology images of healthy sheep. Ileum 
tissues are shown with both H&E A) and ZN B) staining. Microscopy 




3.3 Detection of IS900 by PCR 
 
IS900 PCR was carried out using gDNA from ICLN of each animal as described in 
section 2.1. Ileocecal lymph node (ICLN) was used as this is the draining lymph 
node from the site of infection. The presence of IS900 amplicons, confirmed by 
sequencing of expected size PCR products analysed on 2% agarose gel (figure 3.6) 
from either primer sets were considered a positive identification of MAP in the 
sample/sheep. Two separate primer sets were used to provide confidence of results. 
The absence of amplicon from all PCR reactions in a sample was considered a 
negative result, indicating no MAP infection present. This study found all 
multibacillary and paucibacillary classified sample to be positive and uninfected 
control samples to be negative for the presence of IS900; results of the IS900 PCR 
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Figure 3.6 Representative gel image of IS900 PCR product identified in 
ICLN of paratuberculosis infected samples using A) primers designed by 
(Eishi et al., 2002). Expected product size of 99bp; SH167 (1-2), SH166 (3-
4), SH140 (5-6), SH139 (7-8) and SH199 (9-10), and B) primers designed 
by (Bauerfeind et al., 1996). Expected product size of 314bp; SH167 (1-2), 




3.4 Classification of sheep samples 
 
Information collected from post mortem examination, histopathology of ileum and 
lymph node tissues and IS900 PCR was collated in order to define each animal as 
either multibacillary, paucibacillary infection status or uninfected control. Results of 
infection status for each animal used in this study are shown in table 3.1.
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Table 3.1 MAP infection status of each sheep used in this study. 
*Lesion grade: severity based on both total numbers of epithelioid 
macrophages and leukocyte distribution patterns of the terminal ileum (Nicol 




 Sheep ID IS900 +/- ZN: bacteria  Lesion Grade* Classification 
SH139 + + Severe Multi 
SH140 + + Severe Multi 
SH146 + + Severe Multi 
SH204 + + Severe Multi 
SH190 + + Severe Multi 
SH199 + + Severe Multi 
SH107 + - Mild Pauci 
SH147 + - Mild Pauci 
SH155 + - Mild Pauci 
SH160 + - Mild Pauci 
SH188 + - Moderate Pauci 
SH205 + - Mild Pauci 
K207 - N/A N/A Control 
K208 - N/A N/A Control 
K213 - N/A N/A Control 
K224 - N/A N/A Control 
K227 - N/A N/A Control 





 The presence of MAP bacterium can be seen by ZN staining in the lymph 
node and ileum tissues of multibacillary infected animals; however this is 
not seen in paucibacillary tissues. 
 Inflammation of the ileum tissue, with loss of villi integrity, is noted in 
both paucibacillary and multibacillary animals when compared to 
subclinical animals; as shown by ZN and H&E tissue staining. 
 IS900 PCR has identified the presence of MAP bacterium in both 
multibacillary and paucibacillary infected animals. Control animals are 
IS900 negative. 
 The paraTB infection status of each sheep used in this study have been 
defined as either multibacillary or paucibacillary based on the combined 
data collected from port-mortem examination, histology of lymph node 


















The interleukin 23 (IL23) cytokine is a novel member of the IL12 heterodimeric 
cytokine family that is created by the binding of IL12p40 to a p19 (IL23A) subunit, 
the former of which is shared with IL12. Initially it was thought that IL23stimulated 
Th1 immune responses along with IL12; however, although IL23 and IL12 exhibit 
some similar biological activities, IL12 functions in the differentiation of naïve T 
cells into Th1 lymphocytes and initiates subsequent IFNγ production, whereas IL23 
has been shown to mediate pro-inflammatory responses via the activation of Th17 
lymphocytes and subsequent production of Th17 cytokines including  IL17A and 
IL17F (Kan et al., 2008); creating a link between Th1/Th17 polarization (Kobayashi 
et al., 2008). 
Mice deficient in IL12 receptor subunit (IL12p35), IFNγ, IFNyR or STAT1, which 
are all critical molecules in the IL12/IFNγ induction of Th1 mediated responses, 
exhibit an increased severity of diseases including collagen induced arthritis (CIA), 
IBD and experimental autoimmune encephalomyelitis (EAE); indicating that the 
IL12/IFNγ pathway is not solely responsible for inflammation during autoimmune 
disease (Hunter, 2005.McKenzie et al., 2006). In addition, treatment with mAbs 
against IL12p40 suppresses disease development in both human and animal disease 
models (Mannon et al., 2004). Since the IL12p40 subunit is shared with IL12 and 
IL23, and anti-p40 mAbs inhibit both cytokines, involvement of IL23 in the 
induction of auto-inflammatory responses is suggested (Iwakura and Ishigame, 
2006). In the presence of environmental danger signals and antigen recognition, 
antigen presenting macrophages and dendritic cells produce IL23 (Andersson et al., 
2004.Langrish et al., 2005). During Th17 cell development, naive CD4+ T cells are 
activated by IL6 produced by dendritic cells which acts in conjunction with TGFβ to 
induce expression of the retinoic orphan receptor RORγt and up-regulate expression 
of IL23 receptor (IL23R) on the surface of T cells, thus making them competent for 
Th17 cytokine production via Signal Transducer and Activator of Transcription 3 
(STAT3) signalling (Weaver et al 2007). The IL23R consists of IL12RB1 and IL23R 
subunits and this receptor complex is highly expressed on activated/memory T cells. 
Binding of IL23 and IL23R results in stimulation of memory T cells; IL23 binding to 
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IL23R expressed on Th17 cells triggers the activation of Janus kinase 2 (JAK2) and 
STAT3; resulting in phosphorylation and subsequent dimerization of these molecules 
(Lankford and Frucht, 2003). This in turn stimulates downstream expression of Th17 
cytokines as depicted in figure 4.1. IL17A and IL17F are pro-inflammatory cytokines 
and are the best characterised cytokines of the IL17 family (Gu et al., 2013). IL17A 
displays greater strength of signalling in terms of initiating downstream gene 
expression in comparison to IL17F; however both cytokines have been shown to 
stimulate endothelial cells, macrophages, epithelial cells and fibroblasts to produce 
inflammatory mediators including IL6, TNFα, IL1β and chemokines, leading to 






Figure 4.1 Binding of IL23 cytokine to IL23R. Phosphorylation of STAT3 
molecules induces activation of STAT3 and initiates downstream expression 
of Th17 cytokines. Image adapted from Nature (Di Cesare et al., 2009). 
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The IL23R is a type-1 cytokine receptor containing the highly conserved WSxWS 
motif, where x can be any amino acid; which is essential for receptor activation 
(Dagil et al. 2012). IL23R expression has been detected on macrophages and 
dendritic cells at low levels, which are consequently IL23 responsive (Langrish et al. 
2004). The importance of IL23R signalling in controlling immunity through Th17 
cell activity may explain why the IL23R gene has been implicated in susceptibility 
to, and pathogenesis of, several autoimmune and inflammatory diseases including 
rheumatoid arthritis, psoriasis, ankylosing spondylitis and multiple sclerosis 
(Abraham & Cho., 2009). Furthermore, IL23 plays a key role in the induction of 
intestinal inflammation. Th1 and Th17 immune responses are regulated by IL23 in 
ulcerative colitis (UC) and Crohn’s disease (CD) patients. IL23R was up-regulated in 
CD4+ T cells from both CD and UC patients, whereas IL17A production was 
significantly increased by IL23 in UC, but not CD patients (Kobayashi et al., 2008). 
Yen et al. have also shown that IL23 promotes T cell mediated chronic inflammation 
of the gut by up-regulating IL17 production (Yen et al., 2006). At the gene level, 
variants of the IL23R gene have been identified and linked to susceptibility in IBD 
patients (Duerr et al., 2006). In particular, the exon 9 deletion (Δ9) of IL23R in 
humans has been identified in, and associated with, CD patients when compared to 
healthy controls, however it is yet to be determined whether this variant plays a role 
in initiation of  pathology in CD (Gallagher et al., 2012). A GWAS study identified 
IL23R as one of the genetic factors linked to CD. One missense polymorphism 
within IL23R, the R318Q SNP, was found to be significantly higher amongst healthy 
controls than in diseased patients, suggesting a protective role for this allele from 
immune mediated chronic inflammation (Di Meglio et al., 2011). This SNP 
consisting in a guanine (G) to adenine (A) substitution at DNA level results in an 
arginine (R) to glutamine (Q) substitution within the cytoplasmic domain of IL23R 
(Duerr et al., 2006). A functional study of the R318Q SNP found that IL23-induced 
Th17 cell effector function was impaired in carriers of the protective allele, resulting 
in reduced STAT3 phosphorylation and IL17A production (Di Meglio et al., 2011). 
These findings support a critical role for IL23/IL23R signalling in the generation of 
pathogenic Th17 responses. The IL12RB1 subunit of IL23R has also been implicated 
in human disease, including susceptibility to mycobacterial and Salmonella 
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infections. A lack of IL12RB1 chain expression was identified in individuals 
presenting with severe idiopathic mycobacterial and Salmonella infections (de Jong 
et al., 1998). Sequence analysis revealed genetic mutations resulting in premature 
stop codons in the extracellular domain of IL12RB1. A detrimental lack of 
IL23/IL12 signalling with reduced IFNγ, IL17A and IL17F production resulted in 
human immunodeficiency and susceptibility to intracellular bacterial infection (de 
Jong et al., 1998). Other studies have shown complete IL12RB1 deficiency to be the 
most frequently known genetic aetiology of the syndrome of Mendelian 
susceptibility to mycobacterial disease (MSMD). Reduced IL12RB1 signalling 
results in a lack of STAT3 phosphorylation and downstream induction of gene 
expression (Fieschi et al., 2004. Miller and Robinson, 2012). The studies described 
highlight the importance of IL12Rβ1/IL23R signalling in the induction of both Th1 
and Th17 cell responses to control autoimmune and intracellular bacterial diseases. 
When investigating the role of IL23 in paraTB, Gossner et al. described expression 
levels of the IL23 cytokine subunit IL23A in four sheep groups; uninfected controls, 
asymptomatic, paucibacillary and  multibacillary. It was shown that IL23A transcript 
expression in ileal mucosa from paucibacillary infected animals were significantly 
higher than that of the other three groups; furthermore IL23A expression levels were 
higher at the site of infection, the ileal mucosa, than in lymph node tissues. This 
study also identified an allelic variant present in the sheep IL23A gene. The allelic 
variant was identified when measuring expression levels of IL23A in two distinct 
gastrointestinal disease infections in sheep; pataTB and T. Circumcincta (Gossner et 
al., 2012b). Expression of the p19 subunit (IL23A) by mature monocyte-derived 
dendritic cells is enhanced by peptidoglycan, a major constituent of gram positive 
bacterial cell walls, but not by lipopolysaccharide derived from gram negative 
bacteria (Cummings et al., 2007), which may explain increased expression of IL23 in 
gram positive MAP infected host. 
In this chapter the sequencing of full gene transcripts and transcript variants of the 
IL23 cytokine receptors, IL23R and IL12RB1, as well as sequence of the IL23A 
cytokine subunit, is described in the two pathological forms of sheep paraTB. This 
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chapter also quantifies gene expression levels of IL23A and the two IL23 receptor 
genes, including identified transcript variants, in paraTB infected and control sheep. 
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4.2 Ovine IL23A gene 
4.2.1 Sequencing of IL23A allelic variants in the two pathological forms 
of sheep paraTB 
 
In order to investigate the presence of the known ovine IL23A allelic variants, 
present in exon 1 of sheep IL23A, in the two study groups of paraTB infected 
animals, RT-PCR was performed to amplify partial IL23A sequence as described by 
Gossner and colleagues (Gossner et al., 2012b). Three clones from each animal were 
sequenced to give a representative sample of transcripts within each animal and 
experimental group. Consensus sequence of IL23A clones from both paucibacillary 
and multibacillary groups gave identical sequence. This IL23A sequence (IL23A1) 
was aligned with ovine IL23A sequence containing allelic variant found in two 
separate studies; GenBank FN822243.2 (IL23A2), GenBank NM_001185122.2 
(IL23A3) and sheep genome sequence (OARv3.1). Both nucleotide and protein 
sequence alignments are shown in figure 4.2. There were no allelic variants found in 
















IL23A2          GGAGCCAGCCAGATTGGAGAGGCAGGCAACGAGATGCTGGGGAACAGAGTTGTGATGCTG 60 
IL23A3          GGAGCCAGCCAGATTGGAGAGGCAGGCAACGAGATGCTGGGGAACAGAGTTGTGATGCTG 60 
OARv3.1         GGAGCCAGCCAGATTGGAGAGGCAGGCAACGAGATGCTGGGGAACAGAGTTGT------G 54 
IL23A1          GGAGCCAGCCAGATTGGAGAGGCAGGCAACGAGATGCTGGGGAACAGAGTTGT------G 54 
                *****************************************************      * 
 
IL23A2          CTGCTACTGCTACTGCTGCCCTGGACAGCTCAGGGCCGGGCTGTGTCAGAGGACAGCAGC 120 
IL23A3          CTGCTACTGCTACTGCTGCCCTGGACAGCTCAGGGCCGGGCTGTGTCAGAGGACAGCAGC 120 
OARv3.1         CTGCTACTGCTACTGCTGCCCTGGACAGCTCAGGGCCGGGCTGTGTCAGAGGACAGCAGC 114 
IL23A1          CTGCTACTGCTACTGCTGCCCTGGACAGCTCAGGGCCGGGCTGTGTCAGAGGACAGCAGC 114 
                ************************************************************ 
 
IL23A2          CCTGCTTGGGCTCGGGGCCAACAGCTCTCACAGCAACTCTGCATGCTAGCCTGGAGTGCA 180 
IL23A3          CCTGCTTGGGCTCGGGGCCAACAGCTCTCACAGCAACTCTGCATGCTAGCCTGGAGTGCA 180 
OARv3.1         CCTGCTTGGGCTCGGGGCCAACAGCTCTCACAGCAACTCTGCATGCTAGCCTGGAGTGCA 174 
IL23A1          CCTGCTTGGGCTCGGGGCCAACAGCTCTCACAGCAACTCTGCATGCTAGCCTGGAGTGCA 174 
                ************************************************************ 
 
IL23A2          CACCTACCAATGGGACATGTGGATCTACCAAGAGAAGAAGGAGGTGATGAGACTACAGAT 240 
IL23A3          CACCTACCAATGGGACATGTGGATCTACCAAGAGAAGAAGGAGGTGATGAGACTACAGAT 240 
OARv3.1         CACCTACCAATGGGACATGTGGATCTACCAAGAGAAGAAGGAGGA--------------- 219 
IL23A1          CACCTACCAATGGGACATGTGGATCTACCAAGAGAAGAAGGAGGA--------------- 219 





OARv3.1         MLGNRVV--LLLLLLPWTAQGRAVSEDSSPAWARGQQLSQQLCMLAWSAHLPMGHVDLPR 58 
IL23A1          MLGNRVV--LLLLLLPWTAQGRAVSEDSSPAWARGQQLSQQLCMLAWSAHLPMGHVDLPR 58 
IL23A3          MLGNRVVMLLLLLLLPWTAQGRAVSEDSSPAWARGQQLSQQLCMLAWSAHLPMGHVDLPR 60 
IL23A2          MLGNRVVMLLLLLLLPWTAQGRAVSEDSSPAWARGQQLSQQLCMLAWSAHLPMGHVDLPR 60 
                *******  *************************************************** 
Figure 4.2 Sequence alignment of IL23A alleles, Nucleotide A) and 
amino acid B) and OARV3.1 genome sequence. Previously identified 




4.2.2 Gene expression levels of IL23A 
 
The IL23 cytokine is a heterodimeric ligand composed of IL23p19 (IL23A) and 
IL12p40 (IL12B) subunits. Gene expression levels of IL23A within ICLN were 
measured by RT-qPCR; and found that IL23A could only be identified at >30cyles 
and therefore was too low for accurate measurement. Positive control for this assay 
was carried out using cDNA from paraTB infected animals spiked with IL23A PCR 
product as described in section 2.6.3. The positive control confirms that this assay is 










Figure 4.3 Positive control RT-qPCR assay for IL23A. Cycling A) and melt 
curve B) analysis of pooled cDNA from paraTB infected and control 
animals spiked with IL23A PCR product, shown in red. Cycling and melt 
curve analysis of dilution series (1:4-1:64) pooled cDNA from paraTB 





4.3 Ovine IL23R gene 
4.3.1 Identifying IL23R transcript variants 
 
To identify alternatively spliced transcript variants present in the sheep IL23R gene, 
full length IL23R was amplified by RT-PCR using primers described in table 2.3. At 
least six clones from each animal were sequenced to give a representative sample of 
transcripts present within individual animals and within experimental groups. Each 
clone was aligned against sheep genome assembly OARv3.1 and differences in 
sequence that were present in 2 or more clones from different animals were 
considered transcript variants. Alternatively spliced transcript variants were 
identified in several clones from both paucibacillary and multibacillary affected 
groups as summarised below. Gene maps of variants identified are depicted in figure 
4.4. IL23R sequence and IL23R transcript variant sequences were aligned using 
ClustalW v2.1 (as described in Chapter2) and are shown in figure 4.5. The ovine 
IL23R gene is found on chromosome 1 and consists of 11 exons. Expression patterns 
of each variant was measured using RT-qPCR.  
Cloning and sequencing identified 5 splice variants of ovine IL23R. The IL23R is 
encoded on the plus strand of chromosome 1 (OARv3.1: NC_019458.1). Differences 
between full length IL23R (LN868336) and identified transcript variants are 
described below and are detailed in figures 4.5, 4.6 and 4.7; 
IL23Rv1 (LN868337) has an insertion of 29bp (bp79 – 108) in the 5’ UTR (Chr1: 
42,464,555 – 42,464,584) which results in no change to coding region and the same 
627 aa predicted amino acid sequence as full length IL23R and would presumably 
function as full length IL23R. 
IL23Rv2 (LN868338) has a deletion of 21bp (bp530-551) at the 5’ end of exon 4 
(Chr1: 42,476, 073 – 42,476,094) resulting in a 7 amino acid (YVVYVKS) deletion at 
position 150 and a 2bp insertion (bp857-859) resulting in change of amino acid 
sequence from position 259 consequently leading to a premature stop codon at 
position 287 within the protein; it is predicted that this is a truncated protein. 
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IL23Rv3 (LN868339) has an insertion of 28bp (bp878-906) at the 3’ end of exon 6 
(Chr1: 42,492,950 – 42,492,977) resulting in premature stop codon and a protein of 
268 amino acids. 
IL23Rv4(LN868340) has the deletion of exon 8 (Chr1: 42,512,417 – 42,512,506) and 
encodes a predicted protein of 597 amino acids as a consequence of a 30 amino acid 
(PQVTMKSFQHDTQNSGLLIASIFKKHLTSD) deletion at position 319. This 
deletion causes truncation of the extracellular region; even though this protein still 
contains the conserved motifs. The deletion of exon 8 may lead to changes during 
receptor-ligand binding. 
IL23Rv5 (LN868341) has the deletion of exon 9 (Chr1: 42,515,314 – 42,515,419) 
resulting in a premature stop codon at the 5’ end of exon 10. This is position 356 
within the protein. This protein is comprised of a truncated extracellular region that 
still contains the WSxWS motif but no transmembrane domain. Therefore this 




































































Figure 4.4 Schematic diagrams of the ovine IL23R and splice variants (IL23Rv1-3) 
identified in this study. Boxes represent individual exons with chromosome location 
shown. Grey boxes indicate 5’and 3’UTRs with variant regions highlighted in red. 




Figure 4.4 cont. Schematic diagrams of the ovine IL23R and alternatively spliced 
transcript variants (IL23R v4& v5) identified in this study. Boxes represent 
individual exons with chromosome location shown. Grey boxes indicate 5’ and 3’ 
UTRs with variant regions highlighted in red. The ‘ATG’ is initial start codon and 























































V3                TAAGGAAGACGTGAGGCCGATACGAGGGCAGCAGCCTGGCTCTGAGGGGGAATTATGTGC 60 
V4                TAAGGAAGACGTGAGGCCGATACGAGGGCAGCAGCCTGGCTCTGAGGGGGAATTATGTGC 60 
V2                TAAGGAAGACGTGAGGCCGATACGAGGGCAGCAGCCTGGCTCTGAGGGGGAATTATGTGC 60 
V1                TAAGGAAGACGTGAGGCCGATACGAGGGCAGCAGCCTGGCTCTGAGGGGGAATTATGTGC 60 
V5                TAAGGAAGACGTGAGGCCGATACGAGGGCAGCAGCCTGGCTCTGAGGGGGAATTATGTGC 60 
 Full_sequence      TAAGGAAGACGTGAGGCCGATACGAGGGCAGCAGCCTGGCTCTGAGGGGGAATTATGTGC 60 
                  ************************************************************ 
 
V3                TTCAAACAGGTCGTAAGG------------------------------CATGAACCAGGT 90 
V4                TTCAAACAGGTCGTAAGG------------------------------CATGAACCAGGT 90 
V2                TTCAAACAGGTCGTAAGG------------------------------CATGAACCAGGT 90 
V1                TTCAAACAGGTCGTAAGG-AGCGACAAAGAATTTTTTCTGCTTTCAGGCATGAACCAGGT 120 
V5                TTCAAACAGGTCGTAAGG------------------------------CATGAACCAGGT 90 
Full_sequence     TTCAAACAGGTCGTAAGG------------------------------CATGAACCAGGT 90 
  ****************************** 
 
V3                CACAATTCATTGGGATGTGGTAATAGCTCTCTACATATTCTTCAGTTGGTGTCATGGAGG 150 
V4                CACAATTCATTGGGATGTGGTAATAGCTCTCTACATATTCTTCAGTTGGTGTCATGGAGG 150 
V2                CACAATTCATTGGGATGTGGTAATAGCTCTCTACATATTCTTCAGTTGGTGTCATGGAGG 150 
V1                CACAATTCATTGGGATGTGGTAATAGCTCTCTACATATTCTTCAGTTGGTGTCATGGAGG 180 
V5                CACAATTCATTGGGATGTGGTAATAGCTCTCTACATATTCTTCAGTTGGTGTCATGGAGG 150 
Full_sequence     CACAATTCATTGGGATGTGGTAATAGCTCTCTACATATTCTTCAGTTGGTGTCATGGAGG 150 
                  ************************************************************ 
 
V3                GATTACAAATATAAACTGCTCTGGACACATCTGGGTAGAACCTGCCACAATTTTTAAGAT 210 
V4                GATTACAAATATAGACTGCTCTGGACACATCTGGGTAGAACCTGCCACAATTTTTAAGAT 210 
V2                GATTACAAATATAAACTGCTCTGGACACATCTGGGTAGAACCTGCCACAATTTTTAAGAT 210 
V1                GATTACAAATATAAACTGCTCTGGACACATCTGGGTAGAACCTGCCACAATTTTTAAGAT 240 
V5                GATTACAAATATAAACTGCTCTGGACACATCTGGGTAGAACCTGCCACAATTTTTAAGAT 210 
Full_sequence     GATTACAAATATAAACTGCTCTGGACACATCTGGGTAGAACCTGCCACAATTTTTAAGAT 210 
                  *************.********************************************** 
 
V3                GGGTATGAATATCTCTATATATTGCCAAGCAGCAATTAGGAACTGCCAACCAAGGAAACT 270 
V4                GGGTATGAATATCTCTATATATTGCCAAGCAGCAATTAGGAACTGCCAACCAAGGAAACT 270 
V2                GGGTATGAATATCTCTATATATTGCCAAGCAGCAATTAGGAACTGCCAACCAAGGAAACT 270 
V1                GGGCATGAATATCTCTATATATTGCCAAGCAGCAATTAGGAACTGCCAACCAAGGAAACT 300 
V5                GGGTATGAATATCTCTATATATTGCCAAGCAGCAATTAGGAACTGCCAACCAAGGAAACT 270 
Full_sequence     GGGCATGAATATCTCTATATATTGCCAAGCAGCAATTAGGAACTGCCAACCAAGGAAACT 270 
                  *** ******************************************************** 
 
V3                TTATTTTTATAAAAATGGCATCAAAGAAAGATTTCATATCACAAGAATCAATAAAACAAC 330 
V4                TTATTTTTATAAAAATGGCATCAAAGAAAGATTTCATATCACAAGAATCAATAAAACAAC 330 
V2                TTATTTTTATAAAAATGGCATCAAAGAAAGATTTCATATCACAAGAATCAATAAAACAAC 330 
V1                TTATTTTTATAAAAATGGCATCAAAGAAAGATTTCATATCACAAGAATCAATAAAACAAC 360 
V5                TTATTTTTATAAAAATGGCATCAAAGAAAGATTTCATATCACAAGAATCAATAAAACAAC 330 
Full_sequence     TTATTTTTATAAAAATGGCATCAAAGAAAGATTTCATATCACAAGAATCAATAAAACAAC 330 
                  ************************************************************ 
 
V3                AGCTCGCCTTTGGTATAACAACTTTGTGGAGCCACAAGCCTTTGTGTACTGTACTGCTGA 390 
V4                AGCTCGCCTTTGGTATAACAACTTTGTGGAGCCACAAGCCTTTGTGTACTGTACTGCTGA 390 
V2                AGCTCGCCTTTGGTATAACAACTTTGTGGAGCCACAAGCCTTTGTGTACTGTACTGCTGA 390 
V1                AGCTCGCCTTTGGTATAACAACTTTGTGGAGCCACAAGCCTTTGTGTACTGTACTGCTGA 420 
V5                AGCTCGCCTTTGGTATAACAACTTTGTGGAGCCACAAGCCTTTGTGTACTGTACTGCTGA 390 
Full_sequence     AGCTCGCCTTTGGTATAACAACTTTGTGGAGCCACAAGCCTTTGTGTACTGTACTGCTGA 390 
                  ************************************************************ 
 
V3                ATGTT-CCAGATATTTTCCAGAGACACTGATTT-GTGGAAAAGACATTTCTTCTGGATAT 448 
V4                ATGTT-CCAGATATTTTCCAGAGACACTGATTT-GTGGAAAAGACATTTCTTCTGGATAT 448 
V2                ATGTT-CCAGATATTTTCCAGAGACACTGATTT-GTGGAAAAGACATTTCTTCTGGATAT 448 
V1                ATGTTCCCAGATATTTTTCAGAGACACTGATTTTGTGGAAAAGACATTTCTTCTGGATAT 480 
V5                ATGTT-CCAGATATTTTCCAGAGACACTGATTT-GTGGAAAAGACATTTCTTCTGGATAT 448 
Full_sequence     ATGTT-CCAGATATTTTCCAGAGACACTGATTT-GTGGAAAAGACATTTCTTCTGGATAT 448 
                  ***** *********** *************** ************************** 
 
V3                CCACCAGATGTACCTGACAAAGTAACCTGTGTCATTTATGAATATTCAGGCAACATGACT 508 
V4                CCACCAGATGTACCTGACAAAGTAACCTGTGTCATTTATGAATATTCAGGCAACATGACT 508 
V2                CCACCAGATGTACCTGACAAAGTAACCTGTGTCATTTATGAATATTCAGGCAACATGACT 508 
V1                CCACCAGATGTACCTGACAAAGTAACCTGTGTCATTTATGAATATTCAGGCAACATGACT 540 
V5                CCACCAGATGTACCTGACAAAGTAACCTGTGTCATTTATGAATATTCAGGCAACATGACT 508 
Full_sequence     CCACCAGATGTACCTGACAAAGTAACCTGTGTCATTTATGAATATTCAGGCAACATGACT 508 
                  ************************************************************ 
 
V3                TGTACCTGGAACCCTGGGAGGCCCACCTACATAGACACAAAGTATGTGGTGTACGTGAAG 568 
V4                TGTACCTGGAACCCTGGGAGGCCCACCTACATAGACACAAAGTATGTGGTGTACGTGAAG 568 
V2                TGTACCTGGAACCCTGGGAGGCCCACCTACATAGACACAAA------------------- 549 
V1                TGTACCTGGAACCCTGGGAGGCCCACCTACATAGACACAAAGTATGTGGTGTACGTGAAG 600 
V5                TGTACCTGGAACCCTGGGAGGCCCACCTACATAGACACAAAGTATGTGGTGTACGTGAAG 568 
Full_sequence     TGTACCTGGAACCCTGGGAGGCCCACCTACATAGACACAAAGTATGTGGTGTACGTGAAG 568 





V3                AGTTTAGAGACAGAAGAAGAGCAAGAATATCTCACTTCAAGTTACATTAACATCTCCACT 628 
V4                AGTTTAGAGACAGAAGAAGAGCAAGAATATCTCACTTCAAGTTACATTAACATCTCCACT 628 
V2  --TTTAGAGACAGAAGAAGAGCAAGAATATCTCACTTCAAGTTACATTAACATCTCCACT 607 
V1                AGTTTAGAGACAGAAGAAGAGCAAGAATATCTCACTTCAAGTTACATTAACATCTCCACT 660 
V5                AGTTTAGAGACAGAAGAAGAGCAAGAATATCTCACTTCAAGTTACATTAACATCTCCACT 628 
Full_sequence     AGTTTAGAGACAGAAGAAGAGCAAGAATATCTCACTTCAAGTTACATTAACATCTCCACT 628 
                    ********************************************************** 
 
V3                GATTCATTGCAAAAGGGAAAGAAGTATTTGGTTTGGGTCCAAGCTTCAAATGTACTGGGC 688 
V4                GATTCATTGCAAAAGGGAAAGAAGTATTTGGTTTGGGTCCAAGCTTCAAATGTACTGGGC 688 
V2                GATTCATTGCAAAAGGGAAAGAAGTATTTGGTTTGGGTCCAAGCTTCAAATGTACTGGGC 667 
V1                GATTCATTGCAAAAGGGAAAGAAGTATTTGGTTTGGGTCCAAGCTTCAAATGTACTGGGC 720 
V5                GATTCATTGCAAAAGGGAAAGAAGTATTTGGTTTGGGTCCAAGCTTCAAATGTACTGGGC 688 
Full_sequence     GATTCATTGCAAAAGGGAAAGAAGTATTTGGTTTGGGTCCAAGCTTCAAATGTACTGGGC 688 
                  ************************************************************ 
 
V3                ACGGAAAAGTCAAAACAACTACAAATTCATCTGGACGATATAGTGATACCTTCTGCATCC 748 
V4                ACGGAAAAGTCAAAACAACTACAAATTCATCTGGACGATATAGTGATACCTTCTGCATCC 748 
V2                ACGGAAAAGTCAAAACAACTACAAATTCATCTGGACGATATAGTGATACCTTCTGCATCC 727 
V1                ACGGAAAAGTCAAAACAACTACAAATTCATCTGGACGATATAGTGATACCTTCTGCATCC 780 
V5                ACGGAAAAGTCAAAACAACTACAAATTCATCTGGACGATATAGTGATACCTTCTGCATCC 748 
Full_sequence     ACGGAAAAGTCAAAACAACTACAAATTCATCTGGACGATATAGTGATACCTTCTGCATCC 748 
                  ************************************************************ 
 
V3                ATTATTTCCAGGGCTGAGGATATAAATACTACAGTGTCCAAGACTGTAATCCACTGGAAT 808 
V4                ATTATTTCCAGGGCTGAGGATATAAATACTACAGTGTCCAAGACTGTAATCCACTGGAAT 808 
V2                ATTATTTCCAGGGCTGAGGATATAAATACTACAGTGTCCAAGACTGTAATCCACTGGAAT 787 
V1                ATTATTTCCAGGGCTGAGGATATAAATACTACAGTGTCCAAGACTGTAATCCACTGGAAT 840 
V5                ATTATTTCCAGGGCTGAGGATATAAATACTACAGTGTCCAAGACTGTAATCCACTGGAAT 808 
Full_sequence     ATTATTTCCAGGGCTGAGGATATAAATACTACAGTGTCCAAGACTGTAATCCACTGGAAT 808 
                  ************************************************************ 
 
V3                AGTCAAACATCAATTGAAAAAGTTTCCTGTGAAATGAGATACAAAGCTACAACAAACCAA 868 
V4                AGTCAAACATCAATTGAAAAAGTTTCCTGTGAAATGAGATACAAAGCTACAACAAACCAA 868 
V2                AGTCAAACATCAATTGAAAAAGTTTCCTGTGAAATGAGATACAAAGCTACAACAAACCAA 847 
V1                AGTCAAACATCAATTGAAAAAGTTTCCTGCGAAATGAGATACAAAGCTACAACAAACCAA 900 
V5                AGTCAAACATCAATTGAAAAAGTTTCCTGCGAAATGAGATACAAAGCTACAACAAACCAA 868 
Full_sequence     AGTCAAACATCAATTGAAAAAGTTTCCTGCGAAATGAGATACAAAGCTACAACAAACCAA 868 
                  ***************************** ****************************** 
 
V3                ACTTGGAACGTAAGCTAAATTCACTTTCCTTTTACATGTTAAAGAATTTGATACCAATTT 928 
V4                ACTTGGAACG----------------------------TTAAAGAATTTGATACCAATTT 900 
V2                ACTTGGAACACG--------------------------TTAAAGAATTTGATACCAATTT 881 
V1                ACTTGGAACG----------------------------TTAAAGAATTTGATACCAATTT 932 
V5                ACTTGGAACG----------------------------TTAAAGAATTTGATACCAATTT 900 
Full_sequence     ACTTGGAACG----------------------------TTAAAGAATTTGATACCAATTT 900 
                  *********.                            ********************** 
 
V3                TACATATGAGCAACAGTCAGAATTCTACTTGCAGCCAAATGCTACATACGTATTTCAAGT 988 
V4                TACATATGAGCAACAGTCAGAATTCTACTTGCAGCCAAATGCTACATACGTATTTCAAGT 960 
V2                TACATATGAGCAACAGTCAGAATTCTACTTGCAGCCAAATGCTACATACGTATTTCAAGT 941 
V1                TACATATGAGCAACAGTCAGAATTCTACTTGCAGCCAAATGCTACATACGTATTTCAAGT 992 
V5                TACATATGAGCAACAGTCAGAATTCTACTTGCAGCCAAATGCTACATACGTATTTCAAGT 960 
Full_sequence     TACATATGAGCAACAGTCAGAATTCTACTTGCAGCCAAATGCTACATACGTATTTCAAGT 960 
                  ************************************************************ 
 
V3                GAGATGTCAAGAAACAGGTAAAAGGTACTGGCAGCCCTGGAGTTCACCCTTTTTTCATAA 1048 
V4                GAGATGTCAAGAAACAGGTAAAAGGTACTGGCAACCCTGGAGTTCACCCTTTTTTCATAA 1020 
V2                GAGATGTCAAGAAACAGGTAAAAGGTACTGGCAACCCTGGAGTTCACCCTTTTTTCATAA 1001 
V1                GAGATGTCAAGAAACAGGTAAAAGGTACTGGCAGCCCTGGAGTTCACCCTTTTTTCATAA 1052 
V5                GAGATGTCAAGAAACAGGTAAAAGGTACTGGCAGCCCTGGAGTTCACCCTTTTTTCATAA 1020 
Full_sequence     GAGATGTCAAGAAACAGGTAAAAGGTACTGGCAGCCCTGGAGTTCACCCTTTTTTCATAA 1020 




V3                AACTCCTGAAATAGTTCCTCAGGTCACAATGAAATCATTCCAACATGATACTCAGAATTC 1108 
V4                AACTCCTGAAATAG---------------------------------------------- 1034 
V2                AACTCCTGAAATAGTTCCTCAGGTCACAATGAAATCATTCCAACATGATACTCAGAATTC 1061 
V1                AACTCCTGAAATAGTTCCTCAGGTCACAGTGAAATCATTCCAACATGATACTCAGAATTC 1112 
V5                AACTCCTGAAATAGTTCCTCAGGTCACAATGAAATCATTCCAACATGATACTCAGAATTC 1080 
Full_sequence     AACTCCTGAAATAGTTCCTCAGGTCACAATGAAATCATTCCAACATGATACTCAGAATTC 1080 
                  **************                                               
 
V3                TGGACTTCTAATTGCTTCCATCTTTAAAAAACACCTTACTTCTGACAACGGGAAACAAGA 1168 
V4   --------------------------------------------ACAACGGGAAACAAGA 1050 
V2                TGGACTTCTAATTGCTTCCATCTTTAAAAAACACCTTACTTCTGACAACGGGAAACAAGA 1121 
V1                TGGACTTCTAATTGCTTCCATCTTTAAAAAACACCTTACTTCTGACAACGGGAAACAAGG 1172 
V5                TGGACTTCTAATTGCTTCCATCTTTAAAAAACACCTTACTTCT----------------- 1123 
Full_sequence     TGGACTTCTAATTGCTTCCATCTTTAAAAAACACCTTACTTCTGACAACGGGAAACAAGA 1140 
 
 
V3                CATTGGACTTTTATTGGGAATGGTCTTCTTTGCTGTTATGCTGTCAGTTCTATCTTTGTT 1228 
V4                CATTGGACTTTTATTGGGAATGGTCTTCTTTGCTGTTATGCTGTCAGTTCTATCTTTGTT 1110 
91 
 
V2                CATTGGACTTTTATTGGGAATGGTCTTCTTTGCTGTTATGCTGTCAGTTCTATCTTTGTT 1181 
V1                CATTGGACTTTTATTGGGAATGGTCTTCTTTGCTGTTATGCTGTCAGTTCTATCTTTGTT 1232 
V5  ------------------------------------------------------------ 
Full_sequence     CATTGGACTTTTATTGGGAATGGTCTTCTTTGCTGTTATGCTGTCAGTTCTATCTTTGTT 1200 
 
 
V3                TGGGATATTTAACAAATCGCTTCGAACTGGAATTAAAAGAAGAATCTTATTGCTAATACC 1288 
V4                TGGGATATTTAACAAATCGCTTCGAACTGGAATTAAAAGAAGAATCTTATTGCTAATACC 1170 
V2                TGGGATATTTAACAAATCGCTTCGAACTGGAATTAAAAGAAGAATCTTATTGCTAATACC 1241 
V1                TGGGATATTTAACAAATCGCTTCGAACTGGAATTAAAAGAAGAATCTTATTGCTAATACC 1292 
V5  -----------------------------GAATTAAAAGAAGAATCTTATTGCTAATACC 1154 
Full_sequence     TGGGATATTTAACAAATCGCTTCGAACTGGAATTAAAAGAAGAATCTTATTGCTAATACC 1260 
                                                ******************************* 
 
V3                AAAATGGCTCTATGAAGATATTCCTAAATTGGAAAACAGTAAAGTTGTGAAAATACTTCA 1348 
V4                AAAATGGCTCTATGAAGATATTCCTAAATTGGAAAACAGTAAAGTTGTGAAAATACTTCA 1230 
V2                AAAATGGCTCTATGAAGATATTCCTAAATTGGAAAACAGTAAAGTTGTGAAAATACTTCA 1301 
V1                AAAATGGCTCTATGAAGATATTCCTAAATTGGAAAACAGTAAAGTTGTGAAAATACTTCA 1352 
V5                AAAATGGCTCTATGAAGATATTCCTAAATTGGAAAACAGTAAAGTTGTGAAAATACTTCA 1214 
Full_sequence     AAAATGGCTCTATGAAGATATTCCTAAATTGGAAAACAGTAAAGTTGTGAAAATACTTCA 1320 
                  ************************************************************ 
 
V3                GGAAAAAAATGAATTTATGAATAACAATTCCAGTGAACAGGTCCTATATGTTGATCCGGT 1408 
V4                GGAAAAAAATGAATTTATGAATAACAATTCCAGTGAACAGGTCCTATATGTTGATCCGGT 1290 
V2                GGAAAAAAATGAATTTATGAATAACAATTCCAGTGAACAGGTCCTATATGTTGATCCGGT 1361 
V1                GGAAAAAAATGAATTTATGAATAACAATTCCAGTGAACAGGTCCTATATGTTGATCCGGT 1412 
V5                GAAAAAAATGAATTTATGAATAACAATTCCAGTGAACAGGTCCTATATGTTGATCCGGT 1274 
Full_sequence     GGAAAAAAATGAATTTATGAATAACAATTCCAGTGAACAGGTCCTATATGTTGATCCGGT 1380 
                  ************************************************************ 
 
V3                GATTACAGAGATAGAAATCATTCTCCCAGAAGAAAAACCCATAGGCTACAAGAAAGAAAA 1468 
V4                GATTACAGAGATAGAAATCATTCTCCCAGAAGAAAAACCCATAGGCTACAAGAAAGAAAA 1350 
V2                GATTACAGAGATAGAAATCATTCTCCCAGAAGAAAAACCCATAGGCTACAAGAAAGAAAA 1421 
V1                GATTACAGAGATAGAAATCATTCTCCCAGAAGAAAAACCCATAGGCTACAAGAAAGAAAA 1472 
V5                GATTACAGAGATAGAAATCATTCTCCCAGAAGAAAAACCCATAGGCTACAAGAAAGAAAA 1334 
Full_sequence     GATTACAGAGATAGAAATCATTCTCCCAGAAGAAAAACCCATAGGCTACAAGAAAGAAAA 1440 
                  ************************************************************ 
 
V3                CAATACAGGATGCCTGGAGAGAAAAGAGAGCCTGGAGAAGTCACTACTCACCAACACTAC 1528 
V4                CAATACAGGATGCCTGGAGAGAAAAGAGAGCCTGGAGAAGTCACTACTCACCAACACTAC 1410 
V2                CAATACAGGATGCCTGGAGAGAAAAGAGAGCCTGGAGAAGTCACTACTCACCAACACTAC 1481 
V1                CCATACAGGATGCCTGGAGAGAAAAGAGAGCCTGGAGAAGTCACTACTCACCAACACTAC 1532 
V5                CAATACAGGATGCCTGGAGAGAAAAGAGAGCCTGGAGAAGTCACTACTCACCAACACTAC 1394 
Full_sequence     CAATACAGGATGCCTGGAGAGAAAAGAGAGCCTGGAGAAGTCACTACTCACCAACACTAC 1500 
                  *.********************************************************** 
 
V3                AGTTGTATATATTCCTGATCTCAACACTGGGTATAAACCCCAGATTTCAAGTTTTCTCCC 1588 
V4                AGTTGTATATATTCCTGATCTCAACACTGGGTATAAACCCCAGATTTCAAGTTTTCTCCC 1470 
V2                AGTTGTATATATTCCTGATCTCAACACTGGGTATAAACCCCAGATTTCAAGTTTTCTCCC 1541 
V1                AGTTGTATATATTCCTGATCTCAACACTGGGTATAAACCCCAGATTTCAAGTTTTCTCCC 1592 
V5                AGTTGTATATATTCCTGATCTCAACACTGGGTATAAACCCCAGATTTCAAGTTTTCTCCC 1454 
Full_sequence     AGTTGTATATATTCCTGATCTCAACACTGGGTATAAACCCCAGATTTCAAGTTTTCTCCC 1560 
                  ************************************************************ 
 
V3                TGGGGGAAACCATCTCAGGAATGATGATGAAACAGCTTCCTCAATTCTGGAACCACCAGC 1648 
V4                TGGGGGAAACCATCTCAGGAATGATGATGAAACAGCTTCCTCAATTCTGGAACCACCAGC 1530 
V2                TGGGGGAAACCATCTCAGGAATGATGATGAAACAGCTTCCTCAATTCTGGAACCACCAGC 1601 
V1                TGGGGGAAACCATCTCAGGAATGATGATGAAACAGCTTCCTCAATTCTGGAACCACCAGC 1652 
V5                TGGGGGAAACCATCTCAGGAATGATGATGAAACAGCTTCCTCAATTCTGGAACCACCAGC 1514 
Full_sequence     TGGGGGAAACCATCTCAGGAATGATGATGAAACAGCTTCCTCAATTCTGGAACCACCAGC 1620 
                  ************************************************************ 
 
V3                TGATTCCTTAAACTTGGGAAACAATGCCAGGTTTAAAAAATATCCTGATTTTGCTTTTTC 1708 
V4                TGATTCCTTAAACTTGGGAAACAATGCCAGGTTTAAAAAATATCCTGATTTTGCTTTTTC 1590 
V2                TGATTCCTTAAACTTGGGAAACAATGCCAGGTTTAAAAAATATCCTGATTTTGCTTTTTC 1661 
V1                TGATTCCTTAAACTTGGGAAACAATGCCAGGTTTAAAAAATATCCTGATTTTGCTTTTTC 1712 
V5                TGATTCCTTAAACTTGGGAAACAATGCCAGGTTTAAAAAATATCCTGATTTTGCTTTTTC 1574 
Full_sequence      TGATTCCTTAAACTTGGGAAACAATGCCAGGTTTAAAAAATATCCTGATTTTGCTTTTTC 1680 
                   ************************************************************ 
 
V3                TGTCTCAAGTACAAATTCACTAAGCAACACACTATTTCTTGAAGAATTAAGCCTCATTTT 1768 
V4                TGTCTCAAGTACAAATTCACTAAGCAACACACTATTTCTTGAAGAATTAAGCCTCATTTT 1650 
V2                TGTCTCAAGTACAAATTCACTAAGCAACACACTATTTCTTGAAGAATTAAGCCTCATTTT 1721 
V1                TGTCTCAAGTACAAATTCACTAAGCAACACACTATTTCTTGAAGAATTAAGCCTCATTTT 1772 
V5                TGTCTCAAGTACAAATTCACTAAGCAACACACTATTTCTTGAAGAATTAAGCCTCATTTT 1634 
Full_sequence     TGTCTCAAGTACAAATTCACTAAGCAACACACTATTTCTTGAAGAATTAAGCCTCATTTT 1740 
                  ************************************************************ 
 
V3                AAATCAAGGAGAATGCAGTCCTCCGGACATGCAAAACTCAATAGAGGGGGAAACTGCCAT 1828 
V4                AAATCAAGGAGAATGCAGTCCTCCGGACATGCAAAACTCAATAGAGGGGGAAACTGCCAT 1710 
V2                AAATCAAGGAGAATGCAGTCCTCCGGACATGCAAAACTCAATAGAGGGGGAAACTGCCAT 1781 
V1                AAATCAAGGAGAATGCAGTCCTCCGGACATGCAAAACTCAATAGAGGGGGAAACTGCCAT 1832 
V5                AAATCAAGGAGAATGCAGTCCTCCGGACATGCAAAACTCAATAGAGGGGGAAACTGCCAT 1694 
Full_sequence     AAATCAAGGAGAATGCAGTCCTCCGGACATGCAAAACTCAATAGAGGGGGAAACTGCCAT 1800 
92 
 
                   ************************************************************ 
 
V3                GCTTCTGGAAGATGCATTACTGAATGAAACTATTCCAGAACAAACCCTGCTGCCTGATGA 1888 
V4                GCTTCTGGAAGATGCATTACTGAATGAAACTATTCCAGAACAAACCCTGCTGCCTGATGA 1770 
V2                GCTTCTGGAAGATGCATTACTGAATGAAACTATTCCAGAACAAACCCTGCTGCCTGATGA 1841 
V1                GCTTCTGGAAGATGCATTACTGAATGAAACTATTCCAGAACAAACCCTGCTGCCTGATGA 1892 
V5                GCTTCTGGAAGATGCATTACTGAATGAAACTATTCCAGAACAAACCCTGCTGCCTGATGA 1754 
Full_sequence     GCTTCTGGAAGATGCATTACTGAATGAAACTATTCCAGAACAAACCCTGCTGCCTGATGA 1860 
                  ************************************************************ 
 
V3                ATTTGTCTCCTGTTTGGGGAGCATGAACAAAGAGTTGCCATCTATTAATTCTTATTTTCC 1948 
V4                ATTTGTCTCCTGTTTGGGGAGCATGAACAAAGAGTTGCCATCTATTAATTCTTATTTTCC 1830 
V2                ATTTGTCTCCTGTTTGGGGAGCATGAACAAAGAGTTGCCATCTATTAATTCTTATTTTCC 1901 
V1                ATTTGTCTCCTGTTTGGGGAGCATGAACAAAGAGTTGCCATCTATTAATTCTTATTTTCC 1952 
V5                ATTTGTCTCCTGTTTGGGGAGCATGAACAAAGAGTTGCCATCTATTAATTCTTATTTTCC 1814 
Full_sequence     ATTTGTCTCCTGTTTGGGGAGCATGAACAAAGAGTTGCCATCTATTAATTCTTATTTTCC 1920 
                  ************************************************************ 
 
V3                ACAAAATATTTTGGAAAGCCACTTCAATCGATTTCACTCTTAGAAAACTAGATTTGTGTA 2008 
V4                ACAAAATATTTTGGAAAGCCACTTCAATCGATTTCACTCTTAGAAAACTAGATTTGTGTA 1890 
V2                ACAAAATATTTTGGAAAGCCACTTCAATCGATTTCACTCTTAGAAAACTAGATTTGTGTA 1961 
V1                ACAAAATATTTTGGAAAGCCACTTCAATCGATTTCACTCTTAGAAAACTAGATTTGTGTA 2012 
V5                ACAAAATATTTTGGAAAGCCACTTCAATCGATTTCACTCTTAGAAAACTAGATTTGTGTA 1874 
Full_sequence     ACAAAATATTTTGGAAAGCCACTTCAATCGATTTCACTCTTAGAAAACTAGATTTGTGTA 1980 
                  ************************************************************ 
 
V3                GTCAGAACCTGCCTTGAAAA 2028 
V4                GTCAGAACCTGCCTTGAAAA 1910 
V2                GTCAGAACCTGCCTTGAAAA 1981 
V1                GTCAGAACCTGCCTTGAAAA 2032 
V5                GTCAGAACCTGCCTTGAAAA 1894 
Full_sequence     GTCAGAACCTGCCTTGAAAA 2000 
                  ******************** 
 
Figure 4.5. Nucleotide sequence alignment (ClustalW v2.1) showing IL23R 
full length and splice variant (V) sequences. Sections highlighted in yellow 




4.3.2 Ovine IL23R translated protein sequence analysis 
 
Nucleotide sequences of full length and alternatively spliced variant transcripts of 
ovine IL23R were translated into amino acid sequences and were then aligned using 
ClustalW v2.1 to identify changes to protein structure that occur as a result of 
transcriptional variation (figure 4.6). An alignment of human IL23R and ovine 
IL23R amino acid sequences identified conserved structural regions (Di Meglio et 
al., 2011) of the IL23R protein and the protective R381Q variant found in humans, 
conserved regions are highlighted and described in ‘KEY’. These alignments were 
used to form predicted protein structure maps and predicted biological functions 












R381Q variant site 
 
 
V1             MNQVTIHWDVVIALYIFFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIRNCQ 60 
V4             MNQVTIHWDVVIALYIFFSWCHGGITNIDCSGHIWVEPATIFKMGMNISIYCQAAIRNCQ 60 
Full           MNQVTIHWDVVIALYIFFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIRNCQ 60 
V5             MNQVTIHWDVVIALYIFFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIRNCQ 60 
V3             MNQVTIHWDVVIALYIFFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIRNCQ 60 
V2             MNQVTIHWDVVIALYIFFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIRNCQ 60 
                ****************************:******************************* 
 
V1             PRKLYFYKNGIKERFHITRINKTTARLWYNNFVEPQAFVYCTAECSRYFSETLICGKDIS 120 
V4             PRKLYFYKNGIKERFHITRINKTTARLWYNNFVEPQAFVYCTAECSRYFPETLICGKDIS 120 
Full           PRKLYFYKNGIKERFHITRINKTTARLWYNNFVEPQAFVYCTAECSRYFPETLICGKDIS 120 
V5             PRKLYFYKNGIKERFHITRINKTTARLWYNNFVEPQAFVYCTAECSRYFPETLICGKDIS 120 
V3             PRKLYFYKNGIKERFHITRINKTTARLWYNNFVEPQAFVYCTAECSRYFPETLICGKDIS 120 
V2             PRKLYFYKNGIKERFHITRINKTTARLWYNNFVEPQAFVYCTAECSRYFPETLICGKDIS 120 
                *************************************************.********** 
 
V1             SGYPPDVPDKVTCVIYEYSGNMTCTWNPGRPTYIDTKYVVYVKSLETEEEQEYLTSSYIN 180 
V4             SGYPPDVPDKVTCVIYEYSGNMTCTWNPGRPTYIDTKYVVYVKSLETEEEQEYLTSSYIN 180 
Full           SGYPPDVPDKVTCVIYEYSGNMTCTWNPGRPTYIDTKYVVYVKSLETEEEQEYLTSSYIN 180 
V5             SGYPPDVPDKVTCVIYEYSGNMTCTWNPGRPTYIDTKYVVYVKSLETEEEQEYLTSSYIN 180 
V3             SGYPPDVPDKVTCVIYEYSGNMTCTWNPGRPTYIDTKYVVYVKSLETEEEQEYLTSSYIN 180 
V2             SGYPPDVPDKVTCVIYEYSGNMTCTWNPGRPTYIDTN-------LETEEEQEYLTSSYIN 173 
                ************************************:       **************** 
 
V1             ISTDSLQKGKKYLVWVQASNVLGTEKSKQLQIHLDDIVIPSASIISRAEDINTTVSKTVI 240 
V4             ISTDSLQKGKKYLVWVQASNVLGTEKSKQLQIHLDDIVIPSASIISRAEDINTTVSKTVI 240 
Full           ISTDSLQKGKKYLVWVQASNVLGTEKSKQLQIHLDDIVIPSASIISRAEDINTTVSKTVI 240 
V5             ISTDSLQKGKKYLVWVQASNVLGTEKSKQLQIHLDDIVIPSASIISRAEDINTTVSKTVI 240 
V3             ISTDSLQKGKKYLVWVQASNVLGTEKSKQLQIHLDDIVIPSASIISRAEDINTTVSKTVI 240 
V2             ISTDSLQKGKKYLVWVQASNVLGTEKSKQLQIHLDDIVIPSASIISRAEDINTTVSKTVI 233 
                ************************************************************ 
 
V1             HWNSQTSIEKVSCEMRYKATTNQTWNVKEFDTNFTYEQQSEFYLQPNATYVFQVRCQETG 300 
V4             HWNSQTSIEKVSCEMRYKATTNQTWNVKEFDTNFTYEQQSEFYLQPNATYVFQVRCQETG 300 
Full           HWNSQTSIEKVSCEMRYKATTNQTWNVKEFDTNFTYEQQSEFYLQPNATYVFQVRCQETG 300 
V5             HWNSQTSIEKVSCEMRYKATTNQTWNVKEFDTNFTYEQQSEFYLQPNATYVFQVRCQETG 300 
V3             HWNSQTSIEKVSCEMRYKATTNQTWNVS-------------------------------- 268 
V2             HWNSQTSIEKVSCEMRYKATTNQTWNTLKNLIPILHMSNS-----QNST------CSQML 282 
                **************************. .                                
 
V1             KRYWQPWSSPFFHKTPEIVPQVTVKSFQHDTQNSGLLIASIFKKHLTSDNGKQDIGLLLG 360 
V4             KRYWQPWSSPFFHKTPEID------------------------------NGKQDIGLLLG 330 
Full           KRYWQPWSSPFFHKTPEIVPQVTMKSFQHDTQNSGLLIASIFKKHLTSDNGKQDIGLLLG 360 
V5             KRYWQPWSSPFFHKTPEIVPQVTMKSFQHDTQNSGLLIASIFKKHLTSELK--------- 351 
V3             ------------------------------------------------------------ 
V2             HTYFK------------------------------------------------------- 287 
 
 
V1             MVFFAVMLSVLSLFGIFNKSLRTGIKRRILLLIPKWLYEDIPKLENSKVVKILQEKNEFM 420 
V4             MVFFAVMLSVLSLFGIFNKSLRTGIKRRILLLIPKWLYEDIPKLENSKVVKILQEKNEFM 390 
Full           MVFFAVMLSVLSLFGIFNKSLRTGIKRRILLLIPKWLYEDIPKLENSKVVKILQEKNEFM 420 
V5             --------------------------------------------EESYC----------- 356 
V3             ------------------------------------------------------------ 









V1             NNNSSEQVLYVDPVITEIEIILPEEKPIGYKKENNTGCLERKESLEKSLLTNTTVVYIPD 480 
V4             NNNSSEQVLYVDPVITEIEIILPEEKPIGYKKENNTGCLERKESLEKSLLTNTTVVYIPD 450 
Full           NNNSSEQVLYVDPVITEIEIILPEEKPIGYKKENNTGCLERKESLEKSLLTNTTVVYIPD 480 
V5             ------------------------------------------------------------ 
V3             ------------------------------------------------------------ 
V2             ------------------------------------------------------------ 
 
 
V1             LNTGYKPQISSFLPGGNHLRNDDETASSILEPPADSLNLGNNARFKKYPDFAFSVSSTNS 540 
V4             LNTGYKPQISSFLPGGNHLRNDDETASSILEPPADSLNLGNNARFKKYPDFAFSVSSTNS 510 
Full           LNTGYKPQISSFLPGGNHLRNDDETASSILEPPADSLNLGNNARFKKYPDFAFSVSSTNS 540 
V5             ------------------------------------------------------------ 
V3             ------------------------------------------------------------ 
V2             ------------------------------------------------------------ 
 
 
V1             LSNTLFLEELSLILNQGECSPPDMQNSIEGETAMLLEDALLNETIPEQTLLPDEFVSCLG 600 
V4             LSNTLFLEELSLILNQGECSPPDMQNSIEGETAMLLEDALLNETIPEQTLLPDEFVSCLG 570 
Full           LSNTLFLEELSLILNQGECSPPDMQNSIEGETAMLLEDALLNETIPEQTLLPDEFVSCLG 600 
V5             ------------------------------------------------------------ 
V3             ------------------------------------------------------------ 
V2             ------------------------------------------------------------ 
 
 
V1             SMNKELPSINSYFPQNILESHFNRFHS 627 
V4             SMNKELPSINSYFPQNILESHFNRFHS 597 
Full           SMNKELPSINSYFPQNILESHFNRFHS 627 
V5             --------------------------- 
V3             --------------------------- 
V2             --------------------------- 
 
 
Figure 4.6 Predicted amino acid sequence alignment of IL23R full length and 
IL23Rsplicevariant sequences (ClustalW v2.1) with highlighted conserved 




Figure 4.7Predicted protein expression pattern from IL23R splice variants identified in this study. Each box represents the 
protein encoded by each exon. Grey boxes indicate untranslated regions. The 5’ UTR is located in exon 1 and 5’ end of exon 
2. The 3’ UTR is located at the 3’ end of exon 11. The extracellular region spans exons 2-9 and contains the ‘WSxWS’ motif, in 
blue. The transmembrane region is encoded by exon 10, in yellow; this region contains the R318Q variant, in red. The ‘ATG’ 
indicates the initial start codon and ‘STOP’ indicates stop codons encoded by spice variants that differ from wild type IL23R. 
Annotations based on comparison of ovine sequence to annotated human sequence (Kan et al., 2008). 
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4.3.3 Expression levels of IL23Rand IL23R transcript variants 
 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for IL23R and individual IL23R transcript variants. 
Statistical analysis was carried out on genes where results were within a measureable 
range, with relative expression (ΔCq), fold change between groups and P-values 
shown in figure 4.8. Expression levels of total (primer in an area of gene that 
includes all IL23R transcripts) IL23Rwere measured; however transcript variants 
(IL23Rv1 – v5) were found to have expression levels >30 cycles and were considered 
above  the level of expression for accurate measurement. Positive controls were 
carried out for each of the IL23R transcript variants as described in section 2.6.3. 
Melt curve and cycling analysis for IL23Rv1positive control is shown in figure 4.9. 
Positive control assays for IL23Rv2 – v5can be found in appendix A1-A4. Results 
show no significant difference of IL23R gene expression between multibacillary, 






















 Fold Change P-value 
M vs P 0.98 0.99 
M vs C 1.32 0.6 




































Figure 4.8 IL23R RT-qPCR. A) Relative expression of total 
IL23Rtranscripts with B) fold change values and P-values of comparisons 







Figure 4.9Positive control RT-qPCR assay for IL23Rv1.A) Cycling and 
melt curve analysis of pooled cDNA from paraTB infected and control 
animals spiked with IL23Rv1 PCR product B) Cycling and melt curve 





4.4 Ovine IL12RB1 gene 
4.4.1 Identifying IL12RB1 transcript variants 
 
Primers described in table 2.3 were designed to identify and amplify the ovine 
IL12RB1 gene. 
The ovine IL12RB1 gene is found on chromosome 5 and consists of 16 exons. 
Initially, when amplifying short overlapping sections of the ovine IL12RB1, 
transcript variants were identified in the extracellular region of the gene. Nested PCR 
was carried out on this region (exons 1-9) to amplify and confirm individual variants.  
Subsequently, full length transcripts were sequenced using nested PCR to obtain full 
length and variant transcripts including the 3’ end of coding region. At least 6 clones, 
from separate RT-PCR reactions, were sequenced from each animal to give a 
representative sample of the transcripts present within individual sheep. Sequencing 
of the intracellular region of IL12RB1 (exons 10-16) did not identify any variation. 
Transcript variants of the extracellular region were identified from several clones in 
both paucibacillary and multibacillary animals as summarised below; these are 
shown in figure 4.11. Full length ovine IL12RB1 sequence aligned with predicted 
ovine IL12RB1 sequence (OARv3.1) is shown in figure 4.10. Nucleotide and 
predicted amino acid sequence alignments of IL12RB1 transcript variants can be 
found in appendix A5. 
Cloning and sequencing identified 4 transcript variants of ovine IL12RB1. The full 
lengthIL12RB1 gene is on the plus strand of chromosome 5 and is predicted to 
encode 730 amino acids (OARv3.1: NC_019462.1). Differences between full length 
IL12RB1 (LN878970.1) and identified transcript variants are described below; 
IL12RB1v1 (LN878971.1) contains a deletion spanning from the 3’ end of exon 5 to 
exon 8 (Chr5: 4,857,176 – 4,859,356) resulting in a change of protein frame 
consequently leading to a premature stop codon at position 185 within the protein. 
IL12RB1v2 (LN878972.1) contains a deletion spanning from the 3’ end of exon 1 to 
the 5’ end of exon 7 (Chr5: 4,853,183 – 4,858,549). This 651bp deletion is predicted 
to result in a 217 amino acid deletion at position 16-233 within the protein resulting 
101 
 
in a protein sequence of 515 amino acids. This region encodes part of the 
extracellular region of the protein. 
IL12RB1v3 (LN878973.1) contains a deletion spanning from the 3’ end of exon 3 to 
the 5’ end of exon 7 (Chr5: 4,855,325 – 4,858,535). This 528bp deletion results in 
176aa deletion at position 51-227 within the protein. This region encodes part of the 
extracellular region of the protein. 
IL12RB1v4 (LN878974.1) contains a deletion spanning from the 3’ end of exon 4 to 
the 5’ end of exon 9 (Chr5: 4,855,845 – 4,860,357) resulting in a premature stop 
codon at position 163 within the predicted protein sequence. This region encodes part 




OARV3.1            GGTGCCTAGGGCTTCACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGG 60 
Ovine_IL12RB1      --------------TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGG 46 
                                  ********************************************* 
 
OARV3.1            ACCGGATGGGACAATGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGAC 120 
Ovine_IL12RB1      ACCGGATGGGACAATGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGAC 106 
                   ************************************************************ 
 
OARV3.1            AGGGCGCTGAAGCCTGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATG 180 
Ovine_IL12RB1      AGGGCGCTGAAGCCTGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATG 166 
                   ************************************************************ 
 
OARV3.1            CAGACTCAGGCTCAGCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCG 240 
Ovine_IL12RB1      CAGACTCAGGCTCAGCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCG 226 
                   ************************************************************ 
 
OARV3.1            CTGGTTATGAATGTTCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCA 300 
Ovine_IL12RB1      CTGGTTATGAATGTTCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCA 286 
                   ************************************************************ 
 
OARV3.1            GATGCTGCCTTCAGTCTGGCCGCTGCTGCTTCTTTGCCACAGGCTCAGCCACCAAGCTGC 360 
Ovine_IL12RB1      GATGCTGCCTCCAGTCTGGCCGCTGCTGCTTCTTTGCCACAGGCTCAGCCACCAAGCTGC 346 
                   ********** ************************************************* 
 
OARV3.1            AGTTCTCCGACCAGGATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCC 420 
Ovine_IL12RB1      AGTTCTCCGACCAGGATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCC 406 
                   ************************************************************ 
 
OARV3.1            GGGCCGCCAACCGGACAGAGAAGTCCCCCAATGTTACTCTGAACCTCTACAGCTCGGTTA 480 
Ovine_IL12RB1      GGGCCGCCAACCGGACAGAGAAGTCCCCCAATGTTACTCTGAACCTCTACAGCTCGGTTA 466 
                   ************************************************************ 
 
OARV3.1            AATACGACCCTCCCCCAGGAAACATCAAGGTGTCCAAGTCAGCAGGGAAGCTGCGTATGG 540 
Ovine_IL12RB1      AATACGACCCTCCCCCAGGAAACATCAAGGTGTCCAAGTCAGCAGGGAAGCTGCGTATGG 526 
                   ************************************************************ 
 
OARV3.1            AGTGGGAGACCCCAGCCCGCCAGGATGGTGCCGAGGTACAGTTCCGGCACCGCACACCTG 600 
Ovine_IL12RB1      AGTGGGAGACCCCAGCCCGCCAGGATGGTGCCGAGGTACAGTTCCGGCACCGCACACCTG 586 
                   ************************************************************ 
 
OARV3.1            GCAGCCCGTGGAAGCTGGGTGACTGTGGACGTCAGGATGATGCTGGCTTCGAGTCATGCC 660 
Ovine_IL12RB1      GCAGCCCGTGGAAGCTGGGTGACTGTGGACGTCAGGATGATGCTGGCTTCGAGTCATGCC 646 
                   ************************************************************ 
 
OARV3.1            TCTGCCCCTTGGAGATGGACATGGCCCAGGAATTCCAGCTGCGGCGGCGTCTGGGGCCAG 720 
Ovine_IL12RB1      TCTGCCCCTTGGAGATGGACATGGCCCAGGAATTCCAGCTGCGGCGGCGTCTGGGGCCAG 706 
                   ************************************************************ 
 
OARV3.1            GGGTCCCCGGAGGTCCCTGGAGCAGCTGGAGCAGCCCTGTGTGCATCCCCCCTGAAACCC 780 
Ovine_IL12RB1      GGGTCCCCGGAGGTCCCTGGAGCAGCTGGAGCAGCCCTGTGTGCATCCCCCCTGAAACCC 766 
                   ************************************************************ 
 
OARV3.1            CTCCACAGGCTGAGGTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGG 840 
Ovine_IL12RB1      CTCCACAGGCTGAGGTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGG 826 
                   ************************************************************ 
 
OARV3.1            TGGCCTTACATGAGCAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACC 900 
Ovine_IL12RB1      TGGCCTTACATGAGCAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACC 886 
                   ************************************************************ 
 
OARV3.1            CTGGCATGGAGGTGACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCA 960 
Ovine_IL12RB1      CTGGCATGGAGGTGACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCA 946 
                   ************************************************************ 
 
OARV3.1            GGGCCAAGAAGACTCTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATC 1020 
Ovine_IL12RB1      GGGCCAAGAAGACTCTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATC 1006 
                   ************************************************************ 
 
OARV3.1            TGACCATCGTTTCCCAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTG 1080 
Ovine_IL12RB1      TGACCATCGTTTCCCAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTG 1066 
                   ************************************************************ 
 
OARV3.1            CCTGCATCCACTCAGAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCA 1140 
Ovine_IL12RB1      CCTGCATCCACTCAGAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCA 1126 
                   ************************************************************ 
 
OARV3.1            TGCATTGGCCAGCCCGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCC 1200 
Ovine_IL12RB1      TGCATTGGCCAGCCCGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCC 1186 
                   ************************************************************ 
 
OARV3.1            AGGAGGAGAACCTTGCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAA 1260 
Ovine_IL12RB1      AGGAGGAGAACCTTGCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAA 1246 
                   ************************************************************ 
 
OARV3.1            TGGCAACTCACAGCTGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACA 1320 
Ovine_IL12RB1      TGGCAACTCACAGCTGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACA 1306 
                   ************************************************************ 
 
OARV3.1            TCGCCATCTTTGCCTCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCA 1380 
Ovine_IL12RB1      TCGCCATCTTTGCCTCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCA 1366 






OARV3.1            CCTACCATTTTGGAGGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGA 1440 
Ovine_IL12RB1      CCTACCATTTTGGAGGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGA 1426 
                   ************************************************************ 
 
OARV3.1            AGCTCAGCCAGGATTCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTG 1500 
Ovine_IL12RB1      AGCTCAGCCAGGATTCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTG 1486 
                   ************************************************************ 
 
OARV3.1            GCGTCCTGAAGGAGTACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGC 1560 
Ovine_IL12RB1      GCGTCCTGAAGGAGTACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGC 1546 
                   ************************************************************ 
 
OARV3.1            TGCACGTGAAGCCCACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTT 1620 
Ovine_IL12RB1      TGCACGTGAAGCCCACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTT 1606 
                   ************************************************************ 
 
OARV3.1            ACAAGGTGCAGGTTCGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGC 1680 
Ovine_IL12RB1      ACAAGGTGCAGGTTCGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGC 1666 
                   ************************************************************ 
 
OARV3.1            ATTTCACCATCGAAGTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTT 1740 
Ovine_IL12RB1      ATTTCACCATCGAAGTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTT 1726 
                   ************************************************************ 
 
OARV3.1            TGGGGAGTTTCGTGAGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGG 1800 
Ovine_IL12RB1      TGGGGAGTTTCGTGAGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGG 1786 
                   ************************************************************ 
 
OARV3.1            CTGTAAGGCACCTGTGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCT 1860 
Ovine_IL12RB1      CTGTAAGGCACCTGTGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCT 1846 
                   ************************************************************ 
 
OARV3.1            CTGGCAGCCAGGGGAAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGG 1920 
Ovine_IL12RB1      CTGGCAGCCAGGGGAAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGG 1906 
                   ************************************************************ 
 
OARV3.1            TGTCTCCACACGAGGCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACA 1980 
Ovine_IL12RB1      TGTCTCCACACGAGGCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACA 1966 
                   ************************************************************ 
 
OARV3.1            TGGGCACACTTGGGACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAG 2040 
Ovine_IL12RB1      TGGGCACACTTGGGACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAG 2026 
                   ************************************************************ 
 
OARV3.1            CCCCGGACACAGAGCTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTG 2100 
Ovine_IL12RB1      CCCCGGACACAGAGCTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTG 2086 
                   ************************************************************ 
 
OARV3.1            GGGCTCTGAGGCCTGGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTA 2160 
Ovine_IL12RB1      GGGCTCTGAGGCCTGGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTA 2146 
                   ************************************************************ 
 
OARV3.1            GACCCCCACTGCTGCTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAG 2220 
Ovine_IL12RB1      GACCCCCACTGCTGCTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAG 2206 
                   ************************************************************ 
 
OARV3.1            AAGCAGGAACAGCTGCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGG 2280 
Ovine_IL12RB1      AAGCAGGAACAGCTGCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGG 2266 
                   ************************************************************ 
 
OARV3.1            CTGTTGTTCACTGCACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCG 2340 
Ovine_IL12RB1      CTGTTGTTCACTGCACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCG 2326 
                   ************************************************************ 
 
OARV3.1            ATATGGCTGTCCTATTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCTAGTG 2400 
Ovine_IL12RB1      ATATGGCTGTCCTATTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA---- 2382 
                   *******************************************************:     
 
OARV3.1            GCTGGCCTGGGGCCACACGACACACGCAAG   2430 
Ovine_IL12RB1      ------------------------------   2382 
 
Figure 4.10 Nucleotide sequence alignment of full length ovine 
IL12RB1 sequence and predicted IL12RB1 ovine sequence (ClustalW 

















































































exon 4-6 deletion 
IL12RB1v4  
exon 5-7 deletion 
 ’ 
Figure 4.11 Schematic diagrams of the ovine IL12RB1 gene and splice variants 
(IL12RB1v1-4). Boxes represent individual exons with chromosome location 
shown. Grey boxes indicate UTRs with deleted variant regions highlighted in 





4.4.2 Ovine IL12RB1 translated protein sequence analysis 
 
Nucleotide sequences of full length and alternatively spliced variant transcripts of 
ovine IL12RB1 were translated into amino acid sequences and aligned using 
ClustalW v2.1 to identify changes to protein structure that occur as a result of splice 
variation. Protein alignment of full length IL12RB1 against sheep genome assembly 
OARv3.1 is shown in figure 4.12. Alignment of human IL12RB1 and ovine 
IL12RB1 amino acid sequences identified conserved structural regions of the 
IL12RB1 protein. Conserved regions are highlighted and described in ‘KEY’. This 
alignment can be found in appendix A8. Alignments were used to form predicted 
protein structure maps and predict biological functions based on human IL12RB1 














IL12RB1         MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
OARV3.1         MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
                ************************************************************ 
 
IL12RB1         YECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
OARV3.1         YECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
                ************************************************************ 
 
IL12RB1         ANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRTPGS 180 
OARV3.1         ANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRTPGS 180 
                ************************************************************ 
 
IL12RB1         PWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPETPP 240 
OARV3.1         PWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPETPP 240 
                ************************************************************ 
 
IL12RB1         QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 300 
OARV3.1         QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 300 
                ************************************************************ 
 
IL12RB1         KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 360 
OARV3.1         KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 360 
                ************************************************************ 
 
IL12RB1         WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 420 
OARV3.1         WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 420 
                ************************************************************ 
 
IL12RB1         IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 480 
OARV3.1         IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 480 
                ************************************************************ 
 
IL12RB1         LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 540 
OARV3.1         LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 540 
                ************************************************************ 
 
IL12RB1         TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 600 
OARV3.1         TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 600 
                ************************************************************ 
 
IL12RB1         SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 660 
OARV3.1         SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 660 
                ************************************************************ 
 
IL12RB1         DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 720 
OARV3.1         DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 720 
                ************************************************************ 
 
IL12RB1         GTAASSYRED  730 
OARv3.1         GTAASSYRED  730 
                **********  
 
  Figure. 4.12 Predicted amino acid sequence alignment of ovine IL12RB1 full 
length and sequence from sheep genome assembly OARv3.1 (ClustalW 
v2.1) with highlighted conserved sequence based on annotated human and 
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Figure 4.13Predicted protein expression pattern from IL12RB1 splice variants identified in this study. Each box 
represents the protein encoded by each exon. Grey boxes indicate UTRs. The 5’ UTR is located within the 5’ end of 
exon 1. The 3’ UTR is located at the 3’ end of exon 16. The extracellular region spans exons 1-13 and contains the 
‘WSxWS’ motif, in blue. The transmembrane region is encoded by exon 14, in yellow. The ‘ATG’ indicates the initial start 
codon and ‘STOP’ indicates stop codons encoded by spice variants that differ from full length (wild-type) IL12RB1. 







4.4.3 Expression levels of IL12RB1and IL12RB1 transcript variants 
 
RT-qPCR analysis was performed in multibacillary, paucibacillary and uninfected 
control animals for total (primer in an area of gene that includes all IL12RB1 
transcripts) IL12RB1and individualIL12RB1 transcript variants. Statistical analysis 
was carried out on genes where results were within a measureable range, with 
relative expression (ΔCq), fold change between groups and P-values shown. 
Expression levels of total IL12RB1, IL12RB1v3 and IL12RB1v4 were measured 
(figures 4.14, 4.15, 4.16); transcript variants IL12RB1v1and v2were detected only 
after >30 cycles and so expression levels were too low for accurate measurement. 
Positive controls were carried out for IL12RB1v1 and v2as described in section 2.3.6. 
Melt curve and cycle analysis for each of these assays can be found in appendix A6 
and A7. 
The results show no significant difference in gene expression between groups for 
total IL12RB1and IL12RB1v4; however a 2.1 fold increase in IL12RB1v3 expression 
was found in multibacillary sheep compared to paucibacillary, with a significant P-




















 Fold Change P-value 
M vs P 0.62 0.28 
M vs C 0.97 0.99 



















Figure4.14IL12RB1 RT-qPCR. A) Relative expression of total IL12RB1 
with B) fold change and P-values for comparisons between 

























 Fold Change P-value 
M vs P 2.1 0.04 
M vs C 1.42 0.32 



















Figure 4.15IL12RB1v3 RT-qPCR. A) Relative expression of IL12RB1v3 
gene with B) fold change and P-values for comparisons between 
























 Fold Change P-value 
M vs P 1.87 0.08 
M vs C 1.1 0.89 


































Figure 4.16 IL12RB1v4 RT-qPCR. A) Relative expression of IL12RB1v4 
gene with B) fold change and P-values for comparisons between 








 Previous study has identified an allelic variant present in sheep IL23A 
(Gossner et al., 2012b). This variant was not found in any of the sequenced 
clones from either multibacillary or paucibacillary animals in this study. 
 Sequencing of the ovine IL23R has identified full length sequence and 5 
spliced variants of this gene. 
 Sequencing of the ovine IL12RB1 has identified full length sequence and 4 
spliced variants of this gene.  
 All variants identified, excluding IL23Rv1, alter amino acid sequence and 
may have an effect of IL23R/IL23/IL12 ligand binding or signalling. 
 No differential expression was found between paucibacillary and 
multibacillary groups for total IL23R, IL12RB1and IL12RB1v4 gene 
expression. 
  Expression of IL12RB1v3 was significantly higher in multibacillary animals 
than in paucibacillary animals (P=0.04). This variant has a truncated 
















IL25 is a Th2 cytokine belonging to the IL17 cytokine family (also known as IL17E). 
The interleukin-17 (IL17) family consists of six cytokine members (IL17A-F); five 
function as pro-inflammatory mediators during Th17 immune responses (IL17A, B, 
C, D and F), and IL25 that is largely anti-inflammatory. IL25 was originally 
identified by sequence homology to other IL17 cytokine family members (Gu et al., 
2013). Production of IL17A and IL17F by Th17 cells has been shown to induce a 
Th1-like immune response through stimulation of IL6, IL8 and TNFα (Pappu et al., 
2011). In contrast, IL25 is markedly different as it plays a key role in the stimulation 
and maintenance of Th2 immune responses (Fort et al., 2001). In human studies it 
has been shown that IL25 is present in several tissues including the lung, small 
intestine, colon and stomach. IL25 has been reported in many cell types including 
Th2 cells, macrophages, epithelial cells, eosinophils, basophils and mast cells and 
has been shown to link innate and adaptive immunity by enhancing Th2 cytokine 
production (Pappu et al., 2011). Administration of IL25 induces expression of IL4, 
IL5 and IL13 in Th2 cells (Owyang et al., 2006). Mice injected with exogenous IL-
25 positively regulate Th2 responses in various organs and this has also been shown 
in transgenic mice over-expressing IL25. In these models, IL25 was shown to 
increase IL4 and IL13 expression and serum IgE levels in the lung and digestive tract 
(Fort et al., 2001. Kim et al., 2002. Hurst et al., 2002). In other studies, IL25 
deficient mice were unable to clear parasitic helminths including Nippostrongylus 
and Trichurismuris owing to failed Th2 responses (Fallon et al., 2006. Owyang et 
al., 2006). 
The IL17 receptor family (IL17RA to IL17RE) are a unique group of proteins that 
share minimal structural and signal transduction properties with other receptors 
(Gaffen, 2009). IL17Rs are membrane-bound proteins that contain single 
transmembrane domains and possess a unique structural motif within the cytoplasmic 
tail termed the similar expression to fibroblast growth factor genes/IL17R (SEFIR) 
domain (Novatchkova et al., 2003). NF-κB activator 1 (Act1) is also a member of the 
SEFIR protein family and acts as an adaptor protein in the signal transduction of 
several IL17Rs (Zhang et al., 2014. Chang et al., 2006. Swaidani et al., 2009). 
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The IL25 receptor was initially identified as a receptor for IL17B; however recent 
studies have subsequently shown that this receptor exhibits higher affinity for IL25 
than IL17B (Gu et al., 2013). The IL25 cytokine receptor (IL25R) is composed of 
IL17RA and IL17RB and the biological effects of IL25 are mediated by this receptor 
complex. In humans IL17RB shares approximately 26% amino acid identity with 
IL17RA and IL25 is the high affinity ligand for IL17RB (Gaffen, 2009). In mice, 
cultured splenocytes from either IL17RA knockout or IL17RB knockout models are 
unable to produce IL5 and IL13 in response to IL25 stimulation (Rickel et al., 2008). 
Furthermore, administration of antagonistic mAbs to either IL17RA or IL17RB 
completely blocked IL25 induced pulmonary inflammation; indicating that both 
receptor components are essential for signalling via interaction with the IL25 ligand 
(Rickel et al., 2008). IL25 has been demonstrated to activate NFκB, however the 
molecular mechanisms of IL25R signalling pathways continue to be investigated; 
IL17RB contains a TNF receptor associated factor 6 (TRAF6) binding motif in its 
cytoplasmic tail whereas IL17RA does not have this motif (Gaffen, 2009). The 
TRAF family proteins serve as adaptor proteins in the assembly of receptor 
associated signalling complexes and link upstream receptors to downstream effector 
molecules, including activation of NF-κB. TRAF6 is recruited by Act1 during IL17R 
signalling. Maezawa et al. showed that IL25R-mediated NFκB activation, but not 
MAPK activation, was diminished in a TRAF6 deficient murine model; indicating 
that TRAF6 plays a critical role in IL25R mediated signal transduction and gene 
expression (Maezawa et al., 2006). 
Although IL17RB has been found to interact only with IL17RA, IL17RA has been 
shown to create a receptor complex also with IL17RC (figure 5.1). The IL17RA/C 
receptor complex is required for IL17A and IL17F induction and subsequent 




Figure 5.1 IL17 family cytokine and receptor interactions. Image adapted 
(Zepp et al., 2011) 
 
 
Responses induced by IL25 are characterised by elevated levels of type-2 cytokines, 
often leading to pathological changes in the gut and lungs. Elevated IgE and IgG1, 
epithelial cell hyperplasia and increased mucus secretion are typical pathological 
responses found in IL25 induced inflammation (Dong, 2008). During gut 
inflammation an anti-inflammatory role has been attributed to IL25 in type-1 models 
of disease (Caruso et al., 2009). The mechanism by which IL25 acts to 
reduce/prevent inflammation of the gut has not yet been confirmed, although it has 
been shown that IL25 is associated with the induction of alternatively-activated 
macrophages with anti-inflammatory properties (Rizzo et al., 2012). IL25 is able to 
prevent oxazolone-induced colitis, a murine model of Th2 driven colitis resembling 
UC; subsequently it has been suggested that IL25 may contribute to a broad negative 
effect on inflammatory properties of intestinal macrophages rather than specifically 
suppressing Th1/Th17 pathway components (Franze et al., 2011). Treatment with 
exogenous IL25 was shown to increase expression of type 2 cytokines in mice 
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genetically susceptible to Trichuris muris helminth infection, whilst IL25 knockout 
mice developed severe intestinal inflammation associated with high IFNγ and IL17A 
expression (Owyang et al., 2006). It is considered that IL25, including the IL25 
receptors, act as a critical link between Th1/Th17 inflammatory cell-mediated and 
Th2 immune responses.  
Few studies that have investigated IL17RA and IL17RB at the gene/transcript level 
have identified polymorphisms that may be associated with inflammation of the lung. 
Jung et al. analyzed the association of polymorphisms in the IL17RB gene using 954 
asthmatic patients compared to 265 healthy control subjects. It was found that a rare 
allele of IL17RB (5661G>A) may have a protective role in the development of 
asthma (Jung et al., 2009). Furthermore, 15 SNPs of the IL17RA gene were analyzed 
in 825 healthy control subjects, 143 subjects with Aspirin Exacerbated Respirator 
Disease (AERD) and 411 subjects with aspirin-tolerant asthma (ATA). Three of the 
SNPs (1075A>G, 947A>G, 50C>T) were shown potentially to decrease the risk of 
AERD via attenuation of IL17RA gene (Park et al., 2013).  
In this chapter sequencing of full gene transcripts and transcript variants of the IL25 
cytokine receptors, IL17RB and IL17RA, is described. This chapter will also describe 
expression of the IL25 cytokine and IL25receptor transcripts, including identified 
spliced variants, in multibacillary and paucibacillary paraTB infected and in 





5.2 Ovine IL17RA gene 
 
5.2.1 Sequencing of ovine IL17RA gene 
 
The ovine IL17RA sequence (LN878979.1) was obtained by amplifying gene 
sections by RT-PCR (described in Chapter 2) and compiling a consensus sequence of 
the gene. Initially primers were designed based on a predicted ovine IL17RA 
sequence (XM_012140663.1) template compiled from predicted bovine sequence 
(XM_010827960.1) and a BLAST alignment of known human (NM_014339.6) and 
rat IL17RA(NM_001107883.2) against the sheep genome OARv3.1, this template is 
depicted in figure 5.2. Partial IL17RA was sequenced; however attempts to amplify 
5’ and 3’ coding region using primers designed on the predicted ovine template 
(exons 1 and 13) were unsuccessful.  The partially amplified IL17RA sequence was 
used to design primers for 5’ and 3’ rapid amplification of cDNA ends (RACE) RT-
PCR as described in Chapter 2. At least three clones were sequenced for both 5’ and 
3’ RACE from different animals/RT-PCR reactions that gave a product of expected 
size and consensus sequences were compiled.  
PCR products obtained from 5’ RACE RT-PCR only ever generated sequence as far 
as predicted exon 2 in the 5’ direction, despite several attempts. In order to amplify 
the IL17RA sequence further upstream of exon 2, a search of the ovine IL17RA gene 
was carried out on data collected from RNA-seq analysis (carried out by Dr. Anton 
Gossner). RNA-seq provides short (~100bp) sequenced reads of all RNA in a 
sample; these reads are subsequently mapped to the sheep genome OARv3.1. Results 
are shown as clusters of reads in exon regions using Integrative Genomics Viewer 
v2.3 (IGV - http://www.broadinstitute.org). A representative image of this is shown 
along with the IL17RA 5’ region in figure 5.3. IL17RA 5’ sequence data taken from 
IGV was used to design a primer within sequence upstream of the predicted ovine 
IL17RA start codon, that would amplify the start codon in predicted exon 1and the 5’ 
UTR.  IL17RA sequence obtained from this method gave amplified sequence 5’ and 
3’ of the predicted ovine exon 1; however the predicted exon 1, containing the 
predicted start codon, was not found, this is shown in figure 5.4. When translated to 
protein sequence the ovine IL17RA sequence that did not contain the predicted exon 
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1 presented with a premature stop codon, thus no full protein sequence that matched 
the predicted ovine protein sequence was found (figure 5.5 and 5.6). No transcript 
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Figure 5.2 Gene map of predicted ovine IL17RA sequence template used to 
design primers for ovine IL17RA gene amplification. Template was compiled 
from predicted bovine sequence and sequence from a BLAST alignment of 
known human and rat IL17RA against the sheep genome OARv3.1. 





Figure 5.3 A) Representative image of RNA-seq data analysis using Integrative 
Genome Viewer software, showing short  reads of nucleotide sequences mapped 
to chromosomal locations within sheep genome OARv3.1 and B) RNA-seq data at 
IL17RA 5’ end with predicted ovine start codon region indicated by vertical dotted 
line. Primers were designed upstream and downstream of the predicted ovine 




5.2.2 IL17RA nucleotide sequence analysis 
 
The ovine IL17RA sequence was aligned to the sheep genome OARv3.1. The 3’ 
region of ovine IL17RA was unable to be mapped to a chromosome location of 
OARv3.1 as this area of the sheep genome has yet to be annotated. A schematic 
diagram of the sequence is shown in figure 5.4, with the predicted exon one 
highlighted. This exon was not found in any of the IL17RA clones sequenced. The 
nucleotide sequence alignment of ovine IL17RA mapped to chromosome 3 of 

































































Figure 5.4 Gene map of amplified ovine IL17RAgene sequence. Obtained 
using primers designed 5’ upstream of the predicted exon 1/start codon. The 




5.2.3 Ovine IL17RA translated protein sequence analysis 
 
Consensus sequence of ovine IL17RA gene was translated into amino acid sequence 
and aligned to the coding region amino acid sequence of predicted ovine IL17RA, 
from this it could be seen that there is 77% sequence similarity between the ovine 
IL17RA protein sequence identified in this study and predicted IL17RA sequence 
(figure 5.5 and 5.6); however without the presence of the predicted start codon, the 
ovine IL17RA gene contains a premature stop codon. A second open reading frame 
is shown in sequence a) which may encode a truncated IL17RA protein.  
Furthermore the sequenced and predicted ovine amino acid sequences were aligned 
with the two known isoforms of human IL17RA (Isoform 1: NP_055154.3 and 
Isoform 2: NP_001276834.1); this shows the presence of a conserved transmembrane 
domain sequence in both the sequenced and predicted ovine IL17RA sequences 



















Predicted       ------------------MAGDQELERDPGLFVY---TCLLYTWPENRAPLPAGSPEK-- 37 
Sequenced       MTDVGAVNQKSAWSRSLCQPGAMEFQGTEKLLLPGCPSCREGTWAALQESLEHSRRGKSL 60 
                                   .*  *::    *::    :*   **.  : .*  .   *   
 
Predicted       -RG--GLNCTVKNSTCLDDSWIHPRNLTPSSPKNVQTQLRFAHTQQGHLLPVVHIEWTLQ 94 
Sequenced       SQGPKGLNCTVKNSTCLDDSWIHPRNLTPSSPKNVQTQLRFAHTQQGHLLPVVHIEWTLQ 120 
                 :*  ******************************************************* 
 
Predicted       TDASVLYLEGAELSILQLSTNERLCVRFEFLTTLRHHHKRWRFAFSHFVVEPREEYEVTV 154 
Sequenced       TDASVLYLEGAELSILQLSTNERLCVRFEFLTTLRHHHKRWRFAFSHFVVEPREEYEVTV 180 
                ************************************************************ 
 
Predicted       HHLPKPIPDGDPNHQSRNFLVPDCKDPRMKDTTPCVSSGSLWDPNITVETLEAHQLRLSF 214 
Sequenced       HHLPKPIPDGDPNHQSRNFLVPDCKDPRMKDTTPCVSSGSLWDPNITVETLEAHQLRLSF 240 
                ************************************************************ 
 
Predicted       TPWNESTSYQVLLHSFPPAENQSCFQHVVDMPVPAQEAAPQRCHITVTLRDSSWCCRHHV 274 
Sequenced       TPWNESTSYQVLLHSFPPAENQSCFQHVVDMPVPAQEAAPQRCHITVTLLDSSWCCRHHV 300 
                ************************************************* ********** 
 
Predicted       QIQPFFSSCLNDCLRHSVSVACPEVSHTPGGTRDHTPLWVSAFITGLSILLVGSVILLIL 334 
Sequenced       QIQPFFSSCLNDCLRHSVSMACPEVSHTPDAAEDHTPLWVSAFITGLSILLVGSVILLIL 360 
                *******************:*********..:.*************************** 
 
Predicted       CMTWRLPGKR--KHEDGTKDTEILPAATSLTPPPLKPRKVWIVYSADHPLYVDVVLKFAQ 392 
Sequenced       CMTWRLPGFRQGKHEDGTKDTEILPAATSLTPPPLKPRKVWIVYSADHPLYVDVVLKFAH 420 
                ******** *  ***********************************************: 
 
Predicted       FLLTVCGTEVALDLLEEQAISEVGVMTWVGRQKQEVADSNSKIVVLPRQPRKKRFLSMKT 452 
Sequenced       ----------------GPSLGRPGGQAGVGASGPDAKD-QGFFTRMPCSPQRR--LS--- 458 
                                  ::.. *  : ** .  :. * :. :. :* .*:::  **    
 
Predicted       ESGCWS 458 
Sequenced       ------ 
Figure 5.5 Translated amino acid sequence alignment of ovine IL17RA and 

























Figure 5.6 ExPASy TRANSLATE sequence output of A) sequenced ovine 
IL17RA protein and B) predicted ovine IL17RA protein. Open reading frames are 






Homo_v1        ----------------------MGAARSPPSAVPGPLLGLLLLLLGVLAPGGASLRL-LD 
Homo_v2        ----------------------MGAARSPPSAVPGPLLGLLLLLLGVLAPGGASLRL-LD 
Sequenced      MTDVGAVNQKSAWSRSLCQPGAMEFQGTEKLLLPGC----PSCREGTWAALQESLEHSRR 
Predicted      ------------------MAGDQELERDPGLFVY-------TCLLYTWPENRAPLP---- 
                                               :             .       *      
 
Homo_v1        HRALVCSQPGLNCTVKNSTCLDDSWIHPRNLTPSSPKDLQIQLHFAHTQQGDLFPVAHIE 
Homo_v2        HRALVCSQPGLNCTVKNSTCLDDSWIHPRNLTPSSPKDLQIQLHFAHTQQGDLFPVAHIE 
Sequenced      GKSLSQGPKGLNCTVKNSTCLDDSWIHPRNLTPSSPKNVQTQLRFAHTQQGHLLPVVHIE 
Predicted      -AGSPEKRGGLNCTVKNSTCLDDSWIHPRNLTPSSPKNVQTQLRFAHTQQGHLLPVVHIE 
                 .      ****************************::* **:*******.*:**.*** 
 
Homo_v1        WTLQTDASILYLEGAELSVLQLNTNERLCVRFEFLSKLRHHHRRWRFTFSHFVVDPDQEY 
Homo_v2        WTLQTDASILYLEGAELSVLQLNTNERLCVRFEFLSKLRHHHRRWRFTFSHFVVDPDQEY 
Sequenced      WTLQTDASVLYLEGAELSILQLSTNERLCVRFEFLTTLRHHHKRWRFAFSHFVVEPREEY 
Predicted      WTLQTDASVLYLEGAELSILQLSTNERLCVRFEFLTTLRHHHKRWRFAFSHFVVEPREEY 
               ********:*********:***.************:.*****:****:******:* :** 
 
Homo_v1        EVTVHHLPKPIPDGDPNHQSKNFLVPDCEHARMKVTTPCMSSGSLWDPNITVETLEAHQL 
Homo_v2        EVTVHHLPKPIPDGDPNHQSKNFLVPDCEHARMKVTTPCMSSGSLWDPNITVETLEAHQL 
Sequenced      EVTVHHLPKPIPDGDPNHQSRNFLVPDCKDPRMKDTTPCVSSGSLWDPNITVETLEAHQL 
Predicted      EVTVHHLPKPIPDGDPNHQSRNFLVPDCKDPRMKDTTPCVSSGSLWDPNITVETLEAHQL 
               ********************:*******:. *** ****:******************** 
 
Homo_v1        RVSFTLWNESTHYQILLTSFPHMENHSCFEHMHHIPAPRPEEFHQRSNVTLTLRNLKGCC 
Homo_v2        RVSFTLWNESTHYQILLTSFPHMENHSCFEHMHHIPAPRPEEFHQRSNVTLTLRNLKGCC 
Sequenced      RLSFTPWNESTSYQVLLHSFPPAENQSCFQHVVDMPVPAQEAAPQRCHITVTLLDSSWCC 
Predicted      RLSFTPWNESTSYQVLLHSFPPAENQSCFQHVVDMPVPAQEAAPQRCHITVTLRDSSWCC 
               *:*** ***** **:** ***  **:***:*: .:*.*  *   **..:*:** : . ** 
 
Homo_v1        RHQVQIQPFFSSCLNDCLRHSATVSCPEMPDTPEPIPDYMPLWVYWFITGISILLVGSVI 
Homo_v2        RHQVQIQPFFSSCLNDCLRHSATVSCPEMPDTPEPIP----------------------- 
Sequenced      RHHVQIQPFFSSCLNDCLRHSVSMACPEVSHTPDAAEDHTPLWVSAFITGLSILLVGSVI 
Predicted      RHHVQIQPFFSSCLNDCLRHSVSVACPEVSHTPGGTRDHTPLWVSAFITGLSILLVGSVI 
               **:******************.:::***: .**                            
 
Homo_v1        LLIVCMTWRLAGPGSEKYSDDTKYTDGLPAA-DLIPPPLKPRKVWIIYSADHPLYVDVVL 
Homo_v2        -----------GPGSEKYSDDTKYTDGLPAA-DLIPPPLKPRKVWIIYSADHPLYVDVVL 
Sequenced      LLILCMTWRLPGFRQGKHEDGTKDTEILPAATSLTPPPLKPRKVWIVYSADHPLYVDVVL 
Predicted      LLILCMTWRLPGKR--KHEDGTKDTEILPAATSLTPPPLKPRKVWIVYSADHPLYVDVVL 
                          *    *:.* ** *: **** .* ***********:************* 
 
Homo_v1        KFAQFLLT-ACGTEVALDLLEEQAISEAGVMTWVGRQKQEMVESNSKIIVLCSRGTRAKW 
Homo_v2        KFAQFLLT-ACGTEVALDLLEEQAISEAGVMTWVGRQKQEMVESNSKIIVLCSRGTRAKW 
Sequenced      KFAHGPSLGRPGGQAG-----------------VGASGPDAKD-QGFFTRMPCSPQRRLS 
Predicted      KFAQFLLTV-CGTEVALDLLEEQAISEVGVMTWVGRQKQEVADSNSKIVVLPRQPRKKRF 
               ***:       * :..                 ** .  :  : :. :  :     :    
 
Homo_v1        QALLGRGAPVRLRCDHGKPVGDLFTAAMNMILPDFKRPACFGTYVVCYFSEVSCDGDVPD 
Homo_v2        QALLGRGAPVRLRCDHGKPVGDLFTAAMNMILPDFKRPACFGTYVVCYFSEVSCDGDVPD 
Sequenced      ------------------------------------------------------------ 
Predicted      LSMKTES-------------------------------GCWS------------------ 
                                                                            
 
Homo_v1        LFGAAPRYPLMDRFEEVYFRIQDLEMFQPGRMHRVGELSGDNYLRSPGGRQLRAALDRFR 
Homo_v2        LFGAAPRYPLMDRFEEVYFRIQDLEMFQPGRMHRVGELSGDNYLRSPGGRQLRAALDRFR 
Sequenced      ------------------------------------------------------------ 
Predicted      ------------------------------------------------------------ 
                                                                            
 
Homo_v1        DWQVRCPDWFECENLYSADDQDAPSLDEEVFEEPLLPPGTGIVKRAPLVREPGSQACLAI 
Homo_v2        DWQVRCPDWFECENLYSADDQDAPSLDEEVFEEPLLPPGTGIVKRAPLVREPGSQACLAI 
Sequenced      ------------------------------------------------------------ 
Predicted      ------------------------------------------------------------ 
                                                                            
 
Homo_v1        DPLVGEEGGAAVAKLEPHLQPRGQPAPQPLHTLVLAAEEGALVAAVEPGPLADGAAVRLA 
Homo_v2        DPLVGEEGGAAVAKLEPHLQPRGQPAPQPLHTLVLAAEEGALVAAVEPGPLADGAAVRLA 
Figure 5.7 Amino acid sequence alignment of translated ovine IL17RA, 
predicted ovine IL17RA and two human isoforms of IL17RA; Homo_v1 




5.2.4 Expression levels of IL17RA transcripts 
 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for total IL17RA using available sequence. Statistical 
analysis was carried out on genes where results were within a measureable range, 
with relative expression (ΔCq), fold change between groups and P-values shown in 
figure 5.8. Expression of IL17RA was found to be significantly increased in the 
paucibacillary group when compared to multibacillary (2 fold, P=0.001) and control 





















 Fold Change P-value 
M vs P -2 0.001 
M vs C 0.46 0.43 







































Figure 5.8 IL17RA RT-qPCR. A) Relative expression of total IL17RA 
gene with B) fold change and P-values for comparisons between 





5.3Ovine IL17RB gene 
5.3.1 Identifying IL17RB transcript variants 
 
In order to identify whether there were any transcript variants present in the IL17RB 
gene, full length sequence for IL17RB was amplified by RT-PCR using primers 
described in table 2.3. At least six clones, from separate RT-PCR reactions, for each 
infected animal were sequenced within individual samples. Each clone was aligned 
against the sheep genome OARv3.1 and differences in sequence that were present in 
two or more clones from different animals were considered transcript variants. 
Transcript variants were identified from several clones in both paucibacillary and 
multibacillary animals, along with full length gene transcripts; summarised below. A 
gene map including transcript variants is shown in figure 5.9.  
Full ovine IL17RB transcript sequence and variant transcripts were aligned using 
ClustalW v2.1, this is shown in figure 5.10. 
Cloning and sequencing identified 3 transcript variants of ovine IL17RB. The 
IL17RB gene is encoded on the minus strand of chromosome 19 (OARv3.1: 
NC_019476.1) and is predicted to encode a protein sequence of 497 amino acids. 
Differences between full length IL17RB (LN878975.1) and identified transcript 
variants are described below; 
IL17RBv1 (LN878976.1) has a deletion of 96bp (bp 975-1071) resulting in a 32 
amino acid deletion at position 311 within the predicted protein sequence. This 
results in a truncated intracellular region with a loss of the conserved TRAF6 binding 
motif. 
IL17RBv2 (LN878977.1) has a deletion of exon 4 (Chr19: 47,056,667 – 47,054,190) 
resulting in a change of frame and a premature stop codon at position 96 within the 
protein. 
IL17RBv3 (LN878978.1) has a deletion of exon 4 (Chr19: 47,056,667 – 47,054,190) 
and an insertion of 177bp (bp 651-828) at the 5’ end of exon 8 (Chr19: 47,050,145 – 
47,049,971); resulting in a change of frame and a premature stop codon at position 








































































Figure 5.9 Schematic diagrams of the ovine IL17RB gene and splice variants 
(IL17RBv1-3) identified in this study. Boxes represent individual exons with 
chromosome location shown. Grey boxes indicate untranslated region (UTR) 
with variant regions highlighted in red. The ‘ATG’ is initial start codon and stop 




V2             TCGGCCCGAAGCCGATCCGGACCCCGCGCGGTGGCCCCGCGATGTTGCTAGTACTGCTGA 60 
V3             TCGGCCCGAAGCCGATCCGGACCCCGCGCGGTGGCCCCGCGATGTTGCTAGTACTGCTGA 60 
Full           TCGGCCCGAAGCCGATCCGGACCCCGCGCGGTGGCCCCGCGATGTTGCTAGTACTGCTGA 60 
V1             TCGGCCCGAAGCCGATCCGGACCCCGCGCGGTGGCCCCGCGATGTTGCTAGTACTGCTGA 60 
                ************************************************************ 
 
V2             GCCTGGCCGCGCTGTGCTGGGGGGCCGTGCCTCCGGAGCCGACAATTCAGTGTGGCTCTG 120 
V3             GCCTGGCCGCGCTGTGCTGGGGGGCCGTGCCTCCGGAGCCGACAATTCAGTGTGGCTCTG 120 
Full           GCCTGGCCGCGCTGTGCTGGGGGGCCGTGCCTCCGGAGCCGACAATTCAGTGTGGCTCTG 120 
V1             GCCTGGCCGCGCTGTGCTGGGGGGCCGTGCCTCCGGAGCCGACAATTCAGTGTGGCTCTG 120 
                ************************************************************ 
 
V2             AACCCGGACCGTCTCCAGAGTGGATGGTCCGACACACCCTGACCCCAGGAGACCTAAGGG 180 
V3             AACCCGGACCGTCTCCAGAGTGGATGGTCCGACACACCCTGACCCCAGGAGACCTAAGGG 180 
Full           AACCCGGACCGTCTCCAGAGTGGATGGTCCGACACACCCTGACCCCAGGAGACCTAAGGG 180 
V1             AACCCGGACCGTCTCCAGAGTGGATGGTCCGACACACCCTGACCCCAGGAGACCTAAGGG 180 
                ************************************************************ 
 
V2             ACCTCCGAGTGGAACCTATTAAAAGCAGTGTTGACCTGGAGGACTCTTCAATTTTGATGA 240 
V3             ACCTCCGAGTGGAACCTATTAAAAGCAGTGTTGACCTGGAGGACTCTTCAATTTTGATGA 240 
Full           ACCTCCGAGTGGAACCTATTAAAAGCAGTGTTGACCTGGAGGACTCTTCAATTTTGATGA 240 
V1             ACCTCCGAGTGGAACCTATTAAAAGCAGTGTTGACCTGGAGGACTCTTCAATTTTGATGA 240 
                ************************************************************ 
 
V2             ACATAAGCTGGATACTCCGGGCAGATG--------------------------------- 267 
V3             ACATAAGCTGGATACTCCGGGCAGATG--------------------------------- 267 
Full           ACATAAGCTGGATACTCCGGGCAGATGCCAGCATCCGCTTGTTGAAGGCCACCAAGATCT 300 
V1             ACATAAGCTGGATACTCCGGGCAGATGCCAGCATCCGCTTGTTGAAGGCCACCAAGATCT 300 
                ***************************                                  
 
V2             ------------------------------------------------------------ 
V3             ------------------------------------------------------------ 
Full           GCGTGATGGGCAAAAGCCACTTCCAGTCCCGCAGCTGCATCAGGTGCAATTACACCCAGG 360 
V1             GCGTGATGGGCAAAAGCCACTTCCAGTCCCGCAGCTGCATCAGGTGCAATTACACCCAGG 360 
 
 
V2             -----------------------------------TGGACGTTTTCCTACATTGGTTTTC 292 
V3             -----------------------------------TGGACGTTTTCCTACATTGGTTTTC 292 
Full           CGTTCCGCACTCAGACCAGACACTCTGGTGGCAAATGGACGTTTTCCTACATTGGTTTTC 420 
V1             CGTTCCGCACTCAGACCAGACACTCTGGTGGCAAATGGACGTTTTCCTACATTGGTTTTC 420 
                                                   ************************* 
 
V2             CTGTCGAGCTGAACACAGTCTATTTCATTGGAGCCCATAACATCCCCAATGCAAATATGA 352 
V3             CTGTCGAGCTGAACACAGTCTATTTCATTGGAGCCCATAACATCCCCAATGCAAATATGA 352 
Full            CTGTCGAGCTGAACACAGTCTATTTCATTGGAGCCCATAACATCCCCAATGCAAATATGA 480 
V1             CTGTCGAGCTGAACACAGTCTATTTCATTGGAGCCCATAACATCCCCAATGCAAATATGA 480 
                ************************************************************ 
 
V2             ATGAGGACGGCCCCTCCATGGCTGTGAACTTCACCTCCCCAGGGTGCCTGGACCATGTAA 412 
V3             ATGAGGACGGCCCCTCCATGGCTGTGAACTTCACCTCCCCAGGGTGCCTGGACCACGTAA 412 
Full           ATGAGGACGGCCCCTCCATGGCTGTGAACTTCACCTCCCCAGGGTGCCTGGACCATGTAA 540 
V1             ATGAGGACGGCCCCTCCATGGCTGTGAACTTCACCTCCCCAGGGTGCCTGGACCATGTAA 540 
                ******************************************************* **** 
 
V2             TGAAATATAAAAAAAAATGCATCGAGGCAGGAAGCCTGTGGAAGCCAAACATCACCGCTT 472 
V3             TGAAATAT-AAAAAAAATGCATCGAGGCAGGAAGCCTGTGGAAGCCAAACATCACCGCTT 471 
Full           TGAAATATAAAAAAAAATGCATCGAGGCAGGAAGCCTGTGGAAGCCAAACATCACCGCTT 600 
V1             TGAAATATAAAAAAAAATGCATCGAGGCAGGAAGCCTGTGGAAGCCAAACATCACCGCTT 600 
                ******** *************************************************** 
 
V2             GCAAGAAGAGCGCGAACACGGTGGAAGTGAATTTTACCACCAGTCCCCTTGGAGACAGAT 532 
V3             GCAAGAAGAGCGCGAACACGGTGGAAGTGAATTTTACCACCAGTCCCCTTGGAGACAGAT 531 
Full           GCAAGAAGAGCGCGAACACGGTGGAAGTGAATTTTACCACCAGTCCCCTTGGAGACAGAT 660 
V1             GCAAGAAGAGCGCGAACACGGTGGAAGTGAATTTTACCACCAGTCCCCTTGGAGACAGAT 660 
                ************************************************************ 
 
V2             ACATGGCGCTCATCCAAAATACCTCCGTGATTGGGACTTCCTATGTGTCAGAGAAGGAAC 592 
V3             ACATGGCGCTCATCCAAAATACCTCCGTGATTGGGACTTCCTATGTGTCAGAGAAGGAAC 591 
Full           ACATGGCGCTCATCCAAAATACCTCCGTGATTGGGACTTCCTATGTGTCAGAGAAGGAAC 720 
V1             ACATGGCGCTCATCCAAAATACCTCCGTGATTGGGACTTCCTATGTGTCAGAGAAGGAAC 720 




V2             TAACTCGAACTTCCGTGGTGGTCCACGTGACTGGGGAAAGTGAAGGTGCTGTGGTCCAG- 651 
V3             TAACTCGAACTTCTGTGGTGGTCCACGTGACTGGGGAAAGTGAAGGTGCTGTGGTCCAGG 651 
Full           TAACTCGAACTTCCGTGGTGGTCCACGTGACTGGGGAAAGTGAAGGTGCTGTGGTCCAG- 779 
V1             TAACTCGAACTTCCGTGGTGGTCCACGTGACTGGGGAAAGTGAAGGTGCTGTGGCCCAG- 779 
                ************* **************************************** ****  
 
V2             ------------------------------------------------------------ 
V3             TAAAGCTGAACAAGATGCTCTGACAGGCACAGAACGGGGCTCACTGAAGACCCACTGCAC 711 
Full           ------------------------------------------------------------ 
V1             ------------------------------------------------------------ 
 
 
V2             ------------------------------------------------------------ 
V3             CGCCACTCGCTGCTTTTGAGCAGTCCATTCTGGATGGAGCAGATGCGTTCTCCCCTCGGC 771 
Full           ------------------------------------------------------------ 
V1             ------------------------------------------------------------ 
 
 
V2             --------------------------------------------------------CTGA 655 
V3             TTGCTTCTGCCAGCAGCCTCTCTGGCATTACGTGATGCTGATGGGGAATCCATGAGCTGA 831 
Full           --------------------------------------------------------CTGA 783 
V1             --------------------------------------------------------CTGA 783 
                                                                        **** 
 
V2             CTCCGTATTTCCATACCTGTGGCAACGACTGCATCCGACAAAGAGGAACCGTGGTGCGGT 715 
V3             CTCCGTATTTCCATACCTGTGGCAACGACTGCATCCGACAAAGAGGAACCGTGGTGCGGT 891 
Full           CTCCGTATTTCCATACCTGTGGCAACGACTGCATCCGACAAAGAGGAACCGTGGTGCGGT 843 
V1             CTCCGTATTTCCATACCTGTGGCAACGACTGCATCCGACAAAGAGGAACCGTGGTGCGGT 843 
               ************************************************************ 
 
V2             GCCCACAAACAGGAGTCTCTCCTCAGGATCATGAGAGAAGTGTGCTGGGTGGCTGGCTGC 775 
V3             GCCCACAAACAGGAGTCTCTCCTCAGGATCATGAGAGAAGCGTGCTGGGTGGCTGGCTGC 951 
Full           GCCCACAAACAGGAGTCTCTCCTCAGGATCATGAGAGAAGTGTGCTGGGTGGCTGGCTGC 903 
V1             GCCCACAAACAGGAGTCTCTCCTCAGGATCATGAGAGAAGTGTGCTGGGTGGCTGGCTGC 903 
               **************************************** ******************* 
 
V2             CTCTCCTCCTGTCCGCTCTCCTTGTGGCCACATGGGTGCTGGTGGCTGGCATCTATCTGA 835 
V3             CTCTCCTCCTGTCCGCTCTCCTTGTGGCCACATGGGTGCTGGTGGCTGGCATCTATCTGA 1011 
Full           CTCTCCTCCTGTCCGCTCTCCTTGTGGCCACATGGGTGCTGGTGGCTGGCATCTATCTGA 963 
V1             TCTCCTCCTGTCCGCTCTCCTTGTGGCCACATGGGTGCTGGTGGCTGGCATCTATCTGA  963 
               ************************************************************ 
 
V2             TCTGGAGGCACGAAAGGATCAAGAAGACTTCCTTCTCAACTACCACACTACTGCCCTCTC 895 
V3             TCTGGAGGCACGAAAGGATCAAGAAGACTTCCTTCTCAACTACCACACTACTGCCCTCTC 1071 
Full           TCTGGAGGCACGAAAGGATCAAGAAGACTTCCTTCTCAACTACCACACTACTGCCCTCTC 1023 
V1             TCTGGAGGCACG------------------------------------------------ 975 
               ************                                                 
 
V2             TTAAGGTTCTTGTGGTTTACCCTTCTGAAATATGCTTCCATCACACAGTTTGTTACTTCA 955 
V3             TTAAGGTTCTTGTGGTTTACCCTTCTGAAATATGCTTCCATCACACAGTTTGTTACTTCA 1131 
Full           TTAAGGTTCTTGTGGTTTACCCTTCTGAAATATGCTTCCATCACACAGTTTGTTACTTCA 1083 
V1             ------------------------------------------------TTTGTTACTTCA 987 
                                                                ************ 
 
V2             CTGAATTTCTTCAAAACCGCTGCAGAAGTGAAGTTATCCTTGAAAAGTGGCGGAAAAAGA 1015 
V3             CTGAATTTCTTCAAAACCGCTGCAGAAGTGAAGTTATCCTTGAAAAGTGGCAGAAAAAGA 1191 
Full           CTGAATTTCTTCAAAACCGCTGCAGAAGTGAAGTTATCCTTGAAAAGTGGCAGAAAAAGA 1143 
V1             CTGAATTTCTTCAAAACCGCTGCAGAAGTGAAGTTATTCTTGAAAAGTGGCAGAAAAAGA 1047 
               ************************************* *************.******** 
 
V2             AAATAGCCGAGATGGGTCCCGTGCAGTGGCTCACCACTCAGAAGCAAGCAGCGGATAAGG 1075 
V3             AAATAGCCGAGATGGGTCCCGTGCAGTGGCTCACCACTCAGAAGCAAGCAGCGGATAAGG 1251 
Full           AAATAGCCGAGATGGGTCCCGTGCAGTGGCTCACCACTCAGAAGCAAGCAGCGGATAAGG 1203 
V1             AAATAGCCGAGATGGGTCCCGTGCAGTGGCTCACCACTCAGAAGCAAGCAGCGGATAAGG 1107 
               ************************************************************ 
 
V2             TCATTTTCCTTCTTTCCAATGATAACACCATGTGTGATGGTACCTGTGACAAGAAGGAGG 1135 
V3             TCATTTTCCTTCTTTCCAATGATAACACCATGTGTGATGGTACCTGTGACAAGAAGGAGG 1311 
Full           TCATTTTCCTTCTTTCCAATGATAACACCATGTGTGATGGTACCTGTGACAAGAAGGAGG 1263 
V1             TCATTTTCCTTCTTTCCAATGATAACACCATGTGTGATGGTACCTGTGACAAGAAGGAGG 1167 





V2             GCGGCCCCTGTGAGAACTCCCAAGACCTGTTCCACCTCGCCTTTAACCTCTTCTGCAGTG 1195 
V3             GCGGCCCCTGTGAGAACTCCCAAGACCTGTTCCACCTCGCCTTTAACCTCTTCTGCAGTG 1371 
Full           GCGGCCCCTGTGAGAACTCCCAAGACCTGTTCCACCTCGCCTTTAACCTCTTCTGCAGTG 1323 
V1             GCGGCCCCTGTGAGAACTCCCAAGACCTGTTCCACCTCGCCTTTAACCTCTTCTGCAGTG 1227 
               ************************************************************ 
 
V2             ATCTGAGAAGCCAGACTCATCTGCGCAAGTATGTGGTGGTCTACTTCAGAGAGGGTGACA 1255 
V3             ATCTGAGAAGCCAGACTCATCTGCGCAAGTATGTGGTGGTCTACTTCAGAGAGGGTGACA 1431 
Full           ATCTGAGAAGCCAGACTCATCTGCGCAAGTATGTGGTGGTCTACTTCAGAGAGGGTGACA 1383 
V1             ATCTGAGAAGCCAGACTCATCTGCGCAAGTATGTGGTGGTCTACTTCAGAGAGGGTGACA 1287 
               ************************************************************ 
 
V2             TCAAAGACAGCTACAGTGCGCTCAGTGTCTGCCCCACGTACCGCCTCACGAAGGACGCTA 1315 
V3             TCAAAGACAGCTACAGTGCGCTCAGTGTCTGCCCCACGTACCGCCTCACGAAGGACGCTA 1491 
Full           TCAAAGACAGCTACAGTGCGCTCAGTGTCTGCCCCACGTACCGCCTCACGAAGGACGCTA 1443 
V1             TCAAAGACAGCTACAGTGCGCTCAGTGTCTGCCCCACGTACCGCCTCACGAAGGACGCTA 1347 
               ************************************************************ 
 
V2             CAGATTTCTGTGCGGAGCTTCTCCATGCCAAGCAGCATGTGTCGGTGGGGAGAAGGTCAC 1375 
V3             CAGATTTCTGTGCGGAGCTTCTCCATGCCAAGCAGCATGTGTCGGTGGGGAGAAGGTCAC 1551 
Full           CAGATTTCTGTGCGGAGCTTCTCCATGCCAAGCAGCATGTGTCGGTGGGGAGAAGGTCAC 1503 
V1             CAGATTTCTGTGCGGAGCTTCTCCATGCCAAGCAGCATGTGTCGGTGGGGAGAAGGTCAC 1407 
               ************************************************************ 
 
V2             GCGCCCGTCACTACAGCTGCCTCTCCCTGTAGCCCAACCACGAAGCAGGAGACCCTAAAG 1435 
V3             GCGCCCGTCACTACAGCTGCCTCTCCCTGTAGCCCAACCACGAAGCAGGAGACCCTAAAG 1611 
Full           GCGCCCGTCACTACAGCTGCCTCTCCCTGTAGCCCAACCACGAAGCAGGAGACCCTAAAG 1563 
V1             GCGCCCGTCACTACAGCTGCCTCTCCCTGTAGCCCAACCACGAAGCAGGAGACCCTAAAG 1467 
               ************************************************************ 
 
V2             CCTTCTGACCCA 1447 
V3             CCTTCTGACCCA 1623 
Full           CCTTCTGACCCA 1575 
V1             CCTTCTGACCCA 1479 




Figure 5.10 Nucleotide sequence alignment of ovine IL17RB full length and 
splice variant sequences (ClustalW v2.1). Highlighted sections indicate 




5.3.2 IL17RB translated protein sequence analysis 
 
Nucleotide sequences of full length and alternatively spliced variant transcripts of the 
IL17RB gene were translated into amino acid and then aligned to identify changes to 
protein structure that occur as a result of transcriptional variation figure 5.12. An 
alignment of human IL17RB and ovine IL17RB amino acid sequences identified 
conserved TRAF-6 structural domain (Zhang et al., 2014) within the IL17RB protein 
which is highlighted in red. Alignment of protein sequences shows that IL17RBv2 
and v3 contain a premature stop codon. Transcript variant 1 has a 32 amino acid 
deletion caused by the deletion of 96bp in exon 11. The region of this protein that is 
deleted contains the conserved TRAF-6 binding motif and partial SEFIR domain. 
Conserved regions of this protein were identified by comparison of sequences from 
human, mouse and cattle; the sequence alignment of ovine, human and murine 
IL17RB, showing conserved TRAF6 binding motif and  SEFIR domain location can 




Key: TRAF6 binding motif 
Transmembrane domain 
SEFIR domain 
V2              MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
V3              MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
Full            MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
V1              MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
                ************************************************************ 
 
V2              DSSILMNISWILRADVDV-------------------------FLHWFSCRAEHSLFHWS 95 
V3              DSSILMNISWILRADVDV-------------------------FLHWFSCRAEHSLFHWS 95 
Full            DSSILMNISWILRADASIRLLKATKICVMGKSHFQSRSCIRCNYTQAFRTQTRHSGGKWT 120 
V1              DSSILMNISWILRADASIRLLKATKICVMGKSHFQSRSCIRCNYTQAFRTQTRHSGGKWT 120 
                ***************..:                         : : *  ::.**  :*: 
 
V2              P----------------------------------------------------------- 96 
V3              P----------------------------------------------------------- 96 
Full            FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMAVNFTSPGCLDHVMKYKKKCIEAGSLW 180 
V1              FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMAVNFTSPGCLDHVMKYKKKCIEAGSLW 180 
                 *                                                           
 
V2              ------------------------------------------------------------ 
V3              ------------------------------------------------------------ 
Full            KPNITACKKSANTVEVNFTTSPLGDRYMALIQNTSVIGTSYVSEKELTRTSVVVHVTGES 240 
V1              KPNITACKKSANTVEVNFTTSPLGDRYMALIQNTSVIGTSYVSEKELTRTSVVVHVTGES 240 
 
 
V2              ------------------------------------------------------------ 
V3              ------------------------------------------------------------ 
Full            EGAVVQLTPYFHTCGNDCIRQRGTVVRCPQTGVSPQDHERSVLGGWLPLLLSALLVATWV 300 
V1              EGAVAQLTPYFHTCGNDCIRQRGTVVRCPQTGVSPQDHERSVLGGWLPLLLSALLVATWV 300 
 
 
V2              ------------------------------------------------------------ 
V3              ------------------------------------------------------------ 
Full            LVAGIYLIWRHERIKKTSFSTTTLLPSLKVLVVYPSEICFHHTVCYFTEFLQNRCRSEVI 360 
V1              LVAGIYLIWRH--------------------------------VCYFTEFLQNRCRSEVI 328 
 
 
V2              ------------------------------------------------------------ 
V3              ------------------------------------------------------------ 
Full            LEKWQKKKIAEMGPVQWLTTQKQAADKVIFLLSNDNTMCDGTCDKKEGGPCENSQDLFHL 420 
V1              LEKWQKKKIAEMGPVQWLTTQKQAADKVIFLLSNDNTMCDGTCDKKEGGPCENSQDLFHL 388 
 
 
V2              ------------------------------------------------------------ 
V3              ------------------------------------------------------------ 
Full            AFNLFCSDLRSQTHLRKYVVVYFREGDIKDSYSALSVCPTYRLTKDATDFCAELLHAKQH 480 
V1              AFNLFCSDLRSQTHLRKYVVVYFREGDIKDSYSALSVCPTYRLTKDATDFCAELLHAKQH 448 
 
 
V2              ------------------ 
V3              ------------------ 
Full            VSVGRRSRARHYSCLSL 497 
V1              VSVGRRSRARHYSCLSL 465 
 
 
Figure 5.11 predicted amino acid sequence alignment of ovine IL17RB 
full length and IL17RB splice variant sequences (ClustalW v2.1) with 





















Truncated intracellular region. 


































Figure 5.12 Predicted protein expression pattern IL17RB splice variants identified in this study. Each box represents the 
protein encoded by each exon. Grey boxes indicate UTR. The 5’ UTR is located 5’ upstream of exon 1. The 3’ UTR is 
located at the 3’ end of exon 11. The extracellular region spans exons 1-9.The transmembrane region is encoded by 
exon 10, in yellow. The intracellular region contains the conserved TRAF6 binding motif indicated in red and the SEFIR 
domain indicated in green. The ‘ATG’ indicates the initial start codon and ‘STOP’ indicates stop codons encoded by spice 









5.3.3 Expression levels of IL17RB gene and IL17RB transcript variants 
 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for the IL17RB gene and individualIL17RB transcript 
variants. Statistical analysis was carried out on genes where results were within a 
measureable range, with relative expression (ΔCq), fold change between groups and P-
values shown. Expression levels of total IL17RB, IL17RBv2 and IL17RBv3 were 
measured (figures 5.13 – 5.15); however IL17RBv1 expression levels were >30 cycles 
and was considered too lowly expressed for accurate measurement. A positive control 
assay was carried out for IL17RBv1 as described in section 2.6.3. Melt curve and 
cycling analysis for this assay can be found in appendix A11. 
Expression levels of total IL17RB gene were significantly increased in the 
multibacillary group when compared to control (2.49 fold, P=0.04) but no significant 
difference was found when compared with the paucibacillary group (2.08 fold, but P = 
0.08). No differential expression was found when comparing IL17RBv2or 

















 Fold Change P-value 
M vs P 2.08 0.08 
M vs C 2.49 0.04 





































Figure 5.13 IL17RB RT-qPCR. A) Relative expression of full length IL17RB 
gene with B) fold change and P-values for comparisons between 













 Fold Change P-value 
M vs P 1.2 0.77 
M vs C 1.7 0.24 




































Figure 5.14 IL17RBv2 RT-qPCR. A) Relative expression of IL17RBv2 
gene with B) fold change and P-values for comparisons between 






 Fold Change P-value 
M vs P 1.09 0.88 
M vs C 1.6 0.12 




































Figure 5.15 IL17RBv3 RT-qPCR. A) Relative expression of IL17RBv3 
gene with B) fold change and P-values for comparisons between 





5.4 Expression levels of IL25transcripts 
 
Primers designed by Gossner et al. (Gossner et al., 2011) were used to quantify 
expression levels of the IL25 gene. IL25 gene had expression levels >30 cycles and was 
considered too lowly expressed for accurate measurement. A positive control assay was 
carried out for IL25 as described in section 2.6.3. Melt curve and cycling analysis for 






 Sequencing of the ovine IL17RA and IL17RB genes has identified alternatively spliced 
variants in the IL17RB gene and these variants alter the protein structure of this gene. 
No transcript variants were found in the ovine IL17RA gene 
 Increased expression of total IL17RB was found in multibacillary animals when 
compared to control group; however no differential expression was found for the 
identified IL17RBsplice variants between each infected group. 
 Differential gene expression was identified for IL17RA with increased levels of 
expression found in paucibacillary animals when compared to multibacillary and 
control. 


















Cells control the rate at which genes are transcribed by utilising regulatory DNA 
regions in the vicinity of where gene transcription is initiated. This regulation occurs 
in all cells and requires two components i) short stretches of defined DNA sequence 
(motifs) within the enhancer region and ii) gene regulatory proteins (transcription 
factors) that specifically recognise and bind to these DNA sequences to initiate 
transcription . Transcription factor activity is largely influenced by the levels at 
which the proteins are expressed; T-helper (Th) cell polarisation is controlled by 
differential expression of master transcription factors as well as cytokines and their 
receptors (Zhu et al., 2010).  Master transcription factors stabilize Th cell phenotypes 
and regulate the production of cytokines by Th cells and this is critical for the 
maintenance of appropriate immune responses to specific antigens (Zhu and Paul, 
2010). The differentiation and regulation of Th1, Th2 and Th17cell subsets are 
associated with the master transcription factors; T-bet, GATA3 and RORα/RORγt, 
respectively.  
6.1.1Th1 cell transcriptional regulation 
 
T-bet is an immune cell specific transcription factor of the T-box family, encoded by 
the TBX21 gene. T-box family proteins contain conserved sequences of amino acids 
that bind a specific DNA binding domain known as the T-box domain; all members 
known to date have a conserved region that bind to the DNA sequence TCACACCT 
(Wilson and Conlon, 2002). T-bet is the master transcription factor responsible for 
inducing and stabilizing the Th1 cell lineage, primarily by initiating transcription of 
IFNγ (Szabo et al., 2002). 
T-bet is not expressed in naive CD4+ T cells; its expression is induced in these cells 
in response to TCR and IL12R-STAT4/IFNγ-STAT1 signalling. Initially T-bet 
expression is induced independently of IL12R via TCR/IFNγ-STAT1 signalling. 
IFNγ promotes Th1 development by inducing IL12 expression in macrophages and 
IL12R expression on T-helper cells that have been activated by antigen; subsequent 
T-bet induction by IL12R-STAT4 signalling stabilizes the Th1 cell phenotype 
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(Luckheeram et al., 2012). T-bet directly activates IFNG gene expression by binding 
to the regulatory elements at the IFNG locus and recruiting RNA polymerase for 
gene transcription (Sekimata et al., 2009). IFNγ production by Th1 cells acts in a 
positive feedback loop to further increase T-bet expression by these cells. 
Furthermore, ectopic expression of T-bet in differentiated Th17 or Th2 cells results 
in expression of IFNγ from these cells and their transformation into ‘Th1-like cells’ 
(Afkarian et al., 2002). Mice deficient in IL12, IL12RB1 or STAT4 have 
significantly reduced Th1 cell responses (Gately et al., 1998).  
IFNγ produced by Th1 cells is required for efficient control of intracellular pathogens. 
T-bet deficient CD4+ T cells produce only small amounts of IFNγ under Th1 
polarizing conditions and are unable to induce protective Th1 responses during 
infection with Mycobacterium tuberculosis, Leishmania major and Salmonella 
enterica subsp. enterica (Ravindran et al., 2005.Szabo et al., 2002). However, given 
that over-activation of Th1 cell responses can lead to inflammation associated tissue 
damage, studies investigating Th1/cell mediated inflammation found that T-bet 
deficient mice can incur greater resistance to the development of several autoimmune 
inflammatory disorders including IBD (Neurath et al., 2002), arthritis (Wang et al., 
2006) and experimental autoimmune encephalomyelitis (EAE) (Nath et al., 2006). 
6.1.2 Th2 cell transcriptional regulation 
 
The GATA3 transcription factor is part of the GATA family of transcription factors 
and is encoded by the GATA3 gene (Merika and Orkin, 1993). The GATA family of 
transcription factors consist of conserved proteins that contain one or two C2-C2-
type zinc finger binding motifs that are able to recognise specific DNA sequences 
required for initiation of transcription of downstream genes (Drevet et al., 1994). 
Many DNA binding motifs contain zinc atoms as structural components. Zinc plays a 
key role in maintaining the tertiary structure of several proteins which bind DNA. To 
do this complexes are formed between zinc ions and cysteine and histidine residues 
which stabilizes the polypeptide conformation; they often present as protrusions, 
hence the name zinc ‘finger’ (Alberts et al., 2002). There are several types of zinc 
finger motif, those that are recognised by GATA3 consist of four cysteine side chains 
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(C2C2) (Alberts et al., 2002). These protrusions allow the GATA3 protein to bind 
the target DNA sequence and stabilize the protein-DNA interaction in order for 
GATA3 to initiate transcription of downstream Th2 cell associated cytokines (Yagi 
et al., 2011). GATA3 binds to multiple sites in the IL4, IL5 and IL13 locus and 
initiates transcription of these genes (Zheng and Flavell, 1997.Zhang et al., 
1997.Kishikawa et al., 2001). GATA3 is up-regulated by IL4-STAT6 mediated 
signalling and induces expression of IL4, IL5 and IL13. GATA3 is regarded as the 
master transcription factor for Th2 cell differentiation as ectopic expression of 
GATA3 has been shown to cause a shift from Th1 to Th2 cell cytokine production in 
developing Th1 cells (Ouyang et al., 1998). Furthermore, GATA3 deficient mice fail 
to produce Th2 cytokines, IL5 and IL13 (Zhu et al., 2004). 
GATA3 is associated with the intestinal inflammatory disorder, ulcerative colitis. 
Ohtani et al. found that mucosal expression of GATA3 and STAT4 were 
significantly increased in the acute phase of paediatric UC when compared with 
normal, control mucosa (Ohtani et al., 2010). Furthermore, variants and mutations of 
the GATA3 gene have been associated with human inflammatory pathologies, 
including asthma and antibody mediated allergy. Combinations of GATA3 and IL13 
polymorphisms and their interactions confer increased risk of rhinitis and allergic 
sensitization at a young age (10 years) (Huebner et al., 2008). A genotyping study 
found three haplotypes of GATA3 that were associated with asthma and atopy related 
phenotypes when compared with control subjects (Pykalainen et al., 2005). 
 
6.1.3 Th17 cell transcriptional regulation 
 
The transcriptional mechanisms by which Th17 cell activity is regulated continues to 
be investigated, however studies have shown that the transcription factor orphan 
nuclear receptor-RORγt is associated with expression of Th17 cytokines (Ivanov et 
al., 2006). RORγ is encoded by the RORC gene of which in humans there are two 
isoforms generated by alternative splicing; isoform 1 (encodes RORγ) is a key 
regulator of cellular differentiation and metabolism, expressed in many tissues and is 
mostly associated with metabolism processes (Jetten, 2009.Lee et al., 1995), whereas 
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isoform 2, also known as RORC2 (encodes RORγt) is immune specific and plays a 
key role in the differentiation of uncommitted CD4+ T cells into Th17 cells (Ivanov 
et al., 2006). The two isoforms differ in the 5’ end of the coding region (figure 6.1).  
RORγt is known to induce Th17 activities synergistically with RORα, encoded by 
the RORA gene. RORγt expression is regulated by STAT3 (Laurence et al 2007) and 
over expression of RORγt promotes greater Th17 differentiation and subsequent 
expression of Th17 cytokines including IL23 and IL21 (Ivanov et al., 2006). RORγt 
deficiency was found to reduce Th17 cell differentiation but did not abolish Th17 
cell activity; suggesting that additional factors were involved in Th17 differentiation. 
This is when further investigation found that Th17 cells highly express orphan 
nuclear receptor, RORα (Yang et al., 2008). Both RORγt and RORα contain zinc 
finger binding domains that function to initiate transcription of Th17 associated 
genes (Yang et al., 2008). These transcription factors promote Th17 cell 
differentiation and IL17 and IL17F expression in a TGFβ-IL6-STAT3 dependant 
manner (Hwang, 2010). Furthermore, RORα and RORγt co-expression 
synergistically drive greater Th17 cell differentiation. Double deficiency of RORα 
and RORγt results in entirely impaired Th17 cell differentiation in vitro and so 
synergistic expression of RORα and RORγt is considered essential for efficient 
generation of Th17 cells and subsequent Th17 activities (Yang et al., 2008).  
Variants of the RORA and RORC genes have been associated with disease in 
humans. It is well reported that Th17 associated molecules including IL17F, IL21, 
IL23, IL23R and RORγt are upregulated in the inflamed mucosal tissues of IBD 
patients (Fina et al., 2008.Kamada et al., 2008.Liu et al., 2011). As previously 
described RORγt directs transcriptional activation of IL17. Rauen et al. reported the 
presence of an isoform of RORγt, lacking exons 5-8 within the encoding gene; 
expression of this isoform results in repressed expression of IL17 and IL21 gene 
expression in human T cells, reducing further Th17 cytokine expression and it is 
thought this isoform may act as a negative regulator of RORγt-mediated gene 
expression (Rauen et al., 2012). In humans the RORA gene encodes four isoforms 
(RORA1-4); a GWAS study identified that the isoform RORA1 may be implicated in 
susceptibility to asthma (Moffatt et al., 2007). Furthermore, a microarray analysis 
found that SNPs in exon 1 of RORA were significantly associated with susceptibility 
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to human neovascular age-related macular degeneration (AMD); AMD is of 
unknown aetiology and results in a loss of vision in older adults caused by damage to 




A recent study by Wilkie and colleagues investigated expression levels, and presence 
of transcript variants, of the TBX21, GATA3, RORA and RORC2 genes in sheep 
infected with Teladorsagia circumcinta (Wilkie et al., 2016). This chapter describes 
the expression levels of the master transcription factor genes; TBX21, GATA3, RORA 
and RORC2, in the two pathological forms of sheep paraTB Transcript variants 
reported by Wilkie et al. are described and the expression levels of individual 
transcript variants are also reported. The aim of this section was to determine 
whether the expression of TBX21, GATA3, RORA and RORC2 genes, and transcript 
variants thereof, are associated with the different pathological outcomes of paraTB.  
Figure 6.1 Gene maps of human RORC  isoforms with differing 5’ regions 
(NM_005060.3) and (NM_001001523.1) found on human chromosome 1 
(NC_000001.9). Red boxes indicate exons with UTR shown in green boxes 





Sequencing of the TBX21 gene did not identify any transcript variants; therefore the 
expression of total TBX21 (full length transcript) was measured (Wilkie et al., 2016). 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for total TBX21 gene. Relative expression (ΔCq), fold 
change between groups and P-values are shown in figure 6.2. Results show a 
significant 1.88 fold (P=0.02) increase in gene expression in paucibacillary infected 
sheep when compared with multibacillary sheep and a 2.6 fold increase (P=0.003) 





















 Fold Change P-value 
M vs P -1.88 0.02 
M vs C 1.38 0.59 








































Figure 6.2 TBX21 RT-qPCR. A) Relative expression of total TBX21 gene 
with B) fold change and P-values for comparisons between multibacillary 







Sequencing of the GATA3 gene identified a transcript variant of this gene; 
GATA3v1 differs to that of the full length gene (GATA3) by the deletion of a 
single codon at the 5’ end of exon 3, this represents the deletion of a single amino 
acid within the coding region (Wilkie et al., 2016) 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for totalGATA3 gene and GATA3v1. Relative 
expression (ΔCq), fold change between groups and P-values shown in figures 6.3 
and 6.4.  
A 2.08 fold increase of GATA3 gene expression was found when comparing 
paucibacillary to multibacillary sheep group, this finding was significant with a 
P-value of 0.04. No significant difference in gene expression was found between 










 Fold Change P-value 
M vs P -2.08 0.04 
M vs C -1.6 0.24 







































Figure 6.3 GATA3 RT-qPCR. A) Relative expression of total GATA3 
gene with B) fold change and P-values for comparisons between 



























Fold Change P-value 
M vs P -1.2 0.79 
M vs C -1.5 0.29 




































Figure 6.4GATA3v1 RT-qPCR. A) Relative expression of total 
GATA3v1gene with B) fold change and P-values for comparisons 








Sequencing of the RORC2 gene identified a transcript variant of this gene; 
RORC2v1 differs to that of the full length gene (RORC2) by a 36 bp deletion at 
the 3’ end of exon 7, resulting in 12 amino acid deletion within the coding region 
(Wilkie et al., 2016). 
 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for total RORC2 gene and RORC2v1. Relative 
expression (ΔCq), fold change between groups and P-values shown in figures 6.5 
and 6.6. 
Significant differences were found between multibacillary and control (2.4 fold, 
P=0.02) and paucibacillary and control (3.48 fold, P=0.0003) groups for total 
RORC2 gene. Similarly for RORCv1, a 3.09 fold change (P=0.01) was found 
when comparing multibacillary to control and a fold change of 3.49 (P=0.0003) 
when comparing paucibacillary to control. No significant differences were seen 
in the M vs P comparisons; however total RORC2 was 1.45 fold greater in M 








 Fold Change P-value 
M vs P -1.45 0.09 
M vs C 2.4 0.02 
P vs C 3.48 0.0003 
 
Figure 6.5 RORC2 RT-qPCR. A) Relative expression of total RORC2 gene 
with B) fold change and P-values for comparisons between multibacillary 














 Fold Change P-value 
M vs P -1.12 0.81 
M vs C 3.09 0.01 







































Figure 6.6 RORC2v1 RT-qPCR. A) Relative expression of total 
RORC2v1gene with B) fold change and P-values for comparisons 








Sequencing of the RORA gene identified five transcript variants of this gene; all 
five variants are identical at the 3’ end of the gene from the 5’ end of exon 6 
onwards, however all variants have differential usage of exons 1-6 and therefore 
have differing 5’ UTR lengths. RORAv2 and RORAv4 have identical translation 
start sites and subsequently identical protein sequences; whereas RORAv1, v2, v3 
and v5 have unique start sites (Wilkie et al., 2016). 
 
Real time RT-qPCR analysis was performed in multibacillary, paucibacillary and 
uninfected control animals for all five RORA variants, (RORAv1, v2, v3, v4 and v5). 
Expression levels of RORAv1, RORAv4 and RORAv5 were measured figures 6.7 – 
6.9; transcript variants RORAv2 and RORAv3 were found to have expression levels 
>30 cycles and were considered below the expression level for accurate 
measurement. Positive controls were carried out for RORAv2 and v3. Melt curve 
and cycling analysis for each of these assays can be found in appendix A13 and 
A14. 
 
A significant fold change was found for RORAv1 when comparing multibacillary to 
paucibacillary animals (-1.9, P=0.02) and paucibacillary to control animals (2.49, 
P=0.005). RORAv4 was found to have increased expression in both multibacillary 
(P=0.0008) and paucibacillary (P=0.0004) groups when compared to control with a 
fold change of 2.78 and 2.89 respectively; however no significant difference was 























 Fold Change P-value 
M vs P -1.9 0.02 
M vs C 1.2 0.73 
P vs C 2.49 0.005 
Figure 6.7 RORAv1 RT-qPCR. A) Relative expression of RORAv1 gene 
with B) fold change and P-values for comparisons between multibacillary 



































































 Fold Change P-value 
M vs P -1.04 0.95 
M vs C 2.78 0.0008 










































Figure 6.8 RORAv4 RT-qPCR. A) Relative expression of RORAv4 gene 
with B) fold change and P-values for comparisons between multibacillary 










 Fold Change P-value 
M vs P -1.47 0.39 
M vs C 1.8 0.5 





































Figure 6.9 RORAv5 RT-qPCR. A) Relative expression of RORAv5 gene 
with B) fold change and P-values for comparisons between multibacillary 







 Sequencing of the GATA3, RORC2 and RORA transcription factor genes 
(Wilkie et al. 2016) has identified transcript variants, these variants were 
investigated in both multibacillary and paucibacillary paraTB infected sheep. 
 Increased expression of the TBX21 gene was found when comparing both 
paucibacillary and multibacillary infected groups to control. No differential 
expression was identified between the infected groups. 
 Increased expression of the GATA3 gene was found when comparing 
paucibacillary to multibacillary infected group, No significant difference in 
gene expression was found between multibacillary, paucibacillary and control 
groups for GATA3v1. 
 Increased expression of the RORC2 gene was found when comparing both 
paucibacillary and multibacillary infected groups to control. Similarly for 
RORCv1, increased gene expression was identified when comparing both 
paucibacillary and multibacillary infected groups to control. No significant 
differences were seen in the paucibacillary vs multibacillary comparisons; 
however total RORC2 was 1.45 fold greater in multibacillary than 
paucibacillary, but not significant. 
 Differential expression was identified for RORAv1 when comparing 
multibacillary to paucibacillary animals (-1.9, P=0.02) and paucibacillary to 
control animals (2.49, P=0.005). RORAv4 was found to have increased 
expression in both multibacillary and paucibacillary groups when compared 
to control; however no significant difference was seen for RORAv5 




















This project aimed to contribute to the knowledge of sheep immune responses to 
MAP infection by investigating genes that are known to influence differential T cell 
activation in response to pathogen. We know that differential T cell activation is 
associated with the pathological outcomes of human diseases including IBD, TB and 
leprosy. The two main forms of IBD; Crohn’s disease and ulcerative colitis are 
linked to Th1/Th17 and Th2 responses respectively. Similar immune responses are 
seen inhuman TB and leprosy with differential pathologies relating to differential Th 
cell polarization. Leprosy in humans presents as a spectrum between two distinct 
forms of pathology; tuberculoid (predominantly Th1 response)and 
lepromatous(predominantly Th2 response) lesions (Modlin, 1994). In human leprosy 
the host immune response determines the clinical outcome of infection, with a Th1 
immune response conferring greater host protection by preventing bacterial 
replication (Ottenhoff et al., 1997). When comparing these human diseases with 
paraTB infection in sheep we find that all have multiple clinical manifestations with 
striking similarities in pathology and Th cell polarization (Ottenhoff et al., 1997. 
Coussens, 2004. Greenstein, 2003); the pathological forms of paraTB in sheep are 
defined as paucibacillary (tuberculoid) and multibacillary (lepromatous) and these 
forms are associated with inflammatory Th1/Th17 and Th2 immune responses 
respectively. In some species there is a natural progression from paucibacillary to 
multibacillary form of disease; this is particularly seen in paraTB in cattle (Coussens, 
2004). However it is not known what causes the progression from one disease state 
to another (Coussens, 2001) and this progression is not often seen in sheep (Smeed et 
al., 2008). The mycobacterial causative agents of TB, leprosy and paraTB induce 
immune responses via similar mechanisms (Woo and Czuprynski, 2008.Greenstein, 
2003); and so host immune responses to these pathogen may be similar between 
species. When investigating the pathogenesis of these diseases, the underlying 
questions are the same in both ruminants and humans; what causes the T cell 
differentiation that leads to different pathological forms of disease? Why do certain 
infected individuals present with lepromatous lesions whereas others present with 
tuberculoid lesions? Possible explanations of these questions lie in the genetics of the 
host. Studies in human disease have associated genes that influence differential T cell 
activation with differential pathology, and this has provided us with a basis for the 
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hypothesis that gene pathways associated with differential Th cell activation in the 
human diseases may also be associated with Th cell activities and subsequent 
pathology in sheep paraTB.  
The polarization of Th cell lineages is influenced by many proteins including; 
IL23/IL25 cytokines, IL23/IL25 cytokine receptors, and the transcription factors that 
are associated with T cell differentiation (Zhu et al., 2010). We know that changes in 
mRNA expression levels and/or transcript variation of the genes that encode these 
proteins alter Th cell activity in other species and in some cases can alter the 
outcome of disease; this is discussed in more detail throughout this chapter. 
Significant knowledge gaps still remain in regard to immune response to paraTB in 
sheep and the genes that are involved in the immune responses that drive pathology 
of this disease. Previously, no work has investigated IL23 or IL25 receptor genes and 
T cell transcription factors in relation to sheep paraTB pathology and these genes 
were selected for this study to determine whether or not they are associated with 
differential T cell activation and consequently pathological outcome of sheep paraTB 
infection, in the same way that they are associated with altered Th cell activation and 
pathology of disease in other species (Tesmer et al., 2008. Kidd, 2003).  
The hypothesis tested was that differential gene expression and/or genetic variants of 
IL23 and IL25 cytokines, their receptors and the master transcription factors 
associated with Th1, Th2 and Th17 cell development, contribute to the differential 
polarization of the Th cell immune responses seen in the two pathological disease 
forms of MAP infection in sheep. This hypothesis was tested by sequencing the IL23 
and IL25 cytokine receptors; IL23R/IL12RB1 and IL17RA/IL17RB to identify 
alternatively spliced transcript variants; and then by comparing the expression levels 
of each transcript and variant in multibacillary, paucibacillary and control 
(uninfected) groups.  
There are very few studies that have investigated the role of alternative splicing in 
relation to paraTB (Casey et al., 2015.Ruiz-Larranaga et al., 2010). Alternative 
splicing (AS) involves selectively including or removing exon sequences leading to a 
variety of transcripts from pre-mRNA. Splicing events occur more frequently in 
genes involved in signalling and transcriptional regulation and immune processes, 
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including receptors and transcription factors (Martinez and Lynch, 2013). It is 
thought that these events, and expression of subsequent variants, are valuable in the 
regulation of immune processes where responses can often occur differently at 
different time points and where cells require the ability to adapt to environmental 
changes. It is therefore likely that the key events during immune response to antigen 
are influenced by AS products of immune stimulating genes (Modrek and Lee, 
2002). An aberrant regulation and expression of AS mRNA transcripts is associated 
with disease in other species and it has been hypothesised that AS is likely to be an 
associated cause or consequence of disease (Faustino and Cooper, 2003). This 
information has provided a further reason to investigate the role of AS in the genes 
associated with immune activation in paraTB. Furthermore, there is an increasing 
literature on the association of these transcripts in T cell development and responses 
upon antigen stimulation (Atamas, 1997. Levine, 2008. Talavera et al., 2009). For 
some genes, the evidence of changes in immune responses linked to spliced 
transcripts is based solely on analysis of mRNA transcripts, without confirmation 
that the encoded protein isoforms are expressed and only predicted functions of the 
protein isoforms can be described; consequently there is debate on whether identified 
splicing events are of functional relevance (Lynch, 2015.Martinez and Lynch, 2013). 
However in many other genes there is evidence that multiple protein isoforms are 
produced from a single gene and the function of these isoforms can have opposing 
effects on the outcome of immune responses (Chen et al., 2012.Lynch, 2004). There 
is also increasing evidence of conserved AS transcripts between species and although 
some transcripts are degraded during mRNA processing, the majority are thought to 
contribute to a diverse functional protein pool and act as key influencers in the 
differentiation of immune responses (Kelemen et al., 2013.Chen et al., 2012). Here 
we have investigated the presence and expression of AS transcripts of cytokine 
receptor and transcription factor genes in sheep and sought to determine whether 
they contribute to differential Th cell activity and pathological outcomes of paraTB 
in sheep. The data collected in this study is based on mRNA transcripts. There is no 
evidence of whether these transcripts are translated into protein isoforms in sheep, 
however sequence analysis comparisons between sheep transcripts and those of other 
species has allowed us to identify similarities in gene structure and predict the role 
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that these transcripts may play in relation to paraTB in sheep based on what is known 
in other species. 
The present study sought to better define the immune response in the different 
pathologies seen in paraTB infection in sheep; however there were limitations to 
consider. The time of infection in diseased animals in the present study is unknown 
as they all have naturally-acquired infections; although it is presumed that that they 
were infected as neonates. The tissue samples from infected animals were collected 
at time of euthanasia when chronic infection was already established, therefore it is 
possible that observed differences from other studies may be as a result of 
differences in time since infection. Furthermore some immune responses associated 
with differential pathology of sheep used in this study may have occurred at an 
earlier stage of infection. Variation within groups can also be explained by the 
possibility that these animals have been exposed to MAP for varying lengths of time; 
therefore animals within groups may be a different stages/severity of disease. In a 
study of paraTB in cattle, Coussens et al. identified differential expression of 
immune genes in late sub-clinically infected animals compared to controls (Coussens 
et al., 2004), whereas Robinson et al. found no differential expression between early 
sub-clinically infected deer in comparison to controls; although this may be 
attributed to species difference it was suggested that the time since initial infection 
was a major contributing factor to the level immune gene expression (Robinson et 
al., 2011). In the present study, this limitation was unavoidable due to the selection 
of animals with naturally-acquired infection. As previously mentioned, many studies 
of immune response to paraTB are carried out in cattle (Coussens et al., 2002. 
Coussens et al., 2004. Lee et al., 2001) with fewer studies done in sheep however the 
pathological forms of disease are better defined in sheep with clearer criteria 
available to define multibacillary and paucibacillary pathologies (Clarke, 1997), 
similar to those used in human lepromatous and tuberculoid disease, and so makes 






7.1 Sheep selection & definition of pathological forms of 
paratuberculosis 
 
The initial stage of this study involved careful selection of sheep with defined 
pathological forms of paraTB. All infected animals were naturally-infected but 
variability between animals was reduced as much as possible by selecting only 
females of similar age and breed. Sheep with no/low gastrointestinal nematode 
infection (as assessed by faecal egg count) were selected where possible, this was 
important to ensure that the data collected from gene expression assays showed a 
result from immune response to MAP infection and not a parasite infection. It was 
critical to correctly categorise each animal into three defined study groups; 
multibacillary, paucibacillary or uninfected control, by both histological and 
molecular analysis, so that gene expression results could be assessed in relation to 
defined paraTB pathologies and characteristics. All of the infected sheep had signs of 
inflammation in the terminal ileum and loss of villus structure but neither of these 
signs were observed in control sheep. Molecular methods of paraTB testing are 
regularly used as IS900 is specific to MAP DNA (Collins, 1996) and the PCR 
techniques used to detect this insertion sequence are considered the ‘gold standard’ 
in providing a quick, highly specific marker for precise identification of MAP in 
samples (Green et al., 1989. Moss et al., 1991). All sheep were tested by two 
independent IS900 PCR assays. By using two PCR assays with different primer sets 
for the same insertion sequence we can be confident in our confirmation of infected 
animals that tested positive for IS900 or control animals that were IS900 negative; 
given that these animals did not contain MAP DNA in their tissues they were 
classified as uninfected. Faecal culture can also be used to confirm the presence of 
MAP in infected animals and although this method is highly specific, it is only 
moderately sensitive (30-50%) and is considered very slow since the mycobacteria 
can take up to 16 weeks to grow in culture (Clark et al., 2008) and so in the interest 
of time this method was not used in the current study. Gross pathology observations 
of the terminal ileum along with IS900 PCR analysis provided confirmation of 
whether animals were infected or uninfected; following which it was critical to 
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correctly define the infected animals as having multibacillary or paucibacillary 
lesions. Lepromatous and tuberculoid forms of human mycobacterial disease present 
with very distinct differences in histopathology and fundamentally different 
pathologies; this is also the case in sheep paraTB. Early definition studies of human 
leprosy have described the histology of infected tissues; with both forms of disease 
containing granulomatous lesions (Bhat and Prakash, 2012). In humans, the 
lepromatous form is characterised by a predominant macrophage infiltration with 
most cells infected with numerous mycobacteria; whereas the tuberculoid form is 
characterised by lymphocyte infiltration with low numbers of bacteria, multi-
nucleated giant cells can also be characteristic of tuberculoid disease (Ridley, 1974. 
Modlin et al., 1988); however very few giant cells were noted in tuberculoid tissues 
in the current study. The defining characteristics of these pathologies are mimicked 
in multibacillary and paucibacillary paraTB in sheep (Clarke and Little, 1996). The 
tuberculoid form of human leprosy is considered protective and is sometimes ‘self-
curing’ (Rea and Modlin, 1991); which is not the case in end-stage tuberculoid 
disease in sheep where animals are unable to control intestinal inflammation and 
eventually die or are euthanized. The defining characteristics described in human 
disease were used as the basis of disease characterisation for the animals used in the 
present study. Infected sheep that showed high number of macrophages mostly 
infected with bacteria in the ileum tissues were defined as multibacillary infection 
status. Whereas animals with lymphocytic infiltration of the ileum tissues with low 
or no bacteria present were defined as paucibacillary infection status; assessed by ZN 
staining and histology. The histological and molecular criteria used to distinguish 
between multibacillary and paucibacillary forms of disease in the current study have 
been used in other studies defining the pathological forms of sheep paraTB (Clarke 
and Little, 1996. Gillan et al., 2010. Smeed et al., 2010) and form a robust 





7.2 IL23 axis genes in sheep paratuberculosis 
 
Sequencing of the IL23receptor genes identified five splice variants of IL23R and 
four splice variants of IL12RB1. This is not an unusual finding as multiple transcripts 
of these genes have been identified in other species. This work has provided the first 
investigation of ovine IL23R and IL12RB1 genes and their splice variants, and the 
first study of these genes in relation to the two forms of paraTB pathology in sheep.  
Translated amino acid sequences of the IL23R full length nucleotide sequence and 
variant nucleotide sequences in sheep were annotated based on known human IL23R 
sequence(Kan et al., 2008). This was done by creating sequence alignments of 
known human sequences and the sheep transcripts to identify regions of variation 
that could provide information on the functional consequences of the spliced variants 
found in sheep. Kan et al. described 24 isoforms of human IL23R and discussed the 
predicted biological function of these variants. When analysing protein sequence 
comparisons, similar patterns were noted between the human isoforms and sheep 
IL23R. IL23Rv1 has an extra 29bp sequence at the start of exon 2 which may be a 
consequence of alternate splice sites being used, however this variant uses the same 
start codon as full length IL23R and so the coding sequence is the same and so this 
transcript is thought to possess the same functional abilities as the wild-type (full 
length) transcript. The insertion 5’ of the start codon could possibly have an effect on 
regulatory functions within the 5’ UTR. There are no similar insertions sequences 
reported in this region of the IL23R protein in other species. Four of the sheep splice 
variants (IL23Rv2-v5) encode truncated protein sequences when compared with 
wild-type IL23R (Figure 4.7). The sheep IL23Rv2 and IL23Rv3 only have partial 
extracellular domains and a loss of transmembrane/intracellular regions. IL23Rv2 has 
a 21bp deletion in the 3’ end of exon 4; in human transcripts, exon 4 deletion has 
been identified and encodes a similar truncated protein sequence to that seen in sheep 
IL23Rv2; this transcript in humans is thought to be a target for nonsense mediated 
decay (NMD), a regulatory degradation of malformed mRNA transcripts, and so will 
not be translated into protein (Kan et al., 2008). The sheep IL23Rv3 encodes a 
truncated protein that only contains exons 1-6 due to a premature stop codon in the 
extracellular region; a similar isoform consisting of exons 1-7 is found in humans 
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when a premature stop codon is caused by deletion of exon 6; again this isoform is 
predicted to be a target of NMD. Given the similarities between these sheep and 
human isoforms it is predicted that these variants in sheep lead to non-processed 
transcripts and that these will be of little biological relevance in the immune response 
to paraTB. IL23Rv4 encodes a truncated extracellular region of the IL23R caused by 
the deletion of exon 8. This is an in-frame deletion and this isoform still contains the 
transmembrane domain and intracellular regions; the same isoform with deletion of 
exon 8 is expressed in humans and is predicted to have an effect on the conformation 
of the extracellular ligand binding region and/or changes in downstream signalling 
compared to wild-type IL23R, since the intracellular signalling components are still 
intact (Kan et al., 2008). IL23Rv5 does not contain a complete exon 10 sequence 
(encodes transmembrane domain) and lacks the intracellular region. It is predicted 
that this transcript encodes a soluble isoform of the IL23R. Evidence shows that 
soluble receptors can serve as either antagonists or agonists during disease and 
normal homeostasis (Jones 2005). Comparison of human and sheep IL23R shows 
that exon 10 in sheep corresponds with exon 9 in humans; exon 9 of IL23R in 
humans encodes the transmembrane domain of the receptor protein and deletion of 
this exon creates a naturally occurring soluble isoform of the IL23R (∆9). This 
isoform has been shown to inhibit STAT3 phosphorylation and Th17 cell 
development and the expression of IL17A and IL17F is abolished in the presence of 
the ∆9 isoform; however expression levels of RORγt are unaffected (Yu and 
Gallagher, 2010). This isoform is strongly associated with protection against CD in 
humans by reducing inflammatory Th17 responses (Gallagher et al., 2012). Zhang 
and colleagues also identified six alternatively spliced IL23R variants in humans and 
three of these have deleted sequence that encodes the transmembrane domain. These 
isoforms are expressed in human lung carcinoma tissues and although their precise 
function is unknown it is though that they may regulate IL23 immune activities 
(Zhang et al., 2006). Although the IL23R (∆9) isoform provides protection in human 
inflammatory disease of the gut, it seems that this variant does not provide the same 
protection in sheep paraTB as expression levels of IL23Rv5 were too low to 
accurately quantify in all study groups of the present study and so we are unable to 
conclude that it plays an important role in this disease. This was also the case for 
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IL23Rv4 where expression levels were too low to quantify and so is unlikely to be 
biologically relevant in sheep paraTB. However these variants may play a role in 
other diseases. Furthermore it could be suggested that these variants are expressed as 
a means to regulate Th17 activities during infection and that their low expression 
confers a loss of Th17 regulation in the animals of this study, subsequently 
contributing to the severity of inflammation in the gut tissues. The R381Q variant 
was identified in the predicted protein sequence translated from IL23Rv1, IL23Rv4 
and full length IL23R nucleotide sequences. This variant has been shown to reduce 
Th17 inflammatory responses in humans (Di Meglio et al., 2011); and confers strong 
protection against CD in human populations (Duerr et al., 2006). This protective 
variant may play a similar role in sheep however it was not possible to investigate 
correlation between the presence of this variant and paraTB pathology as the number 
of samples used in this study are far too few to identify a relationship between 
SNP/single amino acid change and pathology; in future studies it would be beneficial 
to analyse the relationship of this variant with paraTB pathology in a larger sample 
population. The sequence encoding the ‘WSXWS’ motif, required for receptor 
activation (Dagil et al., 2012) was identified in all IL23R transcripts in this study, 
however the effect that the spliced regions within the sheep variant transcripts have 
on the function of this motif is unknown. Investigation into the expression of the 
proteins encoded by these transcripts is required to determine their functional 
significance in paraTB infection and sheep immune responses in general. 
Human studies have shown that the IL23/IL17 axis plays an important role in the 
intestinal mucosal immunity, with IL23 being the key cytokine that promotes IL17A 
production by Th17 cells (Iwakura and Ishigame, 2006. Gaffen et al., 2014). IL23 
axis genes were investigated in IBD patients and found that IL23RmRNA expression 
was up-regulated in CD4+ cells isolated from the lamina propria of UC and CD 
patients; furthermore IL23A mRNA expression correlated with increased IL17A 
expression in UC, and increased IFNG expression in CD (Kobayashi et al., 2008). 
The current study investigated expression levels of IL23R and found no significant 
differential expression of total (this assay detects full length and variants) IL23R 
between the three study groups. Expression levels of IL23A were also investigated in 
the three groups; however levels were too low for accurate measurement and so it is 
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thought that this cytokine may not play an important role in Th17 immune responses 
at the time these tissues were collected. This was an unusual finding given that IL17A 
mRNA levels are increased in paraTB infection in other species (Robinson et al., 
2011) and expression of this cytokine is driven by IL23R-mediated signalling. 
Interestingly Robinson et al. found no differential expression of IL23R or IL23A in 
paraTB infected red deer, even though IFNG and IL17A mRNA levels were elevated 
in animals with minimal (largely paucibacillary) or severe (multibacillary) paraTB 
infection compared to controls. They suggested that Th17 activities may not play an 
important role in protective immunity to paraTB in deer (Robinson et al., 2011) and 
this may also be true in sheep paraTB. Furthermore, in another studyIL23A 
expression was up-regulated in the ileal mucosa of paucibacillary infected sheep 
compared to multibacillary infection and control but no differential expression 
between the three groups was identified in mesenteric lymph node tissues (Gossner 
et al., 2012b). This could reflect the MAP-induced inflammation at the site of 
infection and may explain results of low IL23A gene expression found in ileocecal 
lymph node tissues in the current study (figure 4.3) if IL23A production is occurring 
in the ileum tissues during paraTB infection. The IL23R gene is one of the strongest 
associated genes with CD as determined by GWAS (Roberts et al., 2007); many of 
the disease associated variants of IL23R have also been described in UC, ankylosing 
spondylitis and psoriasis patients (Duerr et al., 2006). Here we have shown that 
expression levels of each of the individual IL23R splice variants were too low to 
quantify (≥30 cycles) in the RT-qPCR assays developed. This is a limitation of RT-
qPCR when investigating lowly expressed transcripts. Positive control assays using 
template sample known to contain the variant being measured were used to confirm 
that the expression levels were an accurate reflection of the mRNA transcripts within 
the sample and not a technical assay error. It would be possible in future study to 
increase the volume of initial RNA and subsequently increase the presence of these 
variants in cDNA templates; however it is questionable whether these variants are of 
significant biological relevance in the immune response to paraTB infection if 
expressed at such low levels. IL23 protection against mycobacterial infection was 
demonstrated in a mouse model; whereby double deficient IL12-IL23-knockout mice 
were more susceptible to infection than IL12-deficiency alone. This is due to the 
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presence of the protective IL12p40 subunit and highlights the importance of this 
subunit in IL23-mediated Th17 responses to mycobacterial infection (Cooper et al., 
2002). In contrast the results of the current study show very low expression of IL23A, 
IL23R or IL23R transcript variants in sheep paraTB. The low expressions of the 
IL23R variants suggests a lack of regulation of Th17 responses if the function of 
these variants were to modulate IL23 activities as seen in similar IL23R variants in 
humans. If this were the case it would be expected that IL23A levels would be up-
regulated and driving Th17 inflammation but expression of this gene was also low in 
all study groups; perhaps IL23A is expressed at greater levels in the gut tissues than 
in the lymph node tissues as described by Gossner et al. and is driving inflammation 
at the site of infection (Gossner et al., 2012a). Furthermore, it may be possible that 
the IL23/IL23R activities have occurred earlier in infection during initial activation 
of adaptive responses and so are not seen at the late stage of disease that the animals 
in this study are at. 
IL12RB1 is critical for IL12 and IL23- dependent immune responses in humans: 
CD4+ T cells of individuals with non-functioning IL12RB1 alleles display defective 
Th1 and Th17 polarization (Altare et al., 1998). As a result of these combined 
immunological defects, these individuals are most susceptible to infection with 
mycobacteria, Salmonella and Candida species (de Beaucoudrey et al., 2010). 
Furthermore, IL12R- deficient mice are unable to build cell mediated immune 
responses to sub-lethal doses of Listeria, another intracellular bacterial pathogen 
(Brombacher et al., 1999). Mutations within the IL12RB1 gene have been shown to 
impair the development of IL23-induced Th17 activities and alter host defence 
against infection (de Beaucoudrey et al., 2010). The majority of deleterious 
mutations identified in humans with IL12RB1 deficiency result in premature 
truncation of the protein, in most cases by encoding premature stop codons prior to 
the transmembrane domain (van de Vosse et al., 2003) and here we show that similar 
transcripts are found in sheep. 
In this study sequencing of the sheep IL12RB1 gene identified four splice variants 
(IL12RB1v1-4) that are predicted to encode four distinct proteins (figure 4.12); all of 
which are derived from variation in mRNA sequence that encodes the extracellular 
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region of the protein (exons 1-9). The sheep IL12RB1v1-v4 translated protein 
sequences lack the ‘WSXWS’ motif required for receptor activation and ligand 
binding (Dagil et al., 2012) encoded within exon 7, suggesting that these receptor 
isoforms are unable to initiate downstream signalling in response to IL12 ligand in 
sheep but may function to regulate IL12-induced activities (Levine, 2008). 
IL12RB1v1 and v4both encode two short peptide sequences with truncated 
extracellular region, no transmembrane domain and no intracellular region; truncated 
IL12RB1 isoforms lacking transmembrane and/or intracellular regions 
(IL12RB1Δtm) have been identified in humans and mice (van de Vosse et al., 
2003.van de Vosse et al., 2013). Studies from both human and mice have shown that 
expression of the IL12RB1Δtm variant and the IL12RB1Δtm isoform is induced in 
dendritic cells upon stimulation with mycobacteria or mycobacteria-derived 
products; and in mice promotes M. tuberculosis-specific T cell activation, however 
the mechanisms by which this occurs are unknown (Robinson et al., 2010). 
Furthermore, the absence of alternatively spliced secreted IL12RB1Δtmin mice 
compromised their ability to control M. tuberculosis infection in extra pulmonary 
organs (Ray et al., 2015). These studies have shown that this spliced IL12RB1 
variant lacking a transmembrane domain is required to initiate effective immune 
responses to mycobacterial infection in other species. However this may not be the 
case in the current study as the sheep transcripts differ to those of mouse and human 
variants in that they have truncated extracellular sequence as well as no 
transmembrane or intracellular region. The isoforms in mice and humans contain the 
full extracellular region and so are still able to bind ligand. It is still possible that the 
sheep isoforms bind IL12/IL23 ligands and modulate their activity during infection, 
however functional analysis is required in future to determine whether this is 
possible and also whether these transcripts are even expressed at the protein level or 
are degraded. The IL12RB1v1 transcript was too lowly expressed for accurate 
measurement and so unlikely to be involved in immune responses in the infected 
animals. IL12RB1v4 showed no significant differential expression between any of the 
study groups, although multibacillary sheep had an almost significant 1.87 fold 
increase in expression compared to paucibacillary (p=0.08). A possible explanation 
for this is that the truncated protein may act as a soluble receptor and modulate 
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IL12/IL23 activities in these animals by binding to the ligands and preventing 
downstream signalling. This could contribute to reduced Th1/Th17 responses seen in 
multibacillary animals. IL12RB1v2 and v3 both encode proteins with truncated 
extracellular regions. Fieschi et al. identified a novel form of complete IL12RB1 
deficiency associated with expression of a non-functional cell surface expressed 
IL12RB1. This receptor protein lacks part of the extracellular region and is unable to 
bind IL12 and IL23, reducing downstream activities of STAT4 and IFNγ (Fieschi et 
al., 2004); the clinical implications of this isoform are yet to be determined, however 
several studies have identified IL12RB1 deficiency in patients susceptible to 
mycobacteria and/or Salmonella infections (van de Vosse et al., 2013). The presence 
of these variants in sheep would suggest that they play a similar role to that seen in 
humans and are expressed on the cell surface, bind IL12/IL23 ligands but do not 
initiate downstream signalling; subsequently reducing Th1/Th17 cell activities. 
Expression levels of IL12RB1v2 were too low to quantify; however IL12RB1v3 was 
significantly up-regulated in the ICLN of multibacillary compared to paucibacillary 
animals with a fold change of 2.1 (p=0.04), no difference in expression was noted 
when comparing multibacillary to control or paucibacillary to control. The increased 
expression levels of this transcript in multibacillary paraTB diseased sheep suggests 
a lack of IL12RB1 signalling, which contributes to reduced Th1/Th17 activity. 
Consequently this would contribute to the loss of control of bacterial replication, 
which is characteristic in multibacillary paraTB infection in sheep. 
An investigation of IL12R expression in leprosy found that the IL12RB2 was highly 
expressed in tuberculoid lesions with far lower expression in lepromatous lesions, 
however IL12RB1 expression was similar in both tuberculoid and lepromatous 
lesions; demonstrating that the inability of lepromatous patients to up-regulate 
IL12RB2 correlates with their inability to induce effective Th1 response to M. leprae 
(Kim et al., 2001). Gene expression analysis of total IL12RB1 in the current study 
found no differential expression of this gene between paucibacillary, multibacillary 
and control sheep groups. As is seen in humans, the ability of sheep to mount Th1 
responses to MAP infection may in part rely on the presence of the IL12R subunit, 
IL12RB2. Future studies to investigate expression of IL12RB2 in relation to sheep 
paraTB pathology may provide further insight into the role of IL12R signalling in 
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Th1 cell differentiation and inflammatory responses in tuberculoid and lepromatous 
forms of paraTB.  
The function of many IL12RB1 splice variants identified in humans is still unknown; 
however changes in abundance of each isoform are likely to have an effect on the 
fine tuning of IL12 and IL23 responses to infection and this may also be the case in 
sheep paraTB. Robinson et al. found that although the alternatively spliced 
IL12RB1Δtmdid not contain a transmembrane domain it was still membrane 
associated and was able to enhance DC migration to local lymph nodes, and as a 
result increase T cell activation in response to M. tuberculosis infection (Robinson et 
al., 2010). These studies that have been carried out in human and mouse describe 
IL1RB1 variants expressed in specific cell types. The current study was carried out 
using RNA from sheep lymph node tissues containing mixed cell populations, 
including macrophages and DCs, and so it is unclear of which specific cell types are 
expressing each of the alternatively spliced transcripts. This information could 
provide further insight on the function of these variants and could clarify further their 





7.3 IL25 and IL25 receptor in sheep paratuberculosis 
 
IL25 has been shown to induce and maintain Th2 cell mediated inflammation in 
human and animal studies via IL17RA/IL17RB signalling. Differential expression of 
the IL25 cytokine and its receptors are associated with chronic inflammatory 
disorders including asthma, IBD and helminth infection; it has been demonstrated 
that IL25 deficiency can provide protection from Th2-mediated lung and intestinal 
inflammatory diseases (Kleinschek et al., 2007. Ballantyne et al., 2007. Wang et al., 
2014). Furthermore, there are two main signalling pathways mediated by the shared 
cytokine receptor subunit IL17RA; IL17A/F and IL25, meaning that this receptor 
plays a key role in the balance between IL17A/F induced Th1/Th17 cell mediated 
inflammation and IL25-mediated Th2 inflammation (Gaffen, 2009). IL25 activities 
are regulated by differential expression of the IL25 receptor subunits, IL17RA and 
IL17RB (Rickel et al., 2008). 
This work has provided the first sequencing investigation of ovine IL17RA and 
IL17RB genes, and splice variants of these genes, in relation to the two forms of 
paraTB pathology in sheep. Previous study has described a skew towards Th2 
responses in multibacillary paraTB disease in sheep (Smeed et al., 2007); therefore it 
is thought that these genes may play a role on the regulation of IL25 induced Th2 
activities during paraTB infection. Sequencing of the IL25 receptor genes, IL17RA 
and IL17RB, did not identify any variants in the IL17RA gene, however three splice 
variants of IL17RB were identified (figure 5.9).Variants of both IL17RA and IL17RB 
genes have been identified in other species (Jung et al., 2009.Sohda et al., 2013). 
Characterization of the IL17RA gene was unable to identify the full length sequence 
of this gene according to predicted sequence described in the NCBI nucleotide 
sequence database. Attempts to sequence the 5’ end of the gene did not identify a 
start codon; the start codon of this gene in sheep may be much further 5’ than 
initially anticipated, although attempts to sequence this region using 5’RACE in the 
current study were unsuccessful (figure 5.4). Furthermore when comparing the 
sequence obtained in this project to that of RNA-seq study carried out by colleagues 
(Gossner et al. 2016 – in review), there was no indication of a start codon present in 
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the predicted sequence region from the next generation sequence data. This may be a 
consequence of the predicted sequence that is available in the NCBI database being 
inaccurate. Comparison of the translated sheep IL17RA amino acid sequence with 
the two known human IL17RA isoforms identified the presence of a conserved 
transmembrane domain (figure 5.7); however sequence at the full length of the 
sequenced sheep IL17RA gene did not match to that of human IL17RA. This may be 
an indication that there is transcript variation within the 5’ and 3’ends of the sheep 
IL17RA or it is possibly due to sequence difference between species. 
In humans, a nonsense mutation within the IL17RAgene results in a premature stop 
codon and loss of IL17RA protein expression; IL17RA deficiency abolishes the 
cellular responses to IL17A and IL17F and is associated with susceptibility to 
chronic mucocutaneous candidiasis disease and Staphylococcus aureus infection 
(Puel et al., 2011). Also the expression of an alternatively spliced soluble form of 
IL17RA, lacking the transmembrane region, has been reported in various human 
tissues at the mRNA and protein levels and although it is hypothesised that this 
isoform regulates IL17 and IL25 activities, the biological functions of this protein are 
yet to be confirmed (Sohda et al., 2013). Although transcript variants have been 
identified in humans and mice, in this study there were no variants identified within 
the sequence obtained for the sheep IL17RA gene however further work is required to 
confirm the full gene sequence of ovine IL17RA and so there may be variants present 
that have not been identified in this study. 
Expression levels of IL17RA using primers designed within the obtained sequence 
showed significantly higher expression in paucibacillary animals than both 
multibacillary and control (M vs P fold change of -2, p=0.001 and P vs C fold change 
of 2.2, p= 0.02). No differential expression was noted when comparing multibacillary 
to control group. This result suggests that there is an increase of IL17RA associated 
activities in the paucibacillary animals compared to multibacillary and control 
groups. It has been shown that IL17RA expression is required for both IL25 and 
IL17A/F signalling, however this receptor exhibits greater binding affinity for IL17A 
over IL25 and IL17F (Ely et al., 2009); therefore higher expression of IL17RA in the 
paucibacillary sheep when compared to multibacillary may be relevant to the 
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development of Th17 associated inflammation in paucibacillary infection and is 
consistent with increased levels of IL17A seen in MAP induced lesions in other 
species (Robinson et al 2011). These results are similar to what is seen in humans 
where the role of IL17RA-mediated activities has been described in human 
inflammatory diseases of the gut; Yen et al. found that IL17RA was required for 
IL17A mediated inflammation in colitis and suggested that blockingIL17RA 
signalling would be more efficient at ameliorating intestinal inflammation in IBD 
patients than blocking IL17A alone by simultaneously reducing the activities of 
IL17A and IL17F (Yen et al., 2006).  
Sequencing of the sheep IL17RB gene identified three splice variants (IL17RBv1-v3) 
which are predicted to encode three distinct proteins (figure 5.12). The IL17RB gene 
was sequenced in unrelated human DNA samples and 18 genetic polymorphisms 
were identified; four deletions/insertions and 14 SNPs. Of these only one, an intronic 
polymorphism, was significantly associated with the development of asthma and 
conferred protection by regulating IL17RB mediated IL25 activity at the 
transcriptional level (Jung et al., 2009). This study described a variant within human 
IL17RB that confers protection against Th2 mediated inflammation; and it was 
thought that variants within the sheep IL17RB gene may play a similar role in 
inflammatory Th2 responses during paraTB infection. Sheep IL17RBv2 and v3 gene 
sequences both contain a deletion of exon 4 and IL17RBv3 has an insertion of 177bp 
further downstream at the 5’ end of exon 8. Both of these transcripts are predicted to 
encode identical short extracellular proteins. A change of frame caused by exon 4 
deletion leads to a premature stop codon resulting in a truncated extracellular region 
in both of these variants. Since these variants are predicted to encode proteins that do 
not contain a transmembrane domain or intracellular region; it is presumed that these 
variants would be unable to induce IL17RB-mediated cellular signalling but may 
potentially bind and modulate IL25 activity. This is similar to what is seen in 
experimental models of IL25 induced inflammation where a soluble IL17RB-Fc 
protein is used to block/reduce IL25 activities (Rickel et al., 2008). Here I have 
shown that there is no differential expression present between study groups for 
IL17RBv2 or IL17RBv3. This result suggests that these transcripts do not play a role 
in immune response to paraTB infection but may play a role in modulating IL25 
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activities in other diseases. When comparing sheep IL17RB to that of other species, 
the TRAF-6 binding motif and SEFIR domain were identified in the sheep IL17RB 
sequence (appendix section A10). IL17RBv1 encodes a truncated protein which lacks 
the TRAF6 binding motif and has only partial sequence of the SEFIR domain within 
the intracellular region. Maezawa and colleagues reported that TRAF6 plays a 
critical role in IL25 receptor-mediated gene expression of IL6, TGFβ and CSF3. 
They also found that TRAF6 signalling is required for IL25 receptor-mediated NFκB 
activation and subsequent NFκB-mediated gene expression in mice (Maezawa et al., 
2006). It is predicted that IL17RBv1 in sheep may encode a protein that is unable to 
bind TRAF6 and induce the TRAF6-associated activities during paraTB infection. 
Furthermore the conserved SEFIR domain is required as a ‘binding surface’ for Act1 
recruitment during receptor-ligand signalling. Given that this variant only encodes a 
partial SEFIR domain (as well as loss of the TRAF-6 binding motif), it can be 
deduced that this receptor isoform may act to regulate IL17RB-mediated activities by 
binding ligand without carrying out downstream signalling activities. In the case of 
paraTB infection, this receptor might act to modulate IL25-induced Th2 
inflammation during infection. However when investigating gene expression levels, 
IL17RBv1 was too lowly expressed for accurate measurement and so is not likely to 
be of biological relevance in the immune response to paraTB infection but may play 
a role in other infections in sheep. 
Full length IL17RB expression levels were significantly higher in the multibacillary 
group compared to control with a 2.49 fold change (p=0.04). Expression was also 
higher (2.08 fold) in the multibacillary group compared with the paucibacillary but 
p=0.08. Given that IL17RB expression is required for IL25 mediated activity(Rickel 
et al., 2008) these results indicate that there is greater IL25 activity in multibacillary 
animals than paucibacillary and control sheep. This is consistent with the observed 
increase of Th2 responses in multibacillary animals (Smeed et al., 2007). In order to 
confirm whether there is a true increase of IL17RB expression in multibacillary 
compared to paucibacillary groups (not currently significant) this assay should be 
repeated in a greater sample population in future study. When looking at the results 
from this assay (figure 5.13) there was a wide spread of values within the 
multibacillary group; this may be due to differences in time since infection of these 
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animals, the severity of disease or the different rates of progression of disease in 
these sheep. In future studies, functional analysis of these splice variants is required 
to determine the role of each variant during IL25-mediated activities and to 
determine whether IL17RBv1 could have an effect on IL6, TGFβ and CSF3 
expression in paraTB infected sheep, as seen in other species (Maezawa et al., 2006). 
Transgenic expression of IL25 in mice has been shown to increase eosinophilia, 
serum IgG1 and IgE and gene expression of IL4, IL5, IL10 and IL13 in several 
tissues. In contrast, IL25 knockout mice have impaired Th2 responses to infections, 
particularly helminth infections at mucosal surfaces; resulting in susceptibility to 
infection and chronic inflammation (Zhao et al., 2010. Fallon et al., 2006). In 
induced pulmonary inflammation models, blocking IL25 activity using a soluble 
IL17RB-Fc protein or antagonistic antibodies to IL25 results in reduced Th2-
mediated inflammation (Camelo et al., 2012. Rickel et al., 2008). IL25 mediates 
suppression of CD4+ T cell differentiation into Th1 and Th17 cells, whilst promoting 
Th2 responses. Levels of IL25 were found to be significantly reduced in the sera and 
mucosal tissues of patients with active IBD in comparison to control subjects and so 
these individuals were unable to provide protection by suppressing Th1/Th17 
inflammation; Su et al have postulated that the anti-inflammatory role of IL25 in IBD 
is associated with stimulation of IL10 and subsequent inhibition of Th1/Th17 
responses rather than stimulation of Th2 responses and have suggested that 
administration of IL25 supplements in IBD patients exhibiting low IL25 expression 
may provide a therapy by reducing Th1/Th17 induced inflammation (Su et al., 2013). 
Investigation of IL25 in the current study found expression levels were too low to 
quantify in all groups; a lack of IL25-mediated control of Th1/Th17 responses could 
be associated with the amplification of intestinal inflammation in paraTB infected 
sheep, as is described in IBD patients (Su et al., 2013). Another possibility is that 
there is little expression of IL25 in the lymph node tissues as this cytokine is 
produced by epithelial tissues during pathogen infection (Peterson and Artis, 2014) 
and so future studies could look at the expression of this cytokine in the ileum tissues 




7.4 Transcription factors in sheep paratuberculosis 
 
The differentiation of Th subsets is finely tuned by the cytokine milieu in which the T 
cells are activated. A further contributing factor is the expression of T cell polarizing 
transcription factors. We know that these transcription factors determine the 
expression of specific genes by Th cells and their expression is required for the 
maintenance of immune responses by each subset. Sequencing of the sheep master 
regulator transcription factors that are associated with T cell differentiation by Wilkie 
et al. identified splice variants of these genes (Wilkie et al., 2016) as described in 
Chapter 6 and the expression levels of these and full length transcripts was 
investigated in this study to identify whether they are associated with differential T 
cell polarization and pathological outcomes of paraTB infection in sheep. 
7.4.1 TBX21 
 
T-bet is required to mount efficient Th1 responses by inducing expression of IFNγ; it 
has been shown that T-bet deficient mice exhibit profound defects in developing Th1 
immunity (Szabo et al., 2002). Also, deficient mice infected with Mycobacterium 
avium complex were highly susceptible to infection and developed severe pulmonary 
inflammation compared to T-bet-overexpressing and control mice that were able to 
control infection (Matsuyama et al., 2014). These studies highlight the role of T-bet in 
controlling mycobacterial infection and developing Th1 responses. Given that Th1 
responses are required to control bacterial replication during paraTB infection and 
that this is typically seen in paucibacillary infection, it was thought that expression 
and or variants of this gene may be associated with the paucibacillary form of paraTB 
in sheep. This is similar to what is seen in humans where increased TBX21levels are 
observed in patients with inflammatory diseases of the gut; predominantly 
inflammation associated with increased IFNγ production (Salvati et al., 2002. Neurath 
et al., 2002). Only one transcript of this gene has been identified in mice, cattle and 
humans. SNPs have been identified in human TBX21and are associated with mucosal 
inflammatory diseases; one such SNP was suggested to promote resistance to TB 
when comparing 466 unrelated pulmonary TB patients to 300 healthy controls 
(Sanchez et al., 2013) whilst others have identified SNPs associated with airway 
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hyper- responsiveness in asthma (Raby et al., 2006). Many of these SNPs were 
identified by GWAS and do not provide information on the function of the variants. 
Although there are variants present in the TBX21 gene in other species, no transcript 
variants were identified in sheep. Expression levels of the full length TBX21 sequence 
were measured in the paraTB groups and showed significantly greater expression in 
paucibacillary animals when compared with both multibacillary and control groups 
(M vs P fold change of -1.88, p=0.02 and P vs C fold change of 2.6, p= 0.003). No 
significant difference was noted between expression in multibacillary and control 
groups. T-bet is known to initiate IFNG gene expression and higher expression of 
IFNG has been reported in paucibacillary paraTB infection compared to 
multibacillary and control sheep (Smeed et al 2007). Therefore the increased 
expression of TBX21 in paucibacillary animals found in this study is consistent with 
increased IFNG expression observed in other studies (Smeed et al 2007, Coussens et 
al., 2008). My data suggest that the high levels of IFNG and consequent Th1 
activation in paucibacillary animals are likely to be as a result of T-bet expression. 
This result is different to that seen in red deer infected with paraTB where no 
differential expression of T-bet was noted; deer were experimentally challenged and 
samples collected from clinically affected animals at 20-25 weeks post challenge 
(Robinson et al., 2011). These variables, as well as species differences, may account 
for differences in mRNA expression observed. Similarities were identified between 
the paucibacillary form of sheep paraTB and CD in humans, in terms of pathology 
and immune responses. High levels of IFNG is associated with increased 
inflammation within the gut tissues of both diseases (Smeed et al., 2008. Fais et al., 
1994). TBX21 expression in human Th1 cells contributes to intestinal inflammation in 
CD patients and higher levels of T-bet protein and IFNγ expression were detected in 
the lamina propria CD4+ T cells of CD patients, but not of UC patients or healthy 
controls (Matsuyama et al., 2014). These results correspond to the results that are 
seen in sheep paraTB infection and highlight the role of TBX21 expression in 








GATA3 is required for the differentiation of naive CD4+ T cells to Th2 cells and 
induces production of IL4, IL5 and IL13 (Ho et al., 2009). The GATA3 transcription 
factor is required for Th2 responses but has also been shown to represses the 
development of Th1 responses (Yagi et al., 2011). The expression of GATA3 is down-
regulated during Th1 cell development and up-regulated during Th2 cell development 
(Yagi et al., 2011). The modulation of Th1/Th2 responses by GATA3expression is 
associated with differential T cell polarization in inflammatory diseases including 
IBD, asthma and allergy in humans (Ohtani et al., 2010. Barnes, 2008). 
Two sequence transcripts were identified in the sheep GATA3 gene, one full length 
and one variant sequence. Differences in sequence bet ween the two sheep GATA3 
transcripts are also found in two known human GATA3 transcripts; however no 
phenotype consequences have been reported for the human variant transcript. The 
single deleted amino acid (aa260) does not lie within either of the two conserved zinc 
finger binding motifs or the DNA-binding motif. It is known that mutation of amino 
acids within the DNA-binding motif abolishes Th2-cytokine production and DNA 
binding of GATA3 in other species (Shinnakasu et al., 2006). It is difficult to predict 
the biological role of the sheep GATA3 variant without carrying out functional 
analysis, a possibility for future investigation; however this variant is close to the 
NH2-zinc finger binding domain and could possibly alter protein structure. Human 
studies have identified SNPs of the GATA3 gene which are associated with 
autoimmune diseases, but no such variants were identified in sheep. Combinations of 
SNPs identified in the 5’ promoter region and 3’ UTR of GATA3 and SNPs identified 
in IL13are associated with rhinitis and atopy, both of which display Th2-mediated 
inflammation (Huebner et al., 2008). Similarly, another study identified association of 
SNPs in the GATA3 gene with inflammatory phenotypes in asthmatic patients 
compared to control (Pykalainen et al., 2005). These studies highlight the ways in 
which the GATA3 gene is associated with Th2-associated immune diseases and 
demonstrate the effects that variants within this gene can have on the outcome of 
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disease in humans, in the current study the GATA3 variant sequence was not found to 
be associated with the pathological forms of paraTB. 
Expression of total GATA3 was significantly lower only in multibacillary vs 
paucibacillary comparison, (fold change -2.08, p=0.04). No significant change in 
expression was noted in either of the diseased groups in comparison to controls; 
expression levels seem to be lower in multibacillary compared to control (fold change 
-1.6), although not significantly different (figure 6.3). This result differs to human 
IBD when considering differential T cell activation. Although an overlap in the 
spectrum of IBD is noted, in simplistic terms CD seems to exhibit a Th1 profile 
(similar to paucibacillary paraTB), whereas UC exhibits a Th2 profile (similar to 
multibacillary paraTB); increased expression of GATA3 and IL4 is associated with the 
pathogenesis of UC compared to CD patients and healthy controls (Ohtani et al., 
2010). In the current study the expression of GATA3 was not associated with a Th2 
profile seen with multibacillary paraTB lesions in sheep (Smeed et al., 2007). The 
reduced GATA3 expression in multibacillary form of the disease may indicate a loss 
of Th2 responses in these animals. Similar expression patterns were found in red deer, 
with significantly higher expression of IL4 and GATA3 in minimally diseased 
(paucibacillary) and control groups compared to severely diseased (multibacillary) 
group. It is suggested that Th2 responses act to control immunopathology in paraTB 
infected animals, and loss of these responses leads to the severity of multibacillary 




7.4.3 RORA & RORC2 
 
Th17 cell differentiation is regulated by the TFs RORγt (encoded by RORC2) and 
RORα (encoded by RORA). Although RORγt is the master regulator of transcription 
in Th17 cells, both TFs are required for the induction of Th17 cytokine gene 
expression; blocking either component reduces the expression of IL17A, IL17F and 
IL23 (Skepner et al., 2014. Yang et al., 2008). Human and mouse studies have 
highlighted the importance of Th17 cells in the pathogenesis of a range of immune-
mediated (Yang et al., 2014. Tesmer et al., 2008). 
There are two transcripts of the human RORC gene; RORC1 appears to be expressed 
broadly and is associated with embryo development and liver function, whereas 
RORC2 is expressed exclusively in cells of the immune system and is the functional 
RORC isoform in Th17 development. Both of these transcripts share sequence 
similarity from exon 3 through to the last exon; however RORC2 is shorter than 
RORC1 5’ of exon 3 (Lee et al., 1995. Ivanov et al., 2006). Two RORC2 transcripts 
were identified in sheep (RORC2 and RORC2v1) and analysis of these sequences 
found homology between both of the sheep transcripts and two known human 
transcript variants (Wilkie et al., 2016). RORC2v1 has a 12 amino acid deletion in the 
predicted ligand binding domain; the functional activity of this variant is unknown, 
however it can be predicted that this variant has impaired binding to target ligand 
which may result in lower expression of downstream Th17 associated genes. A 
developmental link between Th17 cells and Treg cells, both requiring TGFβ rich 
environment for differentiation, has been described(Hatton and Weaver, 2009). 
Antigen-activated naive Tcells exposed to TGFβ are induced to co-express Foxp3and 
RORC in the presence of IL6, with the expression of RORC being inhibited when 
Treg differentiation develops as Foxp3expression increases (Hatton and Weaver, 
2009).  It is possible that differential expression levels of RORC2 and RORC2v1in 
paraTB infected sheep could play a role modulation of Th17/Treg activity and 
inflammation in the gut of multibacillary and paucibacillary infection. 
Expression level analysis found that total RORC2 and RORC2v1 expression levels 
were significantly increased in both paucibacillary and multibacillary groups in 
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comparison to the control group. These data imply that RORγt-mediated Th17 
activity is increased in response to paraTB infection, regardless of pathology status. 
RORγt expression is associated with a range of inflammatory diseases in humans; 
psoriasis is a chronic inflammatory disease of the skin characterised by hyperplasia, 
monocyte and T lymphocyte infiltration (Manel et al., 2008. Tesmer et al., 2008). 
This disease is associated with a Th1/Th17 autoimmune response with increased 
levels of IFNG and IL17A (Manel et al., 2008); up-regulation of these cytokines has 
been shown in paraTB infection (Smeed et al., 2007. Robinson et al., 2011). 
Increased expression of RORC2 is correlated with increased production of Th17 
cytokines and enhanced autoimmune inflammation in psoriatic skin compared to 
healthy controls (Tesmer et al., 2008). Furthermore, RORC2 expression was 
increased in asthmatic children compared to healthy controls (Hamzaoui et al., 
2011). Although asthma is typically associated with Th2-inflammatory response, it 
was suggested that Th17 cells could be associated with sustaining inflammatory 
processes in asthmatic patients; in this respect up-regulation of RORC2 in both 
multibacillary and paucibacillary paraTB infected sheep may be associated with the 
sustained Th17 driven chronic inflammation in these animals. 
In humans, four isoforms of RORA have been identified (a-d) which differ in their N-
terminal regions and exhibit distinct DNA-binding properties (Aschrafi et al., 2006). 
Five transcripts of the sheep RORA gene (RORAv1-v5) were identified with no ‘full 
length’ gene assigned (Wilkie et al., 2016). RORAv1 encodes a protein sequence 
containing DNA- and ligand-binding domains and a B domain upstream of the DNA-
binding domain; this isoform is identical to the human RORA isoform d. RORAv2 and 
v4 derived proteins are identical and contain the conserved ligand-binding domain but 
do not have a complete DNA-binding domain. The sheep RORAv3andv5 proteins 
both contain DNA- and ligand-binding domains and identical B domains; these 
sections are of the same sequence as human isoform a, however the sheep variants 
differ in their A domain with RORAv3 possessing an A domain of 13 amino acids 
and RORAv5, an A domain of 44 amino acids; this A domain variation has not been 
identified in any of the human isoforms. Human RORA isoform a has been associated 
with brain function in autism spectrum disorder (ASD) (Sarachana and Hu, 2013). In 
mice, RORA isoforms display the ‘staggerer’ phenotype with specific cerebellar 
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abnormalities showing that RORA plays a key role in the development of the 
cerebellum (Steinmayr et al., 1998). Furthermore, RORA is suggested to be involved 
in lipid metabolism and regulation of the cell cycle (Fitzsimmons et al., 2012. Sato et 
al., 2004). The association of RORA in these human and mice phenotypes does not 
explain the up-regulation of this gene in sheep paraTB, however it is thought that the 
up-regulation of this gene along with RORC2 is key to Th17 development in these 
animals. 
When investigating RORA expression levels, RORAv1 was significantly expressed in 
paucibacillary sheep compared to multibacillary and control groups. RORAv4 had 
significantly higher expression in paucibacillary and multibacillary groups compared 
to control. The A/B domains of human isoform d, identical to sheep RORAv1, is 
known to mediate cytoplasmic localization and is a weak transcription factor with a 
narrow range of targets (Giguere et al., 1994). Furthermore, this isoform may be 
responsible for residual Th17 cell differentiation in the absence of RORγt (Yang et 
al., 2008) and so is likely involved in the induction of Th17 cytokine responses during 
MAP infection. The functional relevance of RORAv4 derived protein is unknown; 
however since this transcription factor only contains the conserved ligand-binding 
domain, it may function to regulate ligand-binding activity (i.e. binding STAT3). No 
differential expression between the three groups was noted for RORAv5 and 
expression levels of RORAv3 and RORA2 were too low for quantification, suggesting 
that these variants may not be biologically relevant in paraTB infection.  
It is known that both RORA and RORC are required for Th17 cytokine production 
and so increased expression of these genes in both paucibacillary and multibacillary 
paraTB groups may signify a role for Th17 activity in the immune response to MAP. 
Robinson et al. suggested that Th17 cells do not play a protective role in paraTB 
infection in deer (Robinson et al., 2011) and so it may be that Th17 responses are 
having an opposite effect; studies have identified that Th17 responses confer long-
lasting, chronic inflammation and that IL17A sustains rather than induces 
inflammation (Shi et al., 2009.Maione et al., 2009). This could suggest that Th17 cell 
activity is responsible for prolonged, chronic pathology seen in both multibacillary 
and paucibacillary paraTB sheep. 
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7.5 Concluding remarks& future study 
 
In conclusion, this study found that transcript variants of the IL23 and IL25 cytokine 
receptors were identified in sheep using sequencing methods. Alongside full length 
transcripts there are five variants of IL23R, four variants of IL12RB1 and three 
variants of IL17RB. Expression analysis of the cytokine receptor genes, transcription 
factor genes and variants identified IL12RB1v3, IL17RA, IL17RB, TBX21 and 
GATA3 to be significantly associated with different pathologies of sheep paraTB. 
When considering the results of this study it is suggested that paucibacillary disease 
is linked to increased Th1/Th17 cell activity and multibacillary animals show a lack 
of strong Th2 or Th1/Th17 cell activities; this may be a contributing factor to the loss 
of control of bacterial replication in multibacillary animals. IL17RB, RORC2, 
RORC2v1, RORA and RORA showed increased expression in infected animals 
compared to uninfected control animals with no differentiation between 
paucibacillary and multibacillary disease forms. 
Alternative splicing is a key regulator of gene expression and protein function; 
however the functional significance of splice variants identified in this study is 
unclear. It is estimated that one third of alternatively spliced mRNA transcripts 
containing premature stop codons are likely to be targets of NMD (Lewis et al., 
2003). As mentioned throughout the discussion, in future studies, further analysis of 
the identified transcript variants to determine whether these mRNA transcripts are 
present at the protein level would be useful when trying to relate mRNA levels to 
pathology, particularly in transcripts where differential expression was found to be 
associated with outcome of paraTB pathology in sheep. However this is a challenge 
in itself as there are very few methods available for isoform detection and those that 
are available are difficult to optimise (Stastna and Van Eyk, 2012). 
Due to time limitations, this study was unable to investigate individual SNPs in the 
cytokine and cytokine receptor genes; future study could investigate whether any 
SNPs present in the gene sequences are associated with pathological forms of 
paraTB. This work would require a large number of sheep samples which are 
difficult to obtain when investigating naturally acquired paraTB infection; 
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controlling variables in such a study would also be challenging when working with 
outbred animals. 
Other considerations for future study are; do these transcripts play a role in the ileum 
tissues of these animals? It is possible that some of the immune processes are 
occurring at the site of MAP infection rather than in the lymph node and so it would 
be useful to investigate this further using similar methods carried out in the current 
study. Are these variants present in other ruminants? It may be worth investigating 
these genes and their variants in other ruminant species, particularly cattle, to 
determine whether the role they play in immune response to paraTB is different to 
that of sheep. Do they play a role in other diseases? Although many of these 
transcripts have not been found to be associated with the different pathological forms 
of paraTB, it may be that they are associated with susceptibility or resistance to other 
diseases and infections in sheep.  
In summary, this study has identified transcript variation in genes that are known to 
influence T cell responses in other species and has provided gene expression profiles 
of these gene and their variants. The key findings of this project are summarised in 
table 7.1. This work contributes to the overall knowledge of sheep immune responses 
to MAP infection, and has provided a foundation upon which further investigation of 












Gene /variant Predicted protein isoform Gene expression  
 
IL23R WT NDE between groups 
 
IL12RB1 WT NDE between groups 
 
IL12RB1v3 Truncated extracellular domain M v P: ↑  
M v C: NDE 
P v C:  NDE 
IL12RB1v4 Short peptide NDE between groups 
 
IL17RA WT M v P: ↓ 
M v C: NDE 
P v C:  ↑ 
IL17RB WT M v P: NDE 
M v C: ↑ 
P v C: NDE 
IL17RBv2 Short peptide NDE between groups 
 
IL17RBv3 Short peptide NDE between groups 
 
TBX21 WT M v P: ↓ 
M v C: NDE 
P v C:  ↑ 
GATA3 WT M v P: ↓ 
M v C: NDE 
P v C:  NDE 
GATA3v1 Single amino acid deletion within  
coding region 
NDE between groups 
 
 
RORC2 WT M v P: ↓ 
M v C: NDE 
P v C:  ↑ 
RORC2v1 12 amino acid deletion within  
coding region 
M v P: ↓ 
M v C: NDE 
P v C:  ↑ 
 
RORAv1 Altered 5’ region M v P: ↓ 
M v C: NDE 
P v C:  ↑ 
 
RORAv4 Altered 5’ region M v P: ↓ 
M v C: NDE 
P v C:  ↑ 
 
RORAv5 Altered 5’ region  NDE 
Summary of results from both wild type (WT) and variant (V) genes investigated in the 
current project. Predicted protein isoforms and expression patterns of each gene in 
multibacillary (M), paucibacillary (P) and control (C) sheep groups are described. NDE: no 
differential expression. 
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A5. IL12RB1 variant nucleotide and protein sequences. 
 
IL12RB1v1 nucleotide 
full            TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
TV1             TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
                ************************************************************ 
 
full            TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
TV1             TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
                ************************************************************ 
 
full            TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
TV1             TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
                ************************************************************ 
 
full            GCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCGCTGGTTATGAATGT 240 
TV1             GCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCGCTGGTTATGAATGT 240 
                ************************************************************ 
 
full            TCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCAGATGCTGCCTCCAG 300 
TV1             TCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCAGCCACTTCCTCAGATGCTGCCTCCAG 300 
                ********************************** ************************* 
 
full            TCTGGCCGCTGCTGCTTCTTTGCCACAGGCTCAGCCACCAAGCTGCAGTTCTCCGACCAG 360 
TV1             TCTGGCCGCTGCTGCTACTTTGCCACAGGCTCAGCCACCAAGCTGCAGTTCTCCGACCAG 360 
                ****************:******************************************* 
 
full            GATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCCGGGCCGCCAACCGG 420 
TV1             GATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCCGGGCCGCCAACCGG 420 
                ************************************************************ 
 
full            ACAGAGAAGTCCCCCAATGTTACTCTGAACCTCTACAGCTCGGTTAAATACGACCCTCCC 480 
TV1             ACAGAGAAGTCCCCCAATGTTACCCTGAACCTCTACAGCTCGGTTAAATACGACCCTCCC 480 
                *********************** ************************************ 
 
full            CCAGGAAACATCAAGGTGTCCAAGTCAGCAGGGAAGCTGCGTATGGAGTGGGAGACCCCA 540 
TV1             CCAGGAAACATCAAGATGTCCAAG------------------------------------ 504 
                ***************.********                                     
 
full            GCCCGCCAGGATGGTGCCGAGGTACAGTTCCGGCACCGCACACCTGGCAGCCCGTGGAAG 600 
TV1             ------------------------------------------------------------ 
 
 
full            CTGGGTGACTGTGGACGTCAGGATGATGCTGGCTTCGAGTCATGCCTCTGCCCCTTGGAG 660 
TV1             ------------------------------------------------------------ 
 
 
full            ATGGACATGGCCCAGGAATTCCAGCTGCGGCGGCGTCTGGGGCCAGGGGTCCCCGGAGGT 720 
TV1             ------------------------------------------------------------ 
 
 
full            CCCTGGAGCAGCTGGAGCAGCCCTGTGTGCATCCCCCCTGAAACCCCTCCACAGGCTGAG 780 
TV1             ------------------------------------------------------------ 
 
 
full            GTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTACATGAG 840 
TV1             ----------------AGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTGTATGAG 548 
                                *************************************. ***** 
 
full            CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 900 
TV1             CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 608 
                ************************************************************ 
 
full            ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 960 
TV1             ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 668 
                ************************************************************ 
 
full            CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 1020 
TV1             CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 728 
232 
 
                ************************************************************ 
 
full            CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 1080 
TV1             CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 788 
                ************************************************************ 
 
full            GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 1140 
TV1             GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 848 
                ************************************************************ 
 
full            CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 1200 
TV1             CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 908 
                ************************************************************ 
 
full            GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 1260 
TV1             GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 968 
                ************************************************************ 
 
full            TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 1320 
TV1             TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 1028 
                ************************************************************ 
 
full            TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 1380 
TV1             TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 1088 
                ************************************************************ 
 
full            GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 1440 
TV1             GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 1148 
                ************************************************************ 
 
full            TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 1500 
TV1             TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 1208 
                ************************************************************ 
 
full            TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 1560 
TV1             TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 1268 
                ************************************************************ 
 
full            ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 1620 
TV1             ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 1328 
                ************************************************************ 
 
full            CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1680 
TV1             CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1388 
                ************************************************************ 
 
full            GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1740 
TV1             GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1448 
                ************************************************************ 
 
full            AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1800 
TV1             AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1508 
                ************************************************************ 
 
full            TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1860 
TV1             TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1568 
                ************************************************************ 
 
full            AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1920 
TV1             AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1628 
                ************************************************************ 
 
full            GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1980 
TV1             GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1688 
                ************************************************************ 
 
full            ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 2040 
TV1             ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 1748 
                ************************************************************ 
 
full            CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 2100 
TV1             CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 1808 




full            GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 2160 
TV1             GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 1868 
                ************************************************************ 
 
full            CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 2220 
TV1             CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 1928 
                ************************************************************ 
 
full            GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 2280 
TV1             GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 1988 
                ************************************************************ 
 
full            ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 2340 
TV1             ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 2048 
                ************************************************************ 
 
full            TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 2382 
TV1             TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 2090 
                ****************************************** 
 
 
   IL12RB1v1 protein 
full            MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
TV1             MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
                ************************************************************ 
 
full            YECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
TV1             YECSWEYEGPAAGVSHFLRCCLQSGRCCYFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
                ************** *************:******************************* 
 
full            ANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRTPGS 180 
TV1             ANRTEKSPNVTLNLYSSVKYDPPPGNIKMSKSS--------------------------- 153 
                ****************************:***:                            
 
full            PWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPETPP 240 
TV1             ---FAQMG---------------------------------GGRWPCMSS---------- 167 
                   :.: *                                 ** *.. **           
 
full            QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 300 
TV1             -----------CPN---------------------------------------------- 170 
                           **:                                               
 
full            KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 360 
TV1             ---------------------WSFQKAALGLTLAWR------------------------ 185 
                                      * :: .** . :**                         
 
full            WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 420 
TV1             ------------------------------------------------------------ 
 
 
full            IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 480 
TV1             ------------------------------------------------------------ 
 
 
full            LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 540 
TV1             ------------------------------------------------------------ 
 
 
full            TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 600 
TV1             ------------------------------------------------------------ 
 
 
full            SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 660 
TV1             ------------------------------------------------------------ 
 
 
full            DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 720 
TV1             ------------------------------------------------------------ 
 
 
full            GTAASSYRED 730 





full            TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
TV2             ------------------------TGGGCTACTGCTCTTCTCAAGGACCGGATGGGACAA 36 
                                         *************  ******************** 
 
full            TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
TV2             TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGT----------------------- 73 
                *************************************                        
 
full            TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
TV2             ------------------------------------------------------------ 
 
 
full            GCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCGCTGGTTATGAATGT 240 
TV2             ------------------------------------------------------------ 
 
 
full            TCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCAGATGCTGCCTCCAG 300 
TV2             ------------------------------------------------------------ 
 
 
full            TCTGGCCGCTGCTGCTTCTTTGCCACAGGCTCAGCCACCAAGCTGCAGTTCTCCGACCAG 360 
TV2             ------------------------------------------------------------ 
 
 
full            GATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCCGGGCCGCCAACCGG 420 
TV2             ------------------------------------------------------------ 
 
 
full            ACAGAGAAGTCCCCCAATGTTACTCTGAACCTCTACAGCTCGGTTAAATACGACCCTCCC 480 
TV2             ------------------------------------------------------------ 
 
 
full            CCAGGAAACATCAAGGTGTCCAAGTCAGCAGGGAAGCTGCGTATGGAGTGGGAGACCCCA 540 
TV2             ------------------------------------------------------------ 
 
 
full            GCCCGCCAGGATGGTGCCGAGGTACAGTTCCGGCACCGCACACCTGGCAGCCCGTGGAAG 600 
TV2             ------------------------------------------------------------ 
 
 
full            CTGGGTGACTGTGGACGTCAGGATGATGCTGGCTTCGAGTCATGCCTCTGCCCCTTGGAG 660 
TV2             ------------------------------------------------------------ 
 
 
full            ATGGACATGGCCCAGGAATTCCAGCTGCGGCGGCGTCTGGGGCCAGGGGTCCCCGGAGGT 720 
TV2             ------------------------------------------------------------ 
 
 
full            CCCTGGAGCAGCTGGAGCAGCCCTGTGTGCATCCCCCCTGAAACCCCTCCACAGGCTGAG 780 
TV2             ----------------------------GCATCCCCCCTGAAACCCCTCCACAGGCTGAG 105 
                                            ******************************** 
 
full            GTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTACATGAG 840 
TV2             GTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTACATGAG 165 
                ************************************************************ 
 
full            CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 900 
TV2             CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 225 
                ************************************************************ 
 
full            ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 960 
TV2             ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 285 
                ************************************************************ 
 
full            CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 1020 
TV2             CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 345 
                ************************************************************ 
 
full            CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 1080 
TV2             CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 405 
235 
 
                ************************************************************ 
 
full            GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 1140 
TV2             GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 465 
                ************************************************************ 
 
full            CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 1200 
TV2             CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 525 
                ************************************************************ 
 
full            GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 1260 
TV2             GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 585 
                ************************************************************ 
 
full            TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 1320 
TV2             TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 645 
                ************************************************************ 
 
full            TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 1380 
TV2             TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 705 
                ************************************************************ 
 
full            GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 1440 
TV2             GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 765 
                ************************************************************ 
 
full            TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 1500 
TV2             TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 825 
                ************************************************************ 
 
full            TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 1560 
TV2             TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 885 
                ************************************************************ 
 
full            ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 1620 
TV2             ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 945 
                ************************************************************ 
 
full            CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1680 
TV2             CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1005 
                ************************************************************ 
 
full            GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1740 
TV2             GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1065 
                ************************************************************ 
 
full            AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1800 
TV2             AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1125 
                ************************************************************ 
 
full            TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1860 
TV2             TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1185 
                ************************************************************ 
 
full            AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1920 
TV2             AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1245 
                ************************************************************ 
 
full            GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1980 
TV2             GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1305 
                ************************************************************ 
 
full            ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 2040 
TV2             ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 1365 
                ************************************************************ 
 
full            CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 2100 
TV2             CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 1425 
                ************************************************************ 
 
full            GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 2160 
TV2             GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 1485 




full            CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 2220 
TV2             CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 1545 
                ************************************************************ 
 
full            GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 2280 
TV2             GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 1605 
                ************************************************************ 
 
full            ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 2340 
TV2             ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 1665 
                ************************************************************ 
 
full            TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 2382 
TV2             TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 1707 




full            MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
TV2             MGQWGFRLVAFLLLLC-------------------------------------------- 16 
                ****************                                             
 
full            YECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
TV2             ------------------------------------------------------------ 
 
 
full            ANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRTPGS 180 
TV2             ------------------------------------------------------------ 
 
 
full            PWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPETPP 240 
TV2             -----------------------------------------------------IPPETPP 23 
                                                                     ******* 
 
full            QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 300 
TV2             QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 83 
                ************************************************************ 
 
full            KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 360 
TV2             KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 143 
                ************************************************************ 
 
full            WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 420 
TV2             WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 203 
                ************************************************************ 
 
full            IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 480 
TV2             IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 263 
                ************************************************************ 
 
full            LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 540 
TV2             LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 323 
                ************************************************************ 
 
full            TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 600 
TV2             TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 383 
                ************************************************************ 
 
full            SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 660 
TV2             SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 443 
                ************************************************************ 
 
full            DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 720 
TV2             DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 503 
                ************************************************************ 
 
full            GTAASSYRED 730 
TV2             GTAASSYRED 515 









full            TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
TV3             TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
                ************************************************************ 
 
full            TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
TV3             TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
                ************************************************************ 
 
full            TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
TV3             TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
                ************************************************************ 
 
full            GCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCGCTGGTTATGAATGT 240 
TV3             GCTTCAGGCCCCCGGGCCCTGAGCT----------------------------------- 205 
                *************************                                    
 
full            TCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCAGATGCTGCCTCCAG 300 
TV3             ------------------------------------------------------------ 
 
 
full            TCTGGCCGCTGCTGCTTCTTTGCCACAGGCTCAGCCACCAAGCTGCAGTTCTCCGACCAG 360 
TV3             ------------------------------------------------------------ 
 
 
full            GATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCCGGGCCGCCAACCGG 420 
TV3             ------------------------------------------------------------ 
 
 
full            ACAGAGAAGTCCCCCAATGTTACTCTGAACCTCTACAGCTCGGTTAAATACGACCCTCCC 480 
TV3             ------------------------------------------------------------ 
 
 
full            CCAGGAAACATCAAGGTGTCCAAGTCAGCAGGGAAGCTGCGTATGGAGTGGGAGACCCCA 540 
TV3             ------------------------------------------------------------ 
 
 
full            GCCCGCCAGGATGGTGCCGAGGTACAGTTCCGGCACCGCACACCTGGCAGCCCGTGGAAG 600 
TV3             ------------------------------------------------------------ 
 
 
full            CTGGGTGACTGTGGACGTCAGGATGATGCTGGCTTCGAGTCATGCCTCTGCCCCTTGGAG 660 
TV3             ------------------------------------------------------------ 
 
 
full            ATGGACATGGCCCAGGAATTCCAGCTGCGGCGGCGTCTGGGGCCAGGGGTCCCCGGAGGT 720 
TV3             ------------------------------------------------------------ 
 
 
full            CCCTGGAGCAGCTGGAGCAGCCCTGTGTGCATCCCCCCTGAAACCCCTCCACAGGCTGAG 780 
TV3             -------------GGAGCAGCCCTGTGTGCATCCCCCCTGAAACCCCTCCACAGGCTGAG 252 
                             *********************************************** 
 
full            GTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTACATGAG 840 
TV3             GTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTACATGAG 312 
                ************************************************************ 
 
full            CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 900 
TV3             CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 372 
                ************************************************************ 
 
full            ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 960 
TV3             ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 432 
                ************************************************************ 
 
full            CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 1020 
TV3             CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 492 
238 
 
                ************************************************************ 
 
full            CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 1080 
TV3             CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 552 
                ************************************************************ 
 
full            GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 1140 
TV3             GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 612 
                ************************************************************ 
 
full            CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 1200 
TV3             CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 672 
                ************************************************************ 
 
full            GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 1260 
TV3             GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 732 
                ************************************************************ 
 
full            TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 1320 
TV3             TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 792 
                ************************************************************ 
 
full            TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 1380 
TV3             TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 852 
                ************************************************************ 
 
full            GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 1440 
TV3             GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 912 
                ************************************************************ 
 
full            TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 1500 
TV3             TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 972 
                ************************************************************ 
 
full            TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 1560 
TV3             TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 1032 
                ************************************************************ 
 
full            ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 1620 
TV3             ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 1092 
                ************************************************************ 
 
full            CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1680 
TV3             CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1152 
                ************************************************************ 
 
full            GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1740 
TV3             GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1212 
                ************************************************************ 
 
full            AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1800 
TV3             AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1272 
                ************************************************************ 
 
full            TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1860 
TV3             TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1332 
                ************************************************************ 
 
full            AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1920 
TV3             AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1392 
                ************************************************************ 
 
full            GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1980 
TV3             GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1452 
                ************************************************************ 
 
full            ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 2040 
TV3             ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 1512 
                ************************************************************ 
 
full            CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 2100 
TV3             CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 1572 




full            GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 2160 
TV3             GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 1632 
                ************************************************************ 
 
full            CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 2220 
TV3             CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 1692 
                ************************************************************ 
 
full            GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 2280 
TV3             GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 1752 
                ************************************************************ 
 
full            ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 2340 
TV3             ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 1812 
                ************************************************************ 
 
full            TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 2382 
TV3             TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 1854 





IL12RB1v3  protein 
full            MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
TV3             MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALS--------- 51 
                ***************************************************          
 
full            YECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
TV3             ------------------------------------------------------------ 
 
 
full            ANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRTPGS 180 
TV3             ------------------------------------------------------------ 
 
 
full            PWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPETPP 240 
TV3             -----------------------------------------------WSSPVCIPPETPP 64 
************* 
 
full            QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 300 
TV3             QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 124 
                ************************************************************ 
 
full            KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 360 
TV3             KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 184 
                ************************************************************ 
 
full            WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 420 
TV3             WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 244 
                ************************************************************ 
 
full            IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 480 
TV3             IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 304 
                ************************************************************ 
 
full            LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 540 
TV3             LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 364 
                ************************************************************ 
 
full            TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 600 
TV3             TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 424 
                ************************************************************ 
 
full            SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 660 
240 
 
TV3             SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 484 
                ************************************************************ 
 
full            DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 720 
TV3             DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 544 
                ************************************************************ 
 
full            GTAASSYRED 730 
TV3             GTAASSYRED 554 




full            TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
TV4             TACCGGCAGCACAGAAGTTCATCTGGGGCTACTGCTCTCTTCAAGGACCGGATGGGACAA 60 
                ************************************************************ 
 
full            TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
TV4             TGGGGGTTCAGGCTGGTTGCCTTCCTTCTCCTCTTGTGCCACAGACAGGGCGCTGAAGCC 120 
                ************************************************************ 
 
full            TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
TV4             TGCGGTACCGTCGGATGCTGTTTTCAGAACCCACCATACCCAGATGCAGACTCAGGCTCA 180 
                ************************************************************ 
 
full            GCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCGCTGGTTATGAATGT 240 
TV4             GCTTCAGGCCCCCGGGCCCTGAGCTGCTACCGGCTGTCCAGCAGCGCTGGTTATGAATGT 240 
                ************************************************************ 
 
full            TCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCAGATGCTGCCTCCAG 300 
TV4             TCCTGGGAGTATGAGGGCCCTGCAGCTGGAGTCATCCACTTCCTCAGATGCTGCCTCCAG 300 
                ************************************************************ 
 
full            TCTGGCCGCTGCTGCTTCTTTGCCACAGGCTCAGCCACCAAGCTGCAGTTCTCCGACCAG 360 
TV4             TCTGGCTGCTGCTGCTTCTTTGCCACAG-------------------------------- 328 
                ****** *********************                                 
 
full            GATGGCATATCCGTGCTCCACAATGTCACTCTCTGGGTGGAATCCCGGGCCGCCAACCGG 420 
TV4             ------------------------------------------------------------ 
 
 
full            ACAGAGAAGTCCCCCAATGTTACTCTGAACCTCTACAGCTCGGTTAAATACGACCCTCCC 480 
TV4             ------------------------------------------------------------ 
 
 
full            CCAGGAAACATCAAGGTGTCCAAGTCAGCAGGGAAGCTGCGTATGGAGTGGGAGACCCCA 540 
TV4             ------------------------------------------------------------ 
 
 
full            GCCCGCCAGGATGGTGCCGAGGTACAGTTCCGGCACCGCACACCTGGCAGCCCGTGGAAG 600 
TV4             ------------------------------------------------------------ 
 
 
full            CTGGGTGACTGTGGACGTCAGGATGATGCTGGCTTCGAGTCATGCCTCTGCCCCTTGGAG 660 
TV4             ------------------------------------------------------------ 
 
 
full            ATGGACATGGCCCAGGAATTCCAGCTGCGGCGGCGTCTGGGGCCAGGGGTCCCCGGAGGT 720 
TV4             ------------------------------------------------------------ 
 
 
full            CCCTGGAGCAGCTGGAGCAGCCCTGTGTGCATCCCCCCTGAAACCCCTCCACAGGCTGAG 780 
TV4             ------------------------------------------------------------ 
 
 
full            GTGAGGTTCTCAGCAGAGCAGCTTTGCCCAGATGGGAGGAGGCAGGTGGCCTTACATGAG 840 
TV4             ------------------------------------------------------------ 
 
 
full            CAGCTGCCCCAACTGGAGCTTCCAGAAGGCTGCCTTGGGCCTGACCCTGGCATGGAGGTG 900 
241 
 
TV4             ------------------------------------------------------------ 
 
 
full            ACCTACAAGATCCATCTCCACATGCTGTCCTGCCCATGTAAGACCAGGGCCAAGAAGACT 960 
TV4             ---------------------------------------------------------GCT 331 
                                                                         .** 
 
full            CTGCGCCTGAAGAGAAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 1020 
TV4             CTGCGCCTGAAGAGCAAGCTCGTCCTCTCGAGTGCTGCCTACGATCTGACCATCGTTTCC 391 
                **************.********************************************* 
 
full            CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 1080 
TV4             CAGAATCGCTTTGGCCTCGGCCCCAATCAGACATGGCGCATTCCTGCCTGCATCCACTCA 451 
                ************************************************************ 
 
full            GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 1140 
TV4             GAACCAGGGCTTCTGAATATCAGTGCGGGAGCCAACGGGACCACCATGCATTGGCCAGCC 511 
                ************************************************************ 
 
full            CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 1200 
TV4             CGGGCCCAGGGAATGAGGTACTGCATTGAGTGGCAGCTCCAGGGCCAGGAGGAGAACCTT 571 
                ************************************************************ 
 
full            GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 1260 
TV4             GCCGCCTGCATCGTGACGGCACCCCAGGACGCAGACGCTGCTGGAATGGCAACTCACAGC 631 
                ************************************************************ 
 
full            TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 1320 
TV4             TGGAGCCAAGAATCTGGAGCACTGGCACAGAAGGCATGTTACCACATCGCCATCTTTGCC 691 
                ************************************************************ 
 
full            TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 1380 
TV4             TCTGCACACCCGGAGAAGCTAACCTCCTGGTCTACAGTCTTGTCCACCTACCATTTTGGA 751 
                ************************************************************ 
 
full            GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 1440 
TV4             GGCAATGCCTCAGCGGCCGGAAGCCCACAGCACGTGTCGGTGAGGAAGCTCAGCCAGGAT 811 
                ************************************************************ 
 
full            TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 1500 
TV4             TCGGTGTCTGTGGACTGGACACCATCTCTGCTGAGCACCTGCCCTGGCGTCCTGAAGGAG 871 
                ************************************************************ 
 
full            TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 1560 
TV4             TACGTTGTGTACTTCCAGGAGGAGGACAGCAACCAAGCGTCTGAGCTGCACGTGAAGCCC 931 
                ************************************************************ 
 
full            ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 1620 
TV4             ACAGAGACCCAGGTCACCCTCCAAGGCCTGCGGGCTGGCACAGCTTACAAGGTGCAGGTT 991 
                ************************************************************ 
 
full            CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1680 
TV4             CGCGCAGACACAGCCAAGTGGAGGGGCGCCTGGAGCCAGCCCCTGCATTTCACCATCGAA 1051 
                ************************************************************ 
 
full            GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1740 
TV4             GTCCAGGTTTCTGAGTTGTCCGACTTGTCCATCTTCCTCGCATCTTTGGGGAGTTTCGTG 1111 
                ************************************************************ 
 
full            AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1800 
TV4             AGCATCCTTCTCCTGGGAATCTTTGGGTACCTCAGCTTGAACAGGGCTGTAAGGCACCTG 1171 
                ************************************************************ 
 
full            TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1860 
TV4             TGCCCACCCTTGCCCACACCTGGTGCCAGCACTGCCATCAAGTTCTCTGGCAGCCAGGGG 1231 
                ************************************************************ 
 
full            AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1920 
TV4             AAGCAGGTTTGGCAGTGGACCAGCCCAGCAGACTTCCCAGAGGAGGTGTCTCCACACGAG 1291 
                ************************************************************ 
 
full            GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1980 
TV4             GCCCTGATGGTGAATATATCCTGGGAAAAAGGCGAGGGAGCTGACATGGGCACACTTGGG 1351 




full            ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 2040 
TV4             ACTCTCAAGGAGAAGATGGAGCTGCCTCTGCGTGCCCCTAAGCCAGCCCCGGACACAGAG 1411 
                ************************************************************ 
 
full            CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 2100 
TV4             CTGCCCTTGAAGGACAGGAAGCAGATGCAAGGATGCCCTGAGGCTGGGGCTCTGAGGCCT 1471 
                ************************************************************ 
 
full            GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 2160 
TV4             GGCTGGCAGGACGGTCTGGTGGAGGACAGCCTTGCCCAGGTGGCTAGACCCCCACTGCTG 1531 
                ************************************************************ 
 
full            CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 2220 
TV4             CTCCTGGGGGGCCTGAGGCAGGCCCCCAGGTTTGGTTCCCAGGGAGAAGCAGGAACAGCT 1591 
                ************************************************************ 
 
full            GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 2280 
TV4             GCCTCCTCTTACAGAGAAGACTGACAACTGCCTCCAGGACGGCTGGCTGTTGTTCACTGC 1651 
                ************************************************************ 
 
full            ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 2340 
TV4             ACACTTGGCCCGTTTTTTCCAGACACTCACGTGATGCCCTTGAGCGATATGGCTGTCCTA 1711 
                ************************************************************ 
 
full            TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 2382 
TV4             TTGACCTATTTCAGTGAGCCTCAGTGAGGTTCAGAGAGGGCA 1753 
                ****************************************** 
 
IL12RB1v4 protein 
Full            MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
TV4             MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSSSAG 60 
                ************************************************************ 
 
Full            YECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVESRA 120 
TV4             YECSWEYEGPAAGVIHFLRCCLQSGCCCFFATGSAP------------------------ 96 
                ************************* *********.                         
 
Full            ANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRTPGS 180 
TV4             ----------------------------------------EEQARPLECCLRSDHRFPES 116 
                                                        *  **   . ::  ** * * 
 
Full            PWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPETPP 240 
TV4             LWP-----RPQSDMAHSCLHP----------LRTR------------------------- 136 
                 *      * :.   .*** *          ** *                          
 
Full            QAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCKTRA 300 
TV4             ------ASEYQCGSQRDHHALAS-------------PGPGNEVLHS-------------- 163 
                      ::*  * . * : ** .             *.** ** :.               
 
Full            KKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGTTMH 360 
TV4             ------------------------------------------------------------ 
 
 
Full            WPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACYHIA 420 
TV4             ------------------------------------------------------------ 
 
 
Full            IFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTCPGV 480 
TV4             ------------------------------------------------------------ 
 
 
Full            LKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQPLHF 540 
TV4             ------------------------------------------------------------ 
 
 
Full            TIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIKFSG 600 





Full            SQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPKPAP 660 
TV4             ------------------------------------------------------------ 
 
 
Full            DTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQGEA 720 
TV4             ------------------------------------------------------------ 
 
 
Full            GTAASSYRED 730 



































Pooled paraTB cDNA 
Positive control 
Positive control 
Pooled paraTB cDNA 
245 
 
A8. IL12RB1 WSxWS motif and transmembrane analysis 
Human IL12RB1: AAI37407.1 
WSxWS motif 
Transmembrane 
human      MEPLVTWVVP---LLFLFLLSRQGAACRTSECCFQDPPYPDADSGSASGPRDLRCYRISS 
sheep      ---MGQWGFRLVAFLLLLCHRQGAEACGTVGCCFQNPPYPDADSGSASGPRALSCYRLSS 
              :  * .    :*:*:   : . ** *  ****:*************** * ***:** 
 
human      -DRYECSWQYEGPTAGVSHFLRCCLSSGRCCYFAAGSATRLQFSDQAGVSVLYTVTLWVE 
sheep      SAGYECSWEYEGPAAGVIHFLRCCLQSGRCCFFATGSATKLQFSDQDGISVLHNVTLWVE 
              *****:****:*** *******.*****:**:****:****** *:***:.****** 
 
human      SWARNQTEKSPEVTLQLYNSVKYEPPLGDIKVSKLAGQLRMEWETPDNQVGAEVQFRHRT 
sheep      SRAANRTEKSPNVTLNLYSSVKYDPPPGNIKVSKSAGKLRMEWETPARQDGAEVQFRHRT 
           * * *:*****:***:**.****:** *:***** **:******** .* ********** 
 
human      PSSPWKLGDCGPQDD-DTESCLCPLEMNVAQEFQLRRRQ-LGSQGSSWSKWSSPVCVPPE 
sheep      PGSPWKLGDCGRQDDAGFESCLCPLEMDMAQEFQLRRRLGPGVPGGPWSSWSSPVCIPPE 
           *.********* ***   *********::*********   *  *. **.******:*** 
 
human      NPPQPQVRFSVEQLGQDGRRRLTLKEQPTQLELPEGCQGLAPGTEVTYRLQLHMLSCPCK 
sheep      TPPQAEVRFSAEQLCPDGRRQVALHEQLPQLELPEGCLGPDPGMEVTYKIHLHMLSCPCK 
           .*** :****.***  ****:::*:**  ******** *  ** ****:::********* 
 
human      AKATRTLHLGKMPYLSGAAYNVAVISSNQFGPGLNQTWHIPADTHTEPVALNISVGTNGT 
sheep      TRAKKTLRLKRKLVLSSAAYDLTIVSQNRFGLGPNQTWRIPACIHSEPGLLNISAGANGT 
           ::*.:**:* :   **.***:::::*.*:** * ****:***  *:**  ****.*:*** 
 
human      TMYWPARAQSMTYCIEWQPVGQDGGLATCSLTAPQDPDPAGMATYSWSRESGAMGQEKCY 
sheep      TMHWPARAQGMRYCIEWQLQGQEENLAACIVTAPQDADAAGMATHSWSQESGALAQKACY 
           **:******.* ******  **:  **:* :***** * *****:***:****:.*: ** 
 
human      YITIFASAHPEKLTLWSTVLSTYHFGGNASAAGTPHHVSVKNHSLDSVSVDWAPSLLSTC 
sheep      HIAIFASAHPEKLTSWSTVLSTYHFGGNASAAGSPQHVSVRKLSQDSVSVDWTPSLLSTC 
           :*:*********** ******************:*:****:: * *******:******* 
 
human      PGVLKEYVVRCRDEDSKQVSEHPVQPTETQVTLSGLRAGVAYTVQVRADTAWLRGVWSQP 
sheep      PGVLKEYVVYFQEEDSNQASELHVKPTETQVTLQGLRAGTAYKVQVRADTAKWRGAWSQP 
           *********  ::***:*.**  *:********.*****.**.********  **.**** 
 
human      QRFSIEVQVS---DWLIFFASLGSFLSILLVGVLGYLGLNRAARHLCPPLPTPCASSAIE 
sheep      LHFTIEVQVSELSDLSIFLASLGSFVSILLLGIFGYLSLNRAVRHLCPPLPTPGASTAIK 
            :*:******   *  **:******:****:*::***.****.********** **:**: 
 
human      FPG--GKETWQWINPVDFQEEASLQEALVVEMSWDKGERTEP------LEKTELPEGAPE 
sheep      FSGSQGKQVWQWTSPADFPEEVSPHEALMVNISWEKGEGADMGTLGTLKEKMELPLRAPK 
           * *  **:.*** .*.** **.* :***:*::**:*** ::        ** ***  **: 
 
human      LALDTELSLEDGDRCKAKM----------------------------------------- 
sheep      PAPDTELPLKDRKQMQGCPEAGALRPGWQDGLVEDSLAQVARPPLLLLGGLRQAPRFGSQ 
            * **** *:* .: :.                                            
 
human      -------------- 






A9. IL17RA gene sequence aligned to OARv3.1 
OARV3.1 Chromosome 3 IL17RA 
Query  2          CTGTCTGC-AAATACAAGGTCCTGAAACAACAAAGACACACTCGCTGATGACGGATGTTG  60 
                  |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212808572  CTGTCTGCAAAATACAAGGTCCTGAAACAACAAAGACACACTCGCTGATGACGGATGTTG  212808631 
 
Query  61         GGGCAGTAAATCAGAAGTCAGCCTGGAGCAGGAGCCTCTGTCAGCCAGGAGCGATGGAGT  120 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212808632  GGGCAGTAAATCAGAAGTCAGCCTGGAGCAGGAGCCTCTGTCAGCCAGGAGCGATGGAGT  212808691 
 
Query  121        TCCAGGGAACAGAGAAGCTCCTGCTGCCCGGGTGCCCTTCCTGCAGAGAGGGCACTTGGG  180 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212808692  TCCAGGGAACAGAGAAGCTCCTGCTGCCCGGGTGCCCTTCCTGCAGAGAGGGCACTTGGG  212808751 
 
Query  181        CAGCCCTCCAAGAGAGTCTAGAGCATTCCAGGAGGGGGAAATGACTGAGCCAAGGCCCGA  240 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212808752  CAGCCCTCCAAGAGAGTCTAGAGCATTCCAGGAGGGGGAAATGACTGAGCCAAGGCCCGA  212808811 
 
Query  241        AGG  243 
                  ||| 
Sbjct  212808812  AGG  212808814 
 
 
>>>>>> EXON 1??<<<<<<< 
 
 
Query  237        CCGAAGGGGCTGAACTGCACAGTCAAGAACAGTA  270 
                  ||| |||||||||||||||||||||||||||||| 
Sbjct  212811829  CCGCAGGGGCTGAACTGCACAGTCAAGAACAGTA  212811862 
 
Query  268        GTACCTGCCTGGACGACAGCTGGATCCACCCTCGGAACCTCACCCCCTCATCCCCCAAAA  327 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212812436  GTACCTGCCTGGACGACAGCTGGATCCACCCTCGGAACCTCACCCCCTCATCCCCCAAAA  212812495 
 
Query  328        ACGTGCAGACCCAGCTGCGCTTCGCCCACACACAGCAAGGACACTTGCTTCCCGTGGTTC  387 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212812496  ACGTGCAGACCCAGCTGCGCTTCGCCCACACACAGCAAGGACACTTGCTTCCCGTGGTTC  212812555 
 
Query  388        ACATCGAGTGGACGCTGCAGACAGATG  414 
                  ||||||||||||||||||||||||||| 






Query  414        GCCAGCGTCCTCTACCTGGAGGGGGCGGAGCTGTCCATCCTGCAGCTGAGCACCAATGAG  473 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212813274  GCCAGCGTCCTCTACCTGGAGGGGGCGGAGCTGTCCATCCTGCAGCTGAGCACCAATGAG  212813333 
 
Query  474        CGTCTGTGTGTCAGGTTTGAGTTTCTGACCACACTGAGGCATCATCACAAGCGG  527 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||| 






Query  527        GTGGCGATTTGCCTTCAGCCACTTTGTGGTAGAACCCAGAGAGGAGTACGAGGTGACCGT  586 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212814463  GTGGCGATTTGCCTTCAGCCACTTTGTGGTAGAACCCAGAGAGGAGTACGAGGTGACCGT  212814522 
 
Query  587        CCACCACCTGCCTAAGCCCATCCCTGACGGGGACCCAAACCACCAATCCAGAAACTTCCT  646 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212814523  CCACCACCTGCCTAAGCCCATCCCTGACGGGGACCCAAACCACCAATCCAGAAACTTCCT  212814582 
 
Query  647        GGTGCCCG  654 
                  |||||||| 







Query  641        CTTCCTGGTGCCC-GACTGCAAGGACCCCAGGATGAAGGACACCACGCCATGCGTGAGCT  699 
                  ||||| ||| | | |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212816102  CTTCCCGGTCCACAGACTGCAAGGACCCCAGGATGAAGGACACCACGCCATGCGTGAGCT  212816161 
 
Query  700        CAGGCAGCCTGTGGG  714 
                  |||| | || ||||| 
247 
 





Query  701        AGGCAGCCTGTGGGACCCCAACATCACCGTGGAGACCCTTGAGGCCCACCAGCTGCGGCT  760 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212816313  AGGCAGCCTGTGGGACCCCAACATCACCGTGGAGACCCTTGAGGCCCACCAGCTGCGGCT  212816372 
 
Query  761        GAGCTTCACCCCATGGAATGAGTCCACCAGTTACCAGGTCCTGCTGCACAGCTTCCCGCC  820 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212816373  GAGCTTCACCCCATGGAATGAGTCCACCAGTTACCAGGTCCTGCTGCACAGCTTCCCGCC  212816432 
 
Query  821        TGCAGAGAACCAGAGCTGCTTCCAACATGTTGTCGACATGCCCGTG  866 
                  |||||||||||||||||||||||||||||||||||||||||||||| 






Query  866        GCCCGCACAGGAAGCCGCCCCGCAGCGCTGCCACATCACGGTCACCCTGCTGGACTCCAG  925 
                  |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  212817228  GCCCGCACAGGAAGCCGCCCCGCAGCGCTGCCACATCACGGTCACCCTGCGGGACTCCAG  212817287 
 
Query  926        CTGGTGCTGCCGCCACCACGTGCAG  950 
                  ||||||||||||||||||||||||| 
Sbjct  212817288  CTGGTGCTGCCGCCACCACGTGCAG  212817312 
 
Query  948        CAGATCCAGCCCTTCTTCAGCAGCTGCCTCAACGACTGCCTCCGACACTCGGTGTCCATG  1007 
                  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  212817546  CAGATCCAGCCCTTCTTCAGCAGCTGCCTCAACGACTGCCTCCGACACTCGGTGTCCGTG  212817605 
 
Query  1008       GCCTGCCCGGAGGTCTCACACACCCCAG  1035 
                  |||||||||||||||||||||||||||| 






Query  1046       AGACCACACGCCTCTGTGGGTGTCTGCGTTCATCACAGGCCTCTCCATCCTACTGGTGGG  1105 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212818524  AGACCACACGCCTCTGTGGGTGTCTGCGTTCATCACAGGCCTCTCCATCCTACTGGTGGG  212818583 
 
Query  1106       CTCCGTCATCCTGCTGATCCTCTGCATGACCTGGAGGCTACCAGG  1150 
                  ||||||||||||||||||||||||||||||||||||||||||||| 





Query  1147       CAGGGTTCCGTCAAGGAAAACATGAAGATGGCACCAAAGACACAG  1191 
                  ||||||||||||||||||||||||||||||||||||||||||||| 





Query  1189CAGAGATCCTGCCCGCTGCCACCAGCCTGAcccccccGCCCCTGAAGCCCAGGAAGGTCT  1248 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  212819604  CAGAGATCCTGCCCGCTGCCACCAGCCTGACCCCCCCGCCCCTGAAGCCCAGGAAGGTCT  212819663 
 
Query  1249       GGATCGTCTACTCCGCCGACCACCCCCTCTACGTGGACGTGGTCCTCAAGTTCGCCCA  1306 
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





Ovisaries breed Texel unplaced genomic scaffold, Oar_v3.1 scaffold005641  
Sequence ID: ref|NW_004083240.1|Length: 4151Number of Matches: 1 
Related Information 
 
Query  1302GCCCATGGGCCCAGCTTGGGGAGGcctgggggccaggctggggtTGGGGCATCAGGCCCT  1361 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3571  GCCCATGGGCCCAGCTTGGGGAGGCCTGGGGGCCAGGCTGGGGTTGGGGCATCAGGCCCT  3512 
 
Query  1362  GATGCTAAAGACCAGGGCTTCTTTACCAGGATGCCCTGTTCCCCGCAGAGGAGGCTGTAG  1421 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3511  GATGCTAAAGACCAGGGCTTCTTTACCAGGATGCCCTGTTCCCCGCAGAGGAGGCTGTAG  3452 
 
Query  1422  ATCAGACACACTGGTCATTTCCAGAGAAAAACTGGATAGAAGTGAATGAGCCCGGATGGC  1481 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
248 
 
Sbjct  3451  ATCAGACACACTGGTCATTTCCAGAGAAAAACTGGATAGAAGTGAATGAGCCCGGATGGC  3392 
 
Query  1482  CTCAGCAGGGCCTGAACCCGCATGTGGCCTCGGTCAGTGGGAGAGCTTTGGCCAAAGGAT  1541 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  3391  CTCAGCAGGGCCTGAACCCGCATGTGGCCTCGGTCAGTGGGAGAGCTTTGGCCAA-GGAT  3333 
 
Query  1542  TCTTCCAGGGTTGCGGGCTGAGCACTGGGCTATAGCATCCAGGCTCAAGAAGAACAAGGA  1601 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3332  TCTTCCAGGGTTGCGGGCTGAGCACTGGGCTATAGCATCCAGGCTCAAGAAGAACAAGGA  3273 
 
Query  1602  GCCCCCCGCCCTGTGCATACTGGGGTCACTGTAGGTTCTCTTTGCCTGAACCTGAGTCCT  1661 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  3272  GCCCCCCGCCCTGTGCATACTGGGGTCACTGTAGGTTCTCTTTGCCTGAACCTGAGTCCT  3213 
 
Query  1662  C-ACTGGAGGTTCAAGCACCTGCAAGGAG-AGGGGAT-CTGAAATTCA-G-AG-AATCAG  1715 
             | ||||||||||||||||||||||||||| ||||||| |||||||||| | || |||||| 
Sbjct  3212  CCACTGGAGGTTCAAGCACCTGCAAGGAGGAGGGGATTCTGAAATTCAAGGAGAAATCAG  3153 
 
Query  1716  ATACCGCGTGTAACATGTGTGTGGTGTTGTGAA-GCGAGCCTCCACTGATAAA-G-ATGG  1772 
             |||||||||||| |||||||||| ||| ||||| |||||| || ||||||||| | |||  
Sbjct  3152  ATACCGCGTGTA-CATGTGTGTG-TGT-GTGAAAGCGAGC-TC-ACTGATAAAAGAATGA  3098 
 
Query  1773  ATAAGTTTT-AA-ctctga  1789 
             |||| |||| || |||||| 










A10. IL17RB TRAF-6 binding domain and SEFIR region analysis 
 
TRAF-6 binding domain 
 
Ovine_V2        MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
Ovine_V3        MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
Ovine           MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
Ovine_V1        MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
Homo            MSLVLLSLAALCRSAVPREPTVQCGSETGPSPEWMLQHDLIPGDLRDLRVEPVTTSVATG 60 
Mus             MLLVLLILAASCRSALPREPTIQCGSETGPSPEWMVQHTLTPGDLRDLQVELVKTSVAAE 60 
                * **** *** * .*:* ***:*****.*******::* * *******:** :.:**    
 
Ovine_V2        DSSILMNISWILRADVDV-------------------------FLHWFSCRAEHSLFHWS 95 
Ovine_V3        DSSILMNISWILRADVDV-------------------------FLHWFSCRAEHSLFHWS 95 
Ovine           DSSILMNISWILRADASIRLLKATKICVMGKSHFQSRSCIRCNYTQAFRTQTRHSGGKWT 120 
Ovine_V1        DSSILMNISWILRADASIRLLKATKICVMGKSHFQSRSCIRCNYTQAFRTQTRHSGGKWT 120 
Homo            DYSILMNVSWVLRADASIRLLKATKICVTGKSNFQSYSCVRCNYTEAFQTQTRPSGGKWT 120 
Mus             EFSILMNISWILRADASIRLLKATKICVSGKNNMNSYSCVRCNYTEAFQSQTRPSGGKWT 120 
                : *****:**:****..:                         : . *  ::. *  :*: 
 
Ovine_V2        PS---------------------------------------------------------- 97 
Ovine_V3        PS---------------------------------------------------------- 97 
Ovine           FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMAVNFTSPGCLDHVMKYKKKCIEAGSLW 180 
Ovine_V1        FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMAVNFTSPGCLDHVMKYKKKCIEAGSLW 180 
Homo            FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMSVNFTSPGCLDHIMKYKKKCVKAGSLW 180 
Mus             FSYVGFPVELSTLYLISAHNIPNANMNEDSPSLSVNFTSPGCLNHVMKYKKQCTEAGSLW 180 
                 *                                                           
 
Ovine_V2        ------------------------------------------------------------ 
Ovine_V3        ------------------------------------------------------------ 
Ovine           KPNITACKKSANTVEVNFTTSPLGDRYMALIQNTSVIGTSYVSEK---ELTRTSVVVHVT 237 
Ovine_V1        KPNITACKKSANTVEVNFTTSPLGDRYMALIQNTSVIGTSYVSEK---ELTRTSVVVHVT 237 
Homo            DPNITACKKNEETVEVNFTTTPLGNRYMALIQHSTIIGFSQVFEPHQKKQTRASVVIPVT 240 
Mus             DPDITACKKNEKMVEVNFTTNPLGNRYTILIQRDTTLGFSRVLEN---KLMRTSVAIPVT 237 
 
 
Ovine_V2        ------------------------------------------------------------ 
Ovine_V3        ------------------------------------------------------------ 
Ovine           GESEGAVVQLTPYFHTCGNDCIRQRGTVVRCPQT-GVSPQDHERSVLGGWLPLLLSALLV 296 
Ovine_V1        GESEGAVAQLTPYFHTCGNDCIRQRGTVVRCPQT-GVSPQDHERSVLGGWLPLLLSALLV 296 
Homo            GDSEGATVQLTPYFPTCGSDCIRHKGTVVLCPQTGVPFPLDNNKSKPGGWLPLLLLSLLV 300 
Mus             EESEGAVVQLTPYLHTCGNDCIRREGTVVLCSETSAPIPPDDNRRMLGGWLPLFLV-LLV 296 
 
 
Ovine_V2        ------------------------------------------------------------ 
Ovine_V3        ------------------------------------------------------------ 
Ovine           ATWVLVAGIYLIWRHERIKKTSFST-TTLLPSLKVLVVYPSEICFHHTVCYFTEFLQNRC 355 
Ovine_V1        ATWVLVAGIYLIWRH---------------------------------VCYFTEFLQNRC 323 
Homo            ATWVLVAGIYLMWRHERIKKTSFST-TTLLPPIKVLVVYPSEICFHHTICYFTEFLQNHC 359 
Mus             AVWVLAAGIYLTWRQGRSTKTSFPISTMLLPLIKVLVVYPSEICFHHTVCRFTDFLQNYC 356 
 
 
Ovine_V2        ------------------------------------------------------------ 
Ovine_V3        ------------------------------------------------------------ 
Ovine           RSEVILEKWQKKKIAEMGPVQWLTTQKQAADKVIFLLSNDN-TMCDGTCDKKEGGPCENS 414 
Ovine_V1        RSEVILEKWQKKKIAEMGPVQWLTTQKQAADKVIFLLSNDN-TMCDGTCDKKEGGPCENS 382 
Homo            RSEVILEKWQKKKIAEMGPVQWLATQKKAADKVVFLLSNDVNSVCDGTCGKSEGSPSENS 419 
Mus             RSEVILEKWQKKKIAEMGPVQWLTTQKQAADKVVFLLPSDVPTLCDSACGHNEGSARENS 416 
 
 
Ovine_V2        ------------------------------------------------------------ 
Ovine_V3        ------------------------------------------------------------ 
Ovine           QDLFHLAFNLFCSDLRSQTHLRKYVVVYFREGDIKDSYSALSVCPTYRLTKDATDFCAEL 474 
Ovine_V1        QDLFHLAFNLFCSDLRSQTHLRKYVVVYFREGDIKDSYSALSVCPTYRLTKDATDFCAEL 442 
Homo            QDLFPLAFNLFCSDLRSQIHLHKYVVVYFREIDTKDDYNALSVCPKYHLMKDATAFCAEL 479 
Mus             QDLFPLAFNLFCSDFSSQTHLHKYLVVYLGGADLKGDYNALSVCPQYHLMKDATAFHTEL 476 
 
 
Ovine_V2        ----------------------- 
Ovine_V3        ----------------------- 
Ovine           LHAKQHVSVGRRSRARHYSCLSL 497 
250 
 
Ovine_V1        LHAKQHVSVGRRSRARHYSCLSL 465 
Homo            LHVKQQVSAGKRSQACHDGCCSL 502 
Mus             LKATQSMSVKKRSQACHDSCSPL 499 
 
Alignment of ovine protein sequence (IL17RB) with Bos Taurus SEFIR domain: GenBank: 
AAI33637.1 
bos             ------------------------------------------------------------ 
ovine           MLLVLLSLAALCWGAVPPEPTIQCGSEPGPSPEWMVRHTLTPGDLRDLRVEPIKSSVDLE 60 
 
 
bos             ------------------------------------------------------------ 
ovine           DSSILMNISWILRADASIRLLKATKICVMGKSHFQSRSCIRCNYTQAFRTQTRHSGGKWT 120 
 
 
bos             ------------------------------------------------------------ 
ovine           FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMAVNFTSPGCLDHVMKYKKKCIEAGSLW 180 
 
 
bos             ------------------------------------------------------------ 
ovine           KPNITACKKSANTVEVNFTTSPLGDRYMALIQNTSVIGTSYVSEKELTRTSVVVHVTGES 240 
 
 
bos             ------------------------------------------------------------ 
ovine           EGAVVQLTPYFHTCGNDCIRQRGTVVRCPQTGVSPQDHERSVLGGWLPLLLSALLVATWV 300 
 
 
bos             ---------------------------IKVLVVYPSEICFHHTVCYFTEFLQNRCRSEVI 33 
ovine           LVAGIYLIWRHERIKKTSFSTTTLLPSLKVLVVYPSEICFHHTVCYFTEFLQNRCRSEVI 360 
                                           :******************************** 
 
bos             LEKWQKKKIAEMGPVQWLTTQKEAADKVIFLLSNGNTTCDGNCDEKEGGPCESSRDLFHL 93 
ovine           LEKWQKKKIAEMGPVQWLTTQKQAADKVIFLLSNDNTMCDGTCDKKEGGPCENSQDLFHL 420 
                **********************:***********.** ***.**:*******.*:***** 
 
bos             AFNLFCSDLRSQAHLHKYVVVYFREGDIADSYRALSVCPTYRLTKDATGFCAEL------ 147 
ovine           AFNLFCSDLRSQTHLRKYVVVYFREGDIKDSYSALSVCPTYRLTKDATDFCAELLHAKQH 480 
                ************:**:************ *** ***************.*****       
 
bos             ----------------- 
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A14. RORAv3 RT-QPCR positive control assay 
  
Pooled paraTB cDNA 
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